

1
2
3
4



5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24

EXPERT PANEL ON EFFECTIVE WAYS OF INVESTING IN HEALTH
(EXPH)

25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48

Access to health services in the European Union

The EXPH approved this opinion for public consultation by written procedure
on 25 September 2015

About the Expert Panel on effective ways of investing in Health (EXPH)

Sound and timely scientific advice is an essential requirement for the Commission to pursue modern, responsive and sustainable health systems. To this end, the Commission has set up a multidisciplinary and independent Expert Panel which provides advice on effective ways of investing in health ([Commission Decision 2012/C 198/06](#)).

The core element of the Expert Panel’s mission is to provide the Commission with sound and independent advice in the form of opinions in response to questions (mandates) submitted by the Commission on matters related to health care modernisation, responsiveness, and sustainability. The advice does not bind the Commission.

The areas of competence of the Expert Panel include, and are not limited to, primary care, hospital care, pharmaceuticals, research and development, prevention and promotion, links with the social protection sector, cross-border issues, system financing, information systems and patient registers, health inequalities, etc.

Expert Panel members

Pedro Barros, Margaret Barry, Helmut Brand, Werner Brouwer, Jan De Maeseneer (Chair), Bengt Jönsson (Vice-Chair), Fernando Lamata, Lasse Lehtonen, Dorjan Marušič, Martin McKee, Walter Ricciardi, Sarah Thomson

Contact

European Commission
DG Health & Food Safety
Directorate D: Health Products and Systems
Unit D3 – eHealth and Health Technology Assessment
Office: B232 B-1049 Brussels

SANTE-EXPERT-PANEL@ec.europa.eu

The opinions of the Expert Panel present the views of the independent scientists who are members of the Expert Panel. They do not necessarily reflect the views of the European Commission nor its services. The opinions are published by the European Union in their original language only.

94 **ACKNOWLEDGMENTS**

95

96 Members of the Working Group are acknowledged for their valuable contribution to
97 this opinion.

98

99 The members of the Working Group are:

100

101 **Expert Panel members**

102 Professor Pedro Barros

103 Professor Margaret Barry

104 Professor Werner Brouwer

105 Professor Jan De Maeseneer (Chair)

106 Dr Fernando Lamata

107 Professor Lasse Lehtonen

108 Professor Martin McKee

109 Dr Sarah Thomson (Rapporteur)

110

111 **External experts**

112 Dr Michele Cecchini

113 Professor Sara Willems

114

115

116 The declarations of the Working Group members are available at:

117 http://ec.europa.eu/health/expert_panel/experts/working_groups/index_en.htm

118

119

120 The Working Group would like to thank Pooja Yerramili and Jens Detollenaere for
121 their help in preparing some of the figures.

122

ABSTRACT

Access is a critical component of universal health coverage. The 28 Member States of the European Union (EU) have a clear mandate to ensure equitable access to health services for everyone living in their countries. This does not mean making everything available to everyone at all times. Rather, it means addressing unmet need for health care by ensuring that the resources required to deliver relevant, appropriate and cost-effective health services are as closely matched to need as possible.

Between 2005 and 2009, EU Member States made huge progress in improving access to health care. The number of people reporting unmet need fell steadily from 24 million in 2005 to 15 million in 2009. Since 2009, however, this positive trend has been reversed – a visible sign of the damage caused by the financial and economic crisis. By 2013, the number of people reporting unmet need for health care had risen to 18 million (3.6% of the population).

Access is multi-dimensional. Barriers to access can be found at the level of individuals, health service providers and the health system. Access is also affected by public policy beyond the health system – especially fiscal policy, but also social protection, education, transport and regional development policy. Survey data suggest that financial barriers are the largest single driver of unmet need in the European Union.

This report aims to highlight key access problems and policy responses in EU health systems. It is structured around eight policy areas: financial resources linked to health need; services affordable for everyone; relevant, appropriate and cost-effective services; well-equipped facilities within easy reach; staff with the right skills in the right place; quality medicines and medical devices available at fair prices; everyone can use services when they need them; services acceptable to everyone. The report includes a focus on three groups of people who are systematically underserved in the European Union: Roma, undocumented migrants and people with mental health problems. A final section of the report discusses the roles and responsibilities of the European Union and its Member States in ensuring equitable access to health services. In particular, it emphasises the need for a new generation of data collection for effective, accessible, resilient and accountable health systems.

The report calls for *better monitoring* to identify the magnitude of access problems in a timely manner, to measure changes over time and across groups of people and to enhance international comparability. The ability to disaggregate data at sub-national level and by sub-groups in the population is essential. The report also calls for *more policy analysis* to enable a deeper understanding of the causes of access problems and to identify cost-effective policy responses, underpinned by *research targeting hard to reach groups of people*. Policy responses should reflect the multi-dimensional nature of access problems, the importance of intersectoral action and the specifics of national and regional context.

Keywords: EXPH, Expert Panel on effective ways of investing in Health, scientific opinion, access to health services

Opinion to be cited as: Expert Panel on effective ways of investing in Health (EXPH), Preliminary Report on Access to Health Services in the European Union, 25 September 2015

180 © European Union, 2015

181 ISSN 2315-1404

ISBN 978-92-79-48150-5

182 doi:10.2875/777023

EW-BA-15-003-EN-N

183 http://ec.europa.eu/health/expert_panel/index_en.htm

184

185

186

187

188

189

190

191

192

193

194

195

196 **NOTE TO THE READER**

197 Each chapter in this report begins with a summary of the chapter's main points.

198

199 *[This page intentionally left blank]*

200	TABLE OF CONTENTS	
201		
202	ACKNOWLEDGMENTS	3
203	ABSTRACT	4
204	TERMS OF REFERENCE.....	8
205	An introduction to access to health services in the European Union	9
206	1. Financial resources are linked to health need	25
207	1.1. Ensuring an adequate level of spending on health	25
208	1.2. Ensuring the distribution of spending meets regional health needs.....	30
209	2. Services are affordable for everyone.....	35
210	2.1. The rationale for public spending on health.....	36
211	2.2. Gaps in publicly financed health coverage	39
212	2.3. The role of VHI in addressing gaps in publicly financed coverage	41
213	3. Services are relevant, appropriate and cost-effective	51
214	4. Well-equipped facilities are within easy reach.....	59
215	5. There are enough health workers, with the right skills, in the right place	65
216	6. Quality medicines and medical devices are available at fair prices	71
217	6.1. Medicines	72
218	6.2. Medical devices	81
219	7. People can use services when they need them	85
220	8. Services are acceptable to everyone	93
221	Access for Roma, undocumented migrants and people with mental health problems	97
222	Ensuring equitable access: EU and Member State responsibilities and responses	109
223	Annex 1 Informal care and its impact on access to health services	123
224	Annex 2 Trends in unmet need for health care in each EU Member State.....	125
225	Annex 3 Indicators for monitoring access in Europe	139
226	LIST OF ABBREVIATIONS	143
227	REFERENCES	147
228		
229		
230		

231 **TERMS OF REFERENCE**

232

233 The Expert Panel on Effective ways of Investing in Health (EXPH) is requested to
234 give its views on options for action to improve equity of access to health services in
235 the EU. In particular, the Expert Panel is requested to provide its assessment on
236 the following points:

237

238

239 **1. Overall impact of poor access**

240

241 How do limitations and variations in access to health care affect EU health systems
242 and the broader economy?

243

244

245 **2. Measuring and monitoring**

246

247 Which groups of people are most likely to suffer from limited access to health care?
248 Can the Expert Panel provide a taxonomy of these groups, highlighting the main
249 mechanisms of exclusion? What can policy makers, professional and patients'
250 associations, and other stakeholders do to identify in a timely way problems in
251 access to health care, including those affecting the most vulnerable population
252 groups, and to reduce inequities in access to health services? Which monitoring
253 tools are already in place and which tools could be developed?

254

255

256 **3. Acceptable variations**

257

258 How can the limits of acceptable variation in health care access within and across
259 Member States be defined?

260

261

262 **4. Policy measures**

263

264 How can the main barriers to access be overcome? Which tools can be used to
265 tackle unmet need for health care and unwarranted variation? What role can the
266 financing of the system, legislative tools or best-practice sharing play? With regard
267 to this point, the opinion of the Expert Panel should focus on general policies and
268 actions which can be taken at health system and health service level. Additionally,
269 the Expert Panel is requested to reflect on how the added-value of EU action on
270 access to health care may be maximised.

271

272 **An introduction to access to health services in the European Union**

273

274 **Chapter summary**

275

276 Access is a critical component of universal health coverage. The 28 Member States
 277 of the European Union (EU) have a clear mandate to ensure equitable access to
 278 health services for everyone living in their countries. This does not mean making
 279 everything available to everyone at all times. Rather, it means addressing unmet
 280 need for health care by ensuring that the resources required to deliver relevant,
 281 appropriate and cost-effective health services are as closely matched to need as
 282 possible.

283


284 Survey data indicate that in 2013 around 18 million people living in the European
 285 Union experienced unmet need for health care (3.6% of the population). Between
 286 2005 and 2009, Member States made huge progress in improving access to health
 287 care: the number of people experiencing unmet need fell from 24 million in 2005
 288 (5%) to 15 million in 2009 (3%). This positive trend has been reversed since 2009
 289 – a very visible sign of the damage caused by the financial and economic crisis.

290

291

292 **Share (%) of the population reporting unmet need for health care due to**
 293 **cost, travel distance and waiting time, EU27, 2005-2013**

294



295

296

Source: Authors based on EU-SILC (2015)

297

298

Note: Lower secondary education refers to people who did not complete their secondary education.

299

300

301

302

303

304 Access is a multi-dimensional issue. Barriers to access can be found at the level of
305 individuals, health service providers and the health system. Access is also affected
306 by public policy beyond the health system – especially fiscal policy, but also social
307 protection, education, transport and regional development policy.

308
309 Survey data suggest that financial barriers to access are the largest single driver of
310 unmet need in the European Union. The figure above shows how unmet need
311 disproportionately affects people of lower socio-economic status, older people and
312 women and girls, although the precise composition of the worst-affected groups
313 varies across countries. The Annex provides details of unmet need by country and
314 over time for all 28 Member States.

315
316 If policy makers responsible for the health system are to avoid or overcome
317 barriers to access and to promote equity in service use, they need to take action in
318 many areas, as highlighted in the figure below. Policy responses should reflect the
319 multi-dimensional nature of access problems, the importance of intersectoral action
320 and the specifics of national and regional context.

321
322 The following chapters discuss these eight policy areas in turn, using a common
323 template. A further chapter focuses on issues and policy responses in relation to
324 three groups of people who are systematically underserved in the European Union:
325 Roma, undocumented migrants and people with mental health problems. A final
326 chapter discusses the roles and responsibilities of the European Union and its
327 Member States in ensuring equitable access to health services; focuses on the
328 need for a new generation of data collection for effective, accessible, resilient and
329 accountable health systems; summarises policy responses identified in previous
330 chapters; and comments on the challenges and opportunities these actions entail.

331
332
333 **Factors affecting equitable access to health services**
334



335
336
337 Source: Authors
338
339

340 **What is access?**

341

342 In 2006, the Council of Health Ministers in the European Union (EU) agreed
343 common values and principles for EU health systems: universality, access to good
344 quality care, equity and solidarity (OJEU 2006: 2). The Council defined these terms
345 as follows:

346

347 Universality means that no one is barred access to health care;
348 solidarity is closely linked to the financial arrangement of our national
349 health systems and the need to ensure accessibility to all; equity relates
350 to equal access according to need, regardless of ethnicity, gender, age,
351 social status or ability to pay.

352

353 Article 35 of the Charter of Fundamental Rights, which has been legally binding on
354 the European Union since 2009 (European Union 2010), states that:

355

356 Everyone has the right of access to preventive health care and the right
357 to benefit from medical treatment under the conditions established by
358 national laws and practices. A high level of human health protection
359 shall be ensured in the definition and implementation of all the Union's
360 policies and activities'.

361

362 These documents commit EU Member States to promote access to health services
363 by:

364

- 365 ▪ reducing the gap between a person's need for health care and their use of
366 health services; that is, addressing unmet need
- 367
- 368 ▪ ensuring people do not experience financial hardship when using health
369 services; having to pay for health care at a given point in time may mean
370 people do not have money to pay for other essentials or on health care in the
371 future
- 372
- 373 ▪ ensuring health services are provided in a way that is responsive to people's
374 needs and expectations; a poor user experience at a given point in time may
375 prevent people from using services in the future
- 376
- 377 ▪ ensuring health services are effective enough to improve health, because
378 access is instrumental to health improvement, and cost-effective, because
379 resources for health care are limited
- 380
- 381 ▪ ensuring equity in all of the above

382

383 Personal preferences may result in legitimate differences in demand and,
384 ultimately, use for a given level of need. For this reason, health systems generally
385 aim to promote equity of access to health services, as opposed to equity in the use
386 of health services.

387

388 Promoting equitable access to health care does not mean making everything
389 available to everyone at all times. Rather, it means addressing unmet need for
390 health care by ensuring that the resources required to deliver relevant, appropriate
391 and cost-effective health services – financial and human resources, facilities and
392 interventions – are as closely matched to need as possible. Access is a critical
393 component of universal health coverage (WHO 2010).

394

395 This report focuses on formal care, but the availability of informal care is an
396 important issue that deserves further policy attention (see Annex 1).

397 **Why does access matter?**

398
399 Access to health services should be a matter of concern for the European Union as
400 a whole, and for each of the Member States, for four main reasons. First, extensive
401 evidence shows how access to effective health care by those in need improves
402 health, prolongs life and prevents suffering. Health is therefore a major
403 determinant of welfare. We know, for example, that there have been substantial
404 reductions in deaths from causes amenable to health care in all Member States in
405 recent decades, although there are considerable differences in what each Member
406 State has achieved (Nolte and McKee 2011).

407
408 Second, there is also evidence that better health drives economic growth, greater
409 labour force participation and higher productivity (Figueras and McKee 2011). This
410 is recognised in the European Union’s inclusion of the theme ‘health is wealth’ in its
411 public health strategy, as well as the endorsement by all Member States in 2008 of
412 the World Health Organization’s Tallinn Charter (WHO 2008).

413
414 Third, persistent inequalities in health within the European Union (Mackenbach et
415 al 2008) conflict with the right to health enshrined in the Charter and with the EU
416 Treaty objective of ensuring ‘the development of human resources with a view to
417 lasting high employment and the combating of exclusion’ (European Union 2008).

418
419 Fourth, survey data routinely collected by the European Union provide evidence of
420 significant variation in unmet need for health care – a major indicator of lack of
421 access – across and within EU Member States. Inadequate access to needed health
422 services affects millions of people across the European Union. These numbers have
423 grown substantially since 2009.


424
425
426 **Evidence of variation in unmet need for health care**

427
428 Health need has been defined as the ability to benefit from health care. This
429 implies that there is information on the presence of a health problem and the
430 existence of a corresponding treatment. It also implies that there is a defined
431 threshold above which treatment is appropriate. In practice, this type of
432 information is not readily available outside surveys undertaken for research
433 purposes, such as those that have looked at the need for hip replacement (Wilcock
434 1979) or treatment for prostatic enlargement (Hunter et al 1995). Given the
435 challenges of undertaking such studies on a large scale, social surveys typically use
436 a question that seeks to elicit self-reported unmet need, asking respondents
437 whether they were unable to obtain health care when they believed it to be
438 medically necessary. The main source of such data within the European Union is
439 the European Union Survey on Income and Living Conditions (EU-SILC),
440 undertaken annually in all EU Member States since 2005 (see Arora et al 2015 for
441 an overview of this data source).

442
443 Figure I.1 shows how the level of self-reported unmet need for health care varies
444 across EU Member States. Most of these data are consistent with other evidence on
445 health system performance, but some are less easily explicable, such as the very
446 low figure for Slovenia. This suggests a need for caution when comparing across
447 countries and additional research to understand how the survey question is
448 understood by different people. The data do, however, present a useful picture of
449 changes over time. Data for each country can be found in Annex 2.

453
454
455

Figure I.1 Share (%) of people reporting unmet need for health care due to cost, travel distance and waiting time, EU28, 2008 and 2013




456
457
458
459
460
461
462

Source: Authors based on EU-SILC (2015)

Note: In Slovenia, in 2013, 0.1% of the population experienced unmet need for 'other reasons'.


463 Figures 1.2, 1.3 and 1.4 show how unmet differs among different groups of people.
 464 Poorer people experience much higher levels of unmet need than richer people.
 465 The gap between the richest and poorest quintiles had narrowed before the crisis,
 466 mainly due to a reduction in unmet need among the poorest quintile (3.5
 467 percentage points between 2005 and 2010), but began to grow again in 2011
 468 (Figure I.2). In comparison to the population as a whole, unmet need is also higher
 469 among unemployed people, older people, girls and women and people who did not
 470 complete their secondary education (Figure I.3).
 471

472 **Figure I.2 Share (%) of people reporting unmet need for health care due**
 473 **to cost, travel distance and waiting time by income group, EU27, 2005-**
 474 **2013**
 475



476
 477 Source: Authors based on EU-SILC (2015)
 478


479
 480 **Figure I.3 Share (%) of people reporting unmet need for health care due**
 481 **to cost, travel distance and waiting time by income, age, gender,**
 482 **education and employment status, EU27, 2005-2013**
 483



484
 485 Source: Authors based on EU-SILC (2015)
 486 Note: Lower secondary education refers to people who did not complete their
 487 secondary education.
 488

489 Figure I.4 shows how cost is by far the most important determinant of unmet need
 490 among poorer people. It is also the aspect of unmet need that has risen most
 491 sharply in recent years.
 492

493 **Figure I.4 Share (%) of people reporting unmet need for health care due**
 494 **to cost, travel distance, waiting time and lack of time, poorest and richest**
 495 **quintiles, EU27, 2005-2013**
 496
 497



498
 499 Source: Authors based on EU-SILC (2015)
 500
 501

502
 503 **The crisis has reversed a downward trend in unmet need**
 504

505 All of these figures indicate changes in unmet need over time. Between 2005 and
 506 2009, unmet need fell by two percentage points across the European Union as a
 507 whole, from 5.0% to 3.0%. From 2009, unmet need began to grow again, reaching
 508 3.6% in 2013. This notable change in trend coincided with the onset of the
 509 financial and economic crisis and the introduction of austerity measures in many
 510 countries, often including a reduction in public spending on health and other forms
 511 of social protection
 512

513 A recent study of the implications of rising unmet need looked at two
 514 counterfactual scenarios (Reeves et al 2015). The first was conservative, assuming
 515 that, in the absence of austerity measures, levels of unmet need would have
 516 plateaued after 2010, resulting in an additional 1.5 million people facing unmet
 517 need in 2013 in comparison to 2008. The second scenario assumed that unmet
 518 need would have continued to decline at the earlier rate, in which case the
 519 equivalent figure facing additional unmet need would be 7.3 million people. In both

520 scenarios, the increase in unmet need was approximately six times larger among
521 people in the poorest quintile compared to the richest quintile.

522
523 Several studies have documented health policy responses to the crisis in Europe
524 and the impact of the crisis on health and health systems (see, for example,
525 Stuckler and Basu 2013, Eurofound 2014, Lamata and Oñorbe 2014, Thomson et al
526 2014, Maresso et al 2015, Thomson et al 2015). Although there are still
527 unanswered questions about the mechanisms leading to rising unmet need, these
528 may include health system factors such as changes to entitlement to publicly
529 financed health services, higher user charges, the de-listing of some publicly
530 financed benefits, large and sustained cuts in public spending on health, the
531 closure of facilities and reduced opening hours. For example, public spending on
532 health per person was lower in 2013 than it had been in 2008 in eight EU Member
533 States (Croatia, Greece, Ireland, Italy, Latvia, Portugal, Spain and Slovenia); five
534 countries reported reducing entitlement to publicly financed health services for
535 relatively vulnerable groups of people in response to the crisis (Cyprus, the Czech
536 Republic, Ireland, Spain and Slovenia); and twelve countries reported increasing
537 user charges in response to the crisis (Thomson et al 2015).

538
539 Non-health systems factors are also highly likely to have played a part, especially
540 rising unemployment and reduced incomes. Table I.1 shows how the share of the
541 population at risk of poverty or social exclusion has increased steadily in the last
542 few years in every EU country except Poland.

543
544
545

Table I.1 The share (%) of the population at risk of poverty or social exclusion, EU28, 2005-2014

	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014
Germany	18.4	20.2	20.6	20.1	20.0	19.7	19.9	19.6	20.3	
Slovenia	18.5	17.1	17.1	18.5	17.1	18.3	19.3	19.6	20.4	
Malta	20.5	19.5	19.7	20.1	20.3	21.2	22.1	23.1	24.0	
Sweden	14.4	16.3	13.9	14.9	15.9	15.0	16.1	15.6	16.4	
Austria	17.4	17.8	16.7	20.6	19.1	18.9	19.2	18.5	18.8	19.2
Ireland	25.0	23.3	23.1	23.7	25.7	27.3	29.4	30.0	29.5	
Spain	24.3	24.0	23.3	24.5	24.7	26.1	26.7	27.2	27.3	29.2
Netherlands	16.7	16.0	15.7	14.9	15.1	15.1	15.7	15.0	15.9	
Luxembourg	17.3	16.5	15.9	15.5	17.8	17.1	16.8	18.4	19.0	
Denmark	17.2	16.7	16.8	16.3	17.6	18.3	18.9	19.0	18.9	
Cyprus	25.3	25.4	25.2	23.3	23.5	24.6	24.6	27.1	27.8	
Hungary	32.1	31.4	29.4	28.2	29.6	29.9	31.0	32.4	33.5	31.1
Lithuania	41.0	35.9	28.7	28.3	29.6	34.0	33.1	32.5	30.8	
Latvia	46.3	42.2	35.1	34.2	37.9	38.2	40.1	36.2	35.1	32.7
Bulgaria		61.3	60.7	44.8	46.2	49.2	49.1	49.3	48.0	
Czech Republic	19.6	18.0	15.8	15.3	14.0	14.4	15.3	15.4	14.6	
Slovakia	32.0	26.7	21.3	20.6	19.6	20.6	20.6	20.5	19.8	
Belgium	22.6	21.5	21.6	20.8	20.2	20.8	21.0	21.6	20.8	
United Kingdom	24.8	23.7	22.6	23.2	22.0	23.2	22.7	24.1	24.8	
EU27 average	25.7	25.3	24.4	23.8	23.3	23.6	24.2	24.7	24.5	
Greece	29.4	29.3	28.3	28.1	27.6	27.7	31.0	34.6	35.7	36.0
Estonia	25.9	22.0	22.0	21.8	23.4	21.7	23.1	23.4	23.5	
Italy	25.0	25.9	26.0	25.3	24.7	24.5	28.2	29.9	28.4	28.1
Portugal	26.1	25.0	25.0	26.0	24.9	25.3	24.4	25.3	27.5	
Romania			45.9	44.2	43.1	41.4	40.3	41.7	40.4	
Finland	17.2	17.1	17.4	17.4	16.9	16.9	17.9	17.2	16.0	17.3
France	18.9	18.8	19.0	18.5	18.5	19.2	19.3	19.1	18.1	
Poland	45.3	39.5	34.4	30.5	27.8	27.8	27.2	26.7	25.8	
Croatia						31.1	32.6	32.6	29.9	

546
547 Source: Authors based on Eurostat (2015)

548
549 Note: Green shading indicates the lowest share since 2005; red shading indicates an
550 increase in the share. Countries are ranked from 2005 to 2013 by the year in which the
551 share has been lowest since 2005.

552
553
554


What causes unmet need?

In 1971 Tudor Hart formulated the Inverse Care Law, which states that 'the availability of good medical care tends to vary inversely with the need for it in the population served' (Tudor Hart 1971). In other words, those with the greatest need for care often have the least access to it. This outcome has been attributed to the behaviour of providers – for example, Illich noted that 'doctors tend to gather where the climate is healthy and where patients can pay for their services' (Illich 1974). It can also be linked to the goals and content of public policy: 'to the extent that health care becomes a commodity it becomes distributed just like champagne ... Rich people gets lots of it, poor people don't get any of it' (Tudor Hart 1971).

Defining need: A prerequisite for health care use is that a person perceives a need for health care (felt need) and formulates a demand for help from the health system (expressed need) (Bradshaw 1972). Use can be triggered by individuals, by health professionals (through referral) and by the health system (through the implementation of screening programmes, for example). Need defined by experts is referred to as normative need. Standards for need may vary across experts (see chapter 3).

Barriers to using health services: Access is a multi-dimensional issue. Barriers that prevent individuals from using necessary health services may be found at different levels: individual people (potential users), health service providers, the health system and – more broadly – public policy in areas beyond the health system, as depicted in Figure I.5.

Figure I.5 The determinants of health service use



Source: Authors, based on Dahlgren and Whitehead (1991)

590 There are likely to be important interactions across these levels and over time. For
591 example, a person's experience of using health services at one point in time can
592 influence health care-seeking behaviour later on. In some instances, barriers may
593 be systematically experienced by an entire group of people, such as people from
594 ethnic minorities, undocumented migrants or people with disabilities. In other
595 instances, barriers will only be experienced by some people – perhaps those with
596 lower incomes or limited mobility.

597
598 Systematic reviews of barriers to effective care for hypertension have identified
599 barriers related to capability (communication skills or ability to recognise risk
600 factors) and intention (health beliefs and fatalism) at the level of health
601 professionals and patients, as well as health system barriers related to the cost and
602 availability of staff, equipment, referral networks and guidelines for treatment.

603
604 **Barriers at the level of individual people:** As noted above, whether or not
605 people feel and express need for health care can be influenced by a wide range of
606 personal characteristics, including beliefs about health, levels of health literacy,
607 coping and communication skills, other psychosocial factors and access to different
608 resources. As a result of differences in personal characteristics, two people with the
609 same 'objective' need may express need and use health services in different ways.

610
611 Health beliefs – people's views about the nature of their health problems, about
612 their ability to take care of problems themselves and the forms of help they regard
613 as appropriate – differ widely across and within social groups (O'Malley and Forrest
614 2002). Although the decision to use health services is an individual choice, this
615 choice is framed by social context (Bussing et al 2003). For example, in the Roma
616 culture the concept of *marime* (meaning polluted, defiled or unclean) is central to
617 their understanding of disease and death and explains why Roma may consider
618 hospitals as potentially dangerous places in which they are unable to adhere to
619 purity rules (Honer 2004). Similarly, higher socioeconomic groups often consider
620 health to be a value in itself, something to be sought and achieved, whereas lower
621 socioeconomic groups might view health from a utilitarian perspective –
622 particularly as a means of being able to work (Chamberlain and O'Neill 1998).

623
624 Health literacy refers to people's knowledge, motivation and competence to access,
625 understand, appraise and apply health information in order to make judgments and
626 take decisions about health care, disease prevention and health promotion to
627 maintain or improve quality of life throughout their lives (UNESCO 2010; Sorensen
628 2012). Low health literacy is linked to reduced safety of care due to medication
629 errors and poor adherence to medication and treatment, less use of preventive
630 care, more hospitalisation, worse health outcomes and greater risk of death
631 (Omachi et al 2013; IOM 2013; Parker and Ratzan 2010).

632
633 In addition to coping and communication skills (requesting information, giving
634 information and opinions and negotiating the system), need and use may be
635 influenced by other psychosocial factors such as self-determination, the time
636 perspective adopted (long-term focused on future gains versus short-term focused
637 on immediate survival), strength of belief in one's own ability to complete tasks
638 and reach goals (self-efficacy) (Bandura 1977), and preferences among competing
639 priorities such as health, food and shelter. Finally, health care use requires
640 recourse to financial resources and other resources such as a supportive social
641 network of family, friends and informal carers. The relevance of these different
642 factors is illustrated in the case of screening for breast cancer (Box I.1).

643
644
645

646 **Box I.1 Low participation of women from lower socioeconomic groups in**
647 **the national breast cancer screening program in Flanders (Belgium)**
648

649 In 2013, 76% of Flemish women in the target group for breast cancer screening
650 reported having had a mammogram in the last two years, ranging from 56%
651 among the least-educated women and 76% among the most-educated women
652 (Drieskens 2015). Physicians indicate that participation rates remain low even after
653 the importance of this screening programme has been explained to the least-
654 educated women. Qualitative research reveals a wide range of barriers to use
655 among this group, beyond knowledge or lack of information: fear of the outcome of
656 the examination, struggles in other areas of life requiring all the women's time and
657 energy and the lack of a supporting network. Outreach interventions tackling the
658 true causes of non-participation were the only ones able to increase the
659 participation rate (Willems 2005).

660
661 **Provider-level barriers:** Provider-level barriers relate to the size, composition
662 and socioeconomic and demographic characteristics of the health workforce, as
663 well as the knowledge, skills, preferences, perceptions attitudes and prejudices of
664 both patients and providers (Goddard and Smith 2001). Good provider-patient
665 communication is associated with better access to care, a higher level of patient
666 satisfaction, better compliance and better care outcomes (Verlinde et al 2012;
667 Bensing 1991; Jensen et al 2010). Sub-optimal doctor-patient relations may lead
668 to a negative experience for the patient, which can in turn become a potential
669 barrier to access in the future (Bensing 1991). The concept of cultural competence
670 encompasses interpersonal and organisational interventions and strategies that
671 enable health systems, agencies and health professionals to understand the needs
672 of diverse patient groups and facilitate the provision of culturally and linguistically
673 appropriate health services (Fortier and Bishop 2003).
674

675 **Health system-level barriers:** To avoid or overcome barriers to using health
676 services and to promote equitable access to health services, policy makers
677 responsible for the health system need to take action in many areas. Figure I.6
678 highlights common areas requiring policy attention. It provides a form of 'checklist'
679 to remind policy makers of the multiple factors that need to be considered when
680 thinking about access to health services. The specific actions needed to address
681 access problems will, of course, vary from one health system to another. These
682 eight policy areas are used to structure the report's discussion of access to
683 (formal) health services in the European Union.
684
685

686
687

Figure I.6 Factors affecting equitable access to health services



688
689
690
691

Source: Authors

692
693
694
695
696
697
698
699
700
701
702

The role of public policy beyond the health system: Non-health areas of public policy such as fiscal policy, social protection, education, transport and regional development (among others) can have an important effect on access to health services. Sometimes the relationship between access to health care and other areas of public policy is direct – for example, where changes in labour market, pension or other non-health benefits affect entitlement to publicly financed health services, or where changes in transport policy affect people’s ability to travel to health facilities. Often, however, the relationship may be more indirect, with changes in public policy affecting socioeconomic status leading to knock-on effects on health status and ability to use health services.

703
704
705
706
707
708
709
710
711
712

Interaction between users, providers, the health system and other areas of public policy: Access barriers are rarely attributable simply to the user, the provider or the health system alone but rather to the lack of alignment between these different levels. Health literacy, for example, is the result of a mismatch between a person’s ability to understand health information and the provider or health system response (Parker and Ratzan 2010). Tackling the negative effects of inadequate health literacy therefore requires a double approach: helping patients to make well-informed decisions and at the same time reducing the complexity of the health system (Parker and Ratzan 2010, IOM 2013).

713
714
715
716
717

Addressing financial barriers to access is another example of the need for awareness of interactions across levels and a multidimensional and intersectoral approach. Financial barriers may be related to an individual’s income, provider attitudes, health system policy regarding the three dimensions of coverage depicted in Figure I.7 (population entitlement, the benefits package and user


718 charges) and broader public policy. Changes at each level can create or exacerbate
719 financial barriers to access at the level of individual people. For example, in
720 countries where fiscal policy promotes greater rich-poor redistribution and
721 pensioners enjoy a standard of living similar to the rest of the population, user
722 charges may not create financial barriers to access or result in income-related
723 inequalities in use.

724

725 An important implication is that policy responses to access to health care should
726 reflect the multidimensional nature of access problems, the need for intersectoral
727 action and the specifics of national or local context.

728

729 **Figure I.7 The three dimensions of health coverage**



730

731 Source: Adapted from WHO (2010)

732


733 Note: In almost every country in the world, the vast majority of pooled funds are public –
734 that is, they are generated through compulsory forms of pre-payment (the government
735 budget or contributions earmarked for health). Quality of care and timely access to care are
736 included under 'services'. Where services provided through pooled funds are not provided in
737 a timely way or are of poor quality, some people may pay out-of-pocket for alternatives.

738

739 Figure I.8 shows where access barriers can occur and how different scenarios may
740 lead to non-use, use and overuse. In the first scenario, people do not face any
741 barriers to access. In the second, they do not perceive their condition to be a
742 problem, perhaps due to health norms in their social context or low health literacy.
743 In the third, people feel a need for health care but are unable to express it due to
744 low health literacy or fear and anxiety. In the fourth, people express need but
745 experience barriers when interacting with the provider or due to the way in which
746 the health facility is organised (for example, limited opening hours). In the fifth,
747 people express need but experience barriers in the organisation of the health
748 system (for example, the system requires registration prior to consultation). In the
749 sixth, people do not feel a need for health care, and experts would agree, but are
750 encouraged by something they saw on television or read on the Internet to seek
751 non-evidence-based treatment, resulting in overuse. In the seventh scenario,
752 people do not feel a need for health care, and experts would agree, but the
753 organisation of the health system induces care (for example, a patient undergoes
754 duplicate diagnostic tests due to the absence of any (electronic) medical record of
755 treatment), resulting in overuse.

756
757
758
759
760
761
762

Figure I.8 Barriers to access and the use, non-use or overuse of health services



769
770
771
772

Source: Authors

773
774

European efforts to monitor access

775
776
777
778
779
780
781
782
783
784

Since the mid-1980s countries and international organisations have invested in tools to monitor population health status and its determinants. The scope of these tools has expanded over time to include dimensions relating to access to health services and quality of care. In 1998, the European Union established a pan-European health monitoring system (Box I.2) and a programme to define and collect a core set of indicators to generate evidence for the implementation of its Health Strategy. The development of these indicators built on the earlier experience of the OECD and the WHO Regional Office for Europe in international data collection and reporting.

785
786
787
788
789
790
791
792

The production of EU-wide statistics is regulated under a multi-year programme and achieved through close collaboration between Eurostat (the EU Statistical Authority), national statistical authorities designated by the Member States, the OECD and WHO. The results of this joint effort constitute the backbone of an online database (Eurostat), which provides data on a relatively comprehensive set of indicators. A significant number of the European Core Health Indicators are based on data collected by Eurostat (see Box I.2). Only a few relate to health services, most of which describe inputs, such as the number of health professionals or

793 hospital beds. Data on unmet need are reported using figures from EU-SILC. They
 794 also include data on the numbers of certain procedures undertaken, although in
 795 most cases the most recent figures are from 2010 or earlier. Moreover, given the
 796 many challenges involved in collecting data from all providers, public and private,
 797 there must be many questions about the validity of the information. Technical and
 798 strategic direction is determined through consultation with the Expert Group on
 799 Health Information (delegates from Member States), which works with the
 800 Commission (mainly DG Santé).

801
 802
 803

Box I.2 The European Core Health Indicators

The European Core Health Indicators (ECHI) are a list of 88 health indicators classified in five areas:

- demography and socio-economic situation
- health status
- determinants of health
- health services
- health promotion

The indicators are selected based on policy relevance and potential policy impact at EU and Member State level and on the magnitude of the public health problems considered. They are usually drawn from existing databases such as Eurostat, the WHO health for all database and OECD health data.

The following indicators are relevant to monitoring access to health services:

- expenditure on health
- insurance coverage
- hospital beds; practising physicians; practising nurses; MRI units and CT scans
- timing of first antenatal visit among pregnant women; patient mobility; waiting times for elective surgeries; equity in unmet need for health care (13 sub-indicators by gender, age, income, educational attainment and labour market status)
- vaccination coverage in children; influenza vaccination rate among older people; breast cancer screening; cervical cancer screening; colon cancer screening; cancer survival rates; 30-day in-hospital case-fatality for acute myocardial infarction and ischaemic stroke; surgical wound infections; cancer treatment quality; diabetes control

804
 805
 806
 807
 808

Source: http://ec.europa.eu/health/indicators/echi/list/index_en.htm

Table I.2 Sources of data collected at EU level

Data routinely provided by national statistical authorities
OECD/Eurostat/WHO-Europe joint questionnaire on non-monetary health care statistics (data on human and technical resources for health) and joint questionnaire on health accounts (data on health expenditure by function)
Data routinely obtained through nationally representative surveys
EU Survey on Income and Living Conditions (EU-SILC)
European Health Interview Survey (EHIS)
Non-routine EU-supported sources of data
PHAMEU: designed to establish an information and knowledge system on the state and development of primary care in Europe, including access to primary care
QUALICOPC: designed to investigate primary care costs, quality and access in 31 countries

809
 810

Source: Authors

811 **About this report**

812

813 This report builds on previous studies of access to health care in high-income
814 countries (see, for example, Gulliford and Morgan 2003 and Healy and McKee
815 2004). It aims to highlight key issues in promoting access to health care in EU
816 health systems and includes a focus on access issues among underserved groups
817 of people.

818

819 The report is structured around the eight policy areas identified in Figure I.6. The
820 next eight chapters discuss each of these policy areas in turn, using a common
821 template. Each chapter begins with an overview of common access problems then
822 reviews the range of tools used to monitor effects on access; comments on data
823 availability at EU level; presents evidence of variation in access across and within
824 countries; notes whether specific groups of people are systematically
825 disadvantaged; and highlights key policy actions to promote equitable access.
826 Where possible, we include examples of good practice from EU Member States.
827 This set of eight chapters is meant to be succinct and illustrative rather than
828 exhaustive.

829

830 A further chapter focuses on issues and policy responses in relation to three groups
831 of people who are systematically underserved in the European Union: Roma,
832 undocumented migrants and people with mental health problems.

833

834 A final chapter discusses the roles and responsibilities of the European Union and
835 its Member States in ensuring equitable access to health services; focuses on the
836 need for a new generation of data collection for effective, accessible, resilient and
837 accountable health systems; summarises policy responses identified in previous
838 chapters; and comments on the challenges and opportunities these actions entail.

839

840 Annex 1 briefly discusses the issue of informal care.

841

842 Annex 2 presents data on unmet need across time and across different groups of
843 people by country for all 28 EU Member States.

844

845 Annex 3 lists access-related indicators that are routinely collected by Eurostat, the
846 OECD or the WHO Regional Office for Europe.

847

848 Every chapter in the report begins with a one-page summary of the chapter's main
849 points.

850

851 **1. Financial resources are linked to health need**

852
853 **Chapter summary**

854
855 Health needs vary across and within countries. Financial resources for the health
856 system should reflect a country's health needs at national and sub-national levels.
857 Failing to match financial resources to need will result in unequal access to health
858 care and is likely to lead to inequalities in the use of health services. It is also
859 inefficient: if some people in need of health care are not able to use services while
860 others are using too much relative to their need, the ensuing mismatch wastes
861 resources. Across and within EU Member States, financial resources for health care
862 vary in ways that are unrelated to health needs.

863
864 The mismatch between need for health care and ability to pay means that
865 collective, public spending, incorporating a degree of redistribution, is essential to
866 ensure equitable access to health. In 2013, public spending on health varied from a
867 low of 3.4% of GDP in Cyprus to a high of 10.3% of GDP in the Netherlands, with a
868 median of 6.1%. The health share of the government budget (total public
869 spending) ranged from 7.5% in Cyprus to 20.7% in the Netherlands, with a median
870 of 13.5%.

871
872 To ensure an adequate level of spending on health:

- 873
874 ▪ All countries should link the availability of public funding for health to
875 population health needs. This is especially important during economic
876 downturns, when funds may decline but needs are likely to increase.
877
878 ▪ Countries with low levels of public spending on health should allocate a higher
879 share of the government budget to the health sector.
880
881 ▪ Countries should ensure that public funding is used effectively, rather than
882 simply driving up the prices of technology or highly specialised staff.
883

884 Evidence from several countries suggests that the relationship between regional
885 health needs and levels of public spending on health is imperfect, even in countries
886 that have developed needs-based resource allocation formulas.

887
888 To ensure the distribution of spending meets regional health needs:

- 889
890 ▪ Countries should introduce and improve sub-national resource allocation
891 formulas, building on the long experience of developing formulas in countries
892 such as England and Sweden. Provider payment should not be based primarily
893 on inputs and should be for population health needs and provider performance.
894
895 ▪ The European Union can facilitate this by routinely collecting data on sub-
896 national health care expenditure patterns; identifying regions and groups in
897 particular need of additional public spending on health; ensuring unmet need is
898 accounted for in country-specific recommendations made as part of the
899 European Semester; and helping countries develop secure systems of record
900 linkage, including unique patient identifiers.

901 **1.1. Ensuring an adequate level of spending on health**

902
903 There is little evidence to suggest that governments of EU Member States explicitly
904 link the availability of public funding for health to population needs and the
905 contents of the publicly financed benefits package. Although all EU Member States
906 carry out long-term forecasts of current and future health care spending, very few

907 report using forecasts to define an overall budget for the health system (OECD
908 budget survey 2014). Linking public funding to health need is especially important
909 when the economy is shrinking (see Box 1.1).

910
911 Inadequate public funding for the health system creates and exacerbates barriers
912 to access. Private spending through voluntary health insurance (VHI) and out-of-
913 pocket payments is sometimes seen as a way to make up for public shortfalls.
914 However, private spending on health is far from a perfect substitute for public
915 spending. Out-of-pocket payments place an undue burden on poorer households
916 and undermine financial protection, potentially leading to access problems (see
917 chapter 2). Both OOPs and VHI can undermine equity of access by skewing the
918 distribution of health spending in favour of richer people, sometimes at the
919 expense of poorer, sicker and older people (see Box 1.2). They are usually more
920 expensive to collect than funding raised from taxation and social insurance. The
921 extent to which this is a concern for public policy will vary across countries.

922
923 **Box 1.1 Economic downturns call for more – not less – public social**
924 **spending**

925
926 The financial and economic crisis has drawn attention to the need for
927 countercyclical (as opposed to pro-cyclical) public social spending, including public
928 spending on health. Linking the availability of public funding for health to
929 population health needs is especially important during economic downturns. First,
930 at such times, health needs can increase, reflecting the health consequences of job
931 loss and cuts to the social sector. Second, health expenditure can, to some extent,
932 act as an automatic stabiliser, increasing demand in the economy, especially where
933 the money is used to increase employment among low-paid workers. Third, health
934 expenditure has a positive impact on economic growth, with a fiscal multiplier
935 effect of three or more (Reeves et al 2013).

936 Cyclicity in public spending on health can occur regardless of the nature of
937 public funding for the health system – whether the health system is funded
938 through direct transfers from the government budget or via earmarked
939 contributions is not important in this respect.

940 A survey of policy responses to the economic crisis in Europe shows how,
941 during the crisis, some EU countries benefited from automatic stabilisers such as
942 health insurance reserves and formulas for government budget transfers to the
943 health insurance system, while others struggled because means-tested entitlement
944 was not automatically linked to additional public funding (Thomson et al 2015).¹
945 Although the largest annual reductions in public spending on health occurred as a
946 result of government decisions (for example, in Greece, Ireland, Latvia and
947 Portugal), as opposed to due to reductions in employment-based revenue, this
948 largely reflected the magnitude of the economic shock, including external
949 intervention through EU-IMF economic adjustment programmes. It also reflected
950 the absence of automatic stabilisers: Greece had no reserves or countercyclical
951 formulas to compensate the health insurance system for falling revenue from
952 payroll taxes, and Ireland had no countercyclical formula to cover a huge increase
953 in the share of the population entitled to means-tested benefits (Thomson et al
954 2015).

955 Overall, just over half of all EU Member States demonstrated pro-cyclical
956 patterns of public spending on health between 2008 and 2013, bucking a global
957 trend in which pro-cyclical social spending has historically been the preserve of
958 low-income countries and countries with weak institutions (Velenyi and Smitz
959 2014).

960

¹ Some automatic stabilisers have the added advantage of helping to moderate growth in public spending on health when the economy is expanding.

Box 1.2 Private spending often undermines equitable access to health care

Richer households usually spend much higher absolute amounts out-of-pocket than poorer households and are much more likely than poorer households to be covered by VHI (OECD 2004, Thomson and Mossialos 2009, Sagan and Thomson 2015). Consistent evidence shows how user charges disproportionately negatively affect access, adherence to medication, cost-effective patterns of use and health outcomes among poorer people (Swartz 2010), even where the poor benefit from reduced user charges or exemptions. VHI not only disproportionately benefits richer people but can sometimes make people who rely on publicly financed services worse off – for example, where doctors have incentives to prioritise treatment of privately financed patients, leading to longer waiting times for publicly financed patients (OECD 2004, Thomson and Mossialos 2009). Tax subsidies for VHI, which also often disproportionately benefit richer people, are not usually a cost-effective use of public revenue.

Tools for monitoring and evidence of variation


Data on national levels of public (and private) spending on health are routinely available from Eurostat, but with a 15-month delay – for example, internationally comparable data for 2013 became available in April 2015.

There is no international standard for the 'right' level of public spending on health, nor any single measure that indicates whether or not public spending levels are adequate to meet population health needs. Such an assessment calls, instead, for a combination of political and technical judgements based on a range of factors and making trade-offs where appropriate between competing goals. Factors to be considered include: historic levels of spending on health (for example, whether there is a backlog of requirements for capital spending); indicators of health system performance, because how available resources are spent is important, not just the absolute amount; the socioeconomic and health context; the fiscal context, including levels of tax fraud; the value of public spending in different sectors; and political values and societal preferences. International comparisons are further complicated by differences in national income, which influences the fiscal space within which decisions are made, political decisions on raising tax revenues, differences in the cost of inputs and differences in price.

Having said that, a low level of public spending on health is likely to lead to access problems. International analysis shows how out-of-pocket payments fall as a share of total spending on health as public spending rises (see Figure 2.1 in chapter 2). There is also some correlation between public spending on health and the levels of unmet need shown in Figure I.1, although there are notable outliers such as France, which has relatively high levels of unmet need and a very high level of public spending on health.

Figure 1.1 shows the extent of variation in public and private spending on health as a share of GDP in EU Member States. Public spending on health ranges from a low of 3.4% of GDP in Cyprus to a high of 10.3% in the Netherlands, with a median of 6.1%. Differences in levels of total spending on health across EU Member States are strongly associated with levels of public spending on health ($R^2 = 0.86$) – in other words, countries that spend a higher share of GDP on health publicly are also likely to spend more on health overall.

1016 **Figure 1.1 Spending on health as a share (%) of GDP, EU28, 2013**



1017
1018 Source: WHO (2015)


1019
1020 Note: Countries ranked from low to high by public spending on health as a share of GDP.

1021
1022
1023 Public spending on health as a share of GDP is a function of the size of government
1024 (tax revenue as a share of GDP) and the 'priority' given to the health sector in
1025 decisions about how to allocate the government budget. Some EU countries
1026 allocate around 20% of the government budget to the health sector (Germany and
1027 the Netherlands), while others do not even allocate 10% (Cyprus and Latvia)
1028 (Figure 1.2).

1029
1030

1031
1032
1033

Figure 1.2 Public spending on health as a share (%) of total government spending, EU28, 2013



1034
1035
1036
1037

Source: WHO (2015)

Policy responses

1038

1039

1040

To ensure an adequate level of spending on health:

1041

1042

1043

1044

1045

1046

1047

1048

1049

1050

1051

1052

1053

1054

1055

1056

1057

1058

- All countries should link the availability of public funding for health to population health needs. This is especially important during economic downturns.
- Countries can also establish mechanisms in which health financing acts as an automatic stabiliser to address fluctuation in need (changes in population size, age structure and health need) and revenue (changes in unemployment, wages and tax revenue).
- Countries with low levels of public spending on health should allocate a higher share of the government budget to the health sector.
- It is important for public funding to be used effectively, rather than simply driving up the prices of resources whose supply is constrained, such as technology or highly specialised staff.

1059 **1.2. Ensuring the distribution of spending meets regional health needs**

1060
1061 To ensure equity of access, countries need to match the allocation of health system
1062 resources to variation in health need across regions. Regions with higher health
1063 need (lower health status and higher unmet need) should benefit from higher
1064 levels of per capita public spending on health. This may be more difficult to achieve
1065 where public revenue collection is decentralised, contribution rates vary across the
1066 country and there are no mechanisms for the (re)allocation of public funds across
1067 the country. It can also be difficult where (re)allocation mechanisms are weak – for
1068 example, they are based on inputs such as the number of beds, they do not adjust
1069 for health risk or they only include crude health risk adjusters (age and sex). The
1070 methods used to pay health care providers or to set priorities for health system
1071 sub-sectors and health care interventions often play an important in linking
1072 resources to need.

1073

1074

1075 **Tools for monitoring and evidence of variation**

1076


1077 To understand the distribution of health spending within a country, it is useful to
1078 compare levels of per capita spending on health by region and to note differences
1079 between richer and poorer regions and differences in health status. Regional
1080 expenditure data are not routinely available at EU level. Qualitative analysis of
1081 resource allocation processes from national to sub-national level is therefore
1082 important in identifying potential access problems, although it is not sufficient for
1083 monitoring.

1084

1085 National data indicate a degree of regional variation that is not linked to need. For
1086 example, data from Spain show there is little relationship between a region's level
1087 of wealth, level of disability and level of public spending on health (Figure 1.3).
1088 While Spain has a formula for allocating resources for public services in a way that
1089 is intended to reflect regional needs (Table 1.1), its health spending patterns
1090 suggest the formula does not adequately reflect regional health needs.

1091

1092 **Figure 1.3 GDP, disability and public spending on health across regions in**
 1093 **Spain, 2013**
 1094



1095 ■ Public spending on health per person ● GDP per person ■ Disability level
 1096 Source: Ministry of Health of Spain (2015), Eurostat (2015)
 1097 Note: Regions ranked from low to high by size of GDP per person and extent of disability
 1098
 1099
 1100 **Table 1.1 Variables used to allocate resources for public services (health,**
 1101 **education and social services) to regions in Spain, 2015**
 1102

Variable	Weighting
Protected population in seven age groups	38.0%
Population size	30.0%
Population aged between 0 and 16	20.5%
Population aged over 65	8.5%
Geographical size of region	1.8%
Distribution of the population across the region	0.6%
Insularity of the region (for example, being an island)	0.6%
Total	100.0%

1103 Source: Ministry of Economy of Spain [http://www.minhap.gob.es/en-](http://www.minhap.gob.es/en-GB/Areas%20Tematicas/Financiacion%20Autonomica/Paginas/Regimen%20comun.aspx)
 1104 [GB/Areas%20Tematicas/Financiacion%20Autonomica/Paginas/Regimen%20comun](http://www.minhap.gob.es/en-GB/Areas%20Tematicas/Financiacion%20Autonomica/Paginas/Regimen%20comun.aspx)
 1105 [.aspx](http://www.minhap.gob.es/en-GB/Areas%20Tematicas/Financiacion%20Autonomica/Paginas/Regimen%20comun.aspx)
 1106

1107
 1108 **Policy responses**

1109 Many EU Member States have already moved away from historical resource
 1110 allocation based on health system inputs (beds, health workers) and other line
 1111 items. To strengthen resource allocation mechanisms, countries should aim to link
 1112 national and sub-national health budgets to objective measures of population
 1113 health need and its determinants, including geographical deprivation. This requires
 1114 going beyond the use of demographic factors (population size, age structure and
 1115 sex). Some countries are also trying to move away from simply reimbursing health
 1116

1117 care provider costs (retrospective payment) towards the use of prospective
1118 payment, including payment linked to objective measures of performance.

1119

1120 Needs-based resource allocation presents different challenges in different contexts.
1121 In a handful of EU countries (for example, Cyprus), it requires reform of public
1122 financial management rules, so that resources do not need to be linked to inputs.
1123 In health systems with competing purchasers (the Czech Republic, Germany, the
1124 Netherlands and Slovakia), it requires access to highly sophisticated, unified
1125 databases. Very few countries currently have the capacity to engage in record
1126 linkage within the health sector or across different social sectors. For example,
1127 many do not yet use unique patient identifiers. Needs-based resource allocation to
1128 regions is easier to achieve, from an information perspective, although
1129 implementation may be challenging for political reasons, as the UK experience
1130 shows (see Box 1.3, Figure 1.4 and Figure 1.5).

1131

1132 The European Union can facilitate this by routinely collecting data on sub-national
1133 health care expenditure patterns; identifying regions in particular need of
1134 additional public spending on health; ensuring unmet need is accounted for in
1135 country-specific recommendations made as part of the European Semester; and
1136 helping countries develop secure systems of record linkage, including unique
1137 patient identifiers.

1138

1139

1140 **Box 1.3 Resource allocation for health in England: the politics of**
1141 **redistribution**

1142

1143 England first developed a regional resource allocation formula in the 1970s, in
1144 response to concerns about unequal access to health care identified by Julian Tudor
1145 Hart and others. The formula is still in use today. It is based on clear principles
1146 that are the result of compromise between what is technically sound and what is
1147 politically feasible:

- 1148 ▪ a target allocation for each region
- 1149 ▪ allocations reflecting population size and health need – ‘weighted capitation’
- 1150 ▪ the formula is defined by independent technical experts
- 1151 ▪ the speed at which target allocations should be reached – the ‘pace of change’
- 1152 – is determined based on political judgement
- 1153 ▪ the formula aims to promote equal access to health care for people at equal
- 1154 risk of ill health
- 1155 ▪ it also aims to reduce avoidable inequalities in health – areas with higher unmet
- 1156 need should receive more funds (a principle introduced by a Labour
- 1157 government in the 1990s)

1158

1159 The formula adjusts for a wide range of factors to reflect not only health needs but
1160 also unavoidable regional differences in the costs of providing health services, such
1161 as wage levels and cross-boundary patient flows. Over time, the formula has been
1162 extended to apply to GP and prescribing services as well as hospitals. The
1163 complexity of the formula is shown in Figure 1.4.

1164

1165 From the outset, the formula revealed a large difference between what regions
1166 were getting and what they should have been getting. This raised a technical
1167 challenge: how quickly could regions adjust to potentially large changes in funding
1168 (increases and reductions)? It also raised a political one: the creation of regional
1169 ‘winners’ and ‘losers’. The solution was to allow target allocations to be met over a
1170 period of time, at a pace to be determined by politicians. What this has meant in
1171 practice is, first, that the formula has always been applied in a way that does not
1172 take funds away from regions and, second, that the amount of money available for
1173 reallocation is quite small. As a result, under-funded areas have never actually
1174 caught up. What is more, the rate of catch-up is slower when the NHS budget is
1175 stable or falling, leading to pro-cyclical allocations that systematically disadvantage
1176 more deprived regions. Figure 1.5 shows the difference between target and actual
1177 allocations in 2011/2012.

1178

1179 The formula was changed by the Conservative-Liberal Democrat coalition
1180 government of 2010-2015, which reduced the weight given to health inequalities
1181 from 15% to 10%. While this makes a significant difference in target allocations, it
1182 has not yet had much impact in practice given the overall squeeze on NHS funding
1183 in recent years. As NHS funding begins to rise, however, the change in formula will
1184 shift resources away from more deprived areas to more affluent areas.

1185


1186 The English experience clearly demonstrates how a technically robust formula
1187 determined by independent experts can be watered down in implementation to
1188 reflect political priorities.

1189

1190 Source: Buck and Dixon (2013)


1191

1192 **Figure 1.4 The weighted capitation formula used to allocate health care**
 1193 **resources in England and its effect in one region, 2009-2011**
 1194



1195
 1196
 1197 Source: Buck and Dixon (2013)
 1198 Note: HCHS = hospital services; PMS = GP services
 1199

1200 **Figure 1.5 Target vs actual allocations by region in England, 2011-2012**
 1201



1202
 1203
 1204 Source: Buck and Dixon (2013)
 1205 Note: SHA = strategic health authority
 1206
 1207

1208 **2. Services are affordable for everyone**

1209

1210 **Chapter summary**

1211

1212 People should not be prevented from using necessary health services because the
1213 costs associated with use are too high. Financial barriers to access can be caused
1214 by a wide range of factors at individual, provider and health system levels,
1215 including factors beyond the health system – for example, the adequacy of
1216 pensions and unemployment benefits or the cost of transport. Affordability issues
1217 most commonly arise where public spending is low as a share of total spending on
1218 health and where there are gaps in the breadth, scope and depth of publicly
1219 financed coverage. As a result of these gaps people have to buy voluntary health
1220 insurance or pay out-of-pocket or – if they cannot afford these options – rely on
1221 health services provided by NGOs.

1222

1223 Lack of affordability is the single most important factor behind self-reported unmet
1224 need in EU countries. In 2013, 12 million people experienced unmet need due to
1225 cost (2.4% of the EU population), which was a particular problem among older
1226 inactive people, unemployed people, retired people, the poorest 40% of the
1227 population, people aged over 75, people with lower educational status and women
1228 and girls. EU-level data mask important differences across countries. While older
1229 people have very good access to health care in many countries, they experience
1230 much higher levels of unmet need due to cost than the general population in
1231 Poland, Bulgaria, Italy, Greece, Latvia and Romania.

1232

1233 To ensure affordable access (see Box 2.4 also) countries should:

1234 ▪ Ensure most spending on health comes from collective public rather than
1235 private sources.

1236 ▪ Ensure out-of-pocket payments are as low as possible. The incidence of
1237 catastrophic and impoverishing spending on health rises as the out-of-pocket
1238 share of total spending on health rises.

1239 ▪ Identify and close gaps in publicly financed coverage of cost-effective services.

1240 ▪ Broaden the basis for entitlement to encompass everyone living in a country,
1241 regardless of legal status.

1242 ▪ Eschew discriminatory approaches such as entitlement linked to employment
1243 status and payment of contributions or situations in which people with different
1244 diagnoses are entitled to different benefits ('inequity by disease').

1245 ▪ Reduce or eliminate user charges so that they do not create financial barriers to
1246 cost-effective services or undermine financial protection.

1247 ▪ Ensure efficiency in spending public resources, paying attention to the scope of
1248 the benefits package, prioritising cost-effective health services, including
1249 elements of performance in provider payment and developing appropriate
1250 pricing strategies.

1251 ▪ Eliminate informal payments using a mix of policy instruments.

1252 ▪ Outside the health sector, fiscal social protection policies are critical to
1253 addressing poverty and income inequality.

1254 The European Union can adapt EU-SILC, its main source of comparable data, to
1255 include proxy measures of financial hardship; require countries to carry out
1256 household budget surveys more regularly; and ensure these surveys use a robust,
1257 standardised, extended health module to enable better estimation of financial
1258 hardship.

1259 **2.1. The rationale for public spending on health**

1260

1261 Need for health care varies widely across the population and both need and health
1262 care are characterised by uncertainty – people cannot always tell if or when they
1263 will become ill, how severe their illness may be or how much their treatment will
1264 cost. Because of this uncertainty, out-of-pocket payments, savings and voluntary
1265 health insurance are relatively inefficient forms of health care financing.

1266

1267 Over the course of the 20th century, compulsory health insurance – pre-payment
1268 with risk pooling, publicly financed through the government budget or via
1269 earmarked contributions (often payroll taxes) – developed and spread to cover
1270 most people in EU countries. During this time the ability of the health system to
1271 prevent, detect and treat acute conditions and chronic disease also grew
1272 exponentially, placing treatment in hospitals and through new and expensive
1273 medicines beyond the financial reach of many people and reinforcing the need for
1274 redistributive financing mechanisms on efficiency and equity grounds (see Box
1275 3.1).

1276

1277 **Box 3.1 The principles underpinning affordable access to health care**

1278

1279 Promoting affordable access to health care for the whole population is regarded as
1280 a predominantly social responsibility in the European Union. The common values
1281 for EU health systems agreed by the Council of Health Ministers in 2006 imply that
1282 revenue for the health system should be raised in line with three closely related
1283 principles (OJEU 2006: 2):

- 1284 ▪ access to health care based on need rather than ability to pay
- 1285 ▪ solidarity in the form of redistribution from healthy to sick, richer to poorer,
1286 active to non-active, younger to older
- 1287 ▪ equity in financing, meaning that payment for health care should be
1288 proportionate to income (all people pay the same share of income) or
1289 progressive (richer people pay a higher share of income than poorer people)
1290 and should not be regressive (poorer people pay a higher share of income than
1291 richer people)

1292

1293 The degree to which these principles are upheld varies across countries, but the
1294 principles themselves are broadly accepted and often explicitly stated in national
1295 health documents. Nevertheless, they are not inviolable. In future they may come
1296 under challenge as progressive 19th and 20th century movements to establish
1297 human rights, rights for workers and social cohesion in the wake of the industrial
1298 revolution and two world wars fade from public consciousness. The institutions of
1299 the new global economy also increasingly enable the richest people to avoid and
1300 evade taxes, placing ever greater responsibility for financing public benefits such
1301 as pensions, education and health care on the middle classes.

1302

1303 Affordability issues most commonly arise where there are gaps in publicly financed
1304 health coverage – for example, where people lack entitlement to publicly financed
1305 health coverage, the benefits package excludes needed services or user charges
1306 are imposed (see below). Gaps in publicly financed health coverage mean people
1307 have to purchase voluntary health insurance (VHI) or pay out-of-pocket. If they
1308 cannot afford either of these options, they will have to rely on health services
1309 provided by charitable (non-governmental) organisations (NGOs).


1310

1311 Promoting affordable access to health care requires keeping out-of-pocket
1312 payments as low as possible. Figure 2.1 shows the extent of the relationship
1313 between levels of public spending on health and levels of out-of-pocket payments
1314 in the European Union. To reduce out-of-pocket payments, countries will need to


1315 ensure first, that a large majority of total funding for the health system comes
 1316 from public sources and second, that the level of public funding is adequate (see
 1317 chapter 1). How public revenues for health are spent is also important.

1318
 1319
 1320
 1321

Figure 2.1 Relationship between out-of-pocket payments and public spending on health, EU28, 2013



1322




1323
 1324
 1325
 1326

Source: Authors based on WHO (2015)
 Note: OOPs = out-of-pocket payments


1327 Levels of public spending on health vary substantially across EU Member States,
 1328 both as a share of GDP (see Figure 1.1) and as a share of total spending on health
 1329 (Figure 2.2). The out-of-pocket share of total spending on health also varies,
 1330 ranging from under 10% in France, the Netherlands and the United Kingdom to
 1331 over 35% in Latvia, Bulgaria and Cyprus (Figure 2.3).
 1332

1333 **Figure 2.2 Public as a share (%) of total spending on health, EU28, 2013**
 1334



1335 Source: WHO (2015)

1336 **Figure 2.3 OOPs as a share (%) of total spending on health, EU28, 2013**
 1337
 1338
 1339



1340 Source: WHO (2015)

1341
 1342

2.2. Gaps in publicly financed health coverage

Policies on health coverage play a key role in ensuring affordable access to health care. Health coverage has three dimensions (see Figure I.7). Gaps in the breadth, scope or depth of publicly financed health coverage are a major source of affordability problems. These gaps mean people have to buy voluntary health insurance (VHI) or pay out-of-pocket or – if they cannot afford these options – rely on health services provided by charitable (non-governmental) organisations (NGOs).

Population entitlement: In the last twenty years the share of the population entitled to publicly financed health services has grown where coverage was not already universal. Entitlement is now increasingly based on residence rather than more restrictive categories such as citizenship or employment status (see Box 2.2). However, entitlement for migrant workers from countries outside the EU and undocumented migrants is often extremely limited (see Table 2.1).

Box 2.2 The basis for entitlement to publicly financed health care

Linking entitlement to employment status or payment of contributions generally makes health care less widely accessible and affordable, since those who lose their entitlement tend to be poorer people. For example, some EU Member States (among them Estonia and Greece) remove entitlement from people who are long-term unemployed, even though these people may have paid contributions for most of their working lives.

In recent years, some countries have considered linking entitlement to payment of contributions (Latvia, for example) as a way of encouraging employers and employees in the informal sector to pay taxes. However, making tax compliance the responsibility of the health sector has not been shown to be an effective strategy for formalising the economy and creates barriers to access.

Requiring people to show evidence of a permanent address or renew a health card on a regular basis can create administrative barriers to entitlement and is likely systematically to prevent certain groups from accessing publicly financed health services – for example, homeless people.

Table 2.1 Access to health services for undocumented migrants, EU28, 2014

Level of entitlement	Countries
Access to emergency care only	Austria, Bulgaria, Cyprus, the Czech Republic, Denmark, Estonia, Germany, Greece, Finland, Hungary, Ireland, Lithuania, Luxembourg, Latvia, Malta, Poland, Romania, Slovakia, Slovenia
Explicit entitlement for specific services or groups only	Belgium, Italy, Spain, Sweden, the United Kingdom
Full access	France, the Netherlands, Portugal

Source: Cuadra and Cattacin (2011) with author updates

The benefits package: Although most EU countries cover a relatively wide range of services, there is evidence of cross-national variation in the content of the benefits package, especially with regard to medicines for chronic conditions and new and expensive medicines. There is also significant variation in expectations

1388 and norms around the way in which covered services are delivered – for example,
1389 around the use of referral and evidence-based clinical pathways and guidelines.

1390

1391 **User charges:** All EU Member States have some formal user charges for health
1392 services. User charges are most widespread for outpatient prescription drugs, but
1393 are also often applied to other health services. The depth of publicly financed
1394 coverage varies widely across countries. Countries generally apply user charges for
1395 three reasons: to limit access to health care in the hope that this will contain public
1396 spending on health, to direct people towards more cost-effective services or
1397 patterns of use and to raise revenue for the health system. There is little evidence
1398 to suggest user charges are an effective instrument for achieving any of these
1399 aims. In fact, the need to protect access to cost-effective services, interventions
1400 that aim to prevent disease and services used by poorer people and people with
1401 chronic conditions is increasingly recognised. However, although there have been
1402 improvements in some EU countries, the design of user charges continues to lack
1403 any evidence base and is sub-optimal in many countries.

1404

1405 **Informal payments:** Informal payments are frequent in health systems in some
1406 Member States, especially some of those in central Europe that joined the EU after
1407 2004. They have been characterised as a form of informal exit (“inexit”) from the
1408 health system, occurring when supply is limited and the classic mechanisms of
1409 exit, such as moving into the private sector, or voice, such as applying political
1410 pressure for reform of the system, are unavailable or dysfunctional (Gaál and
1411 McKee 2004).

1412

1413 Informal payments have many adverse consequences. First, they are regressive in
1414 nature, taking a higher proportion of the income of the poor. Second, because they
1415 are typically used for access to interventions, they may encourage oversupply and
1416 waste. Third, they create an alternative line of accountability of physicians to those
1417 who can pay rather than to those charged with managing the overall system. As a
1418 result, they form a powerful barrier to health system reform (Gaál et al 2006).

1419

1420 Because of their covert and pervasive nature, informal payments have proven
1421 difficult to overcome. Given what is known of their role, the most promising avenue
1422 to addressing them is a comprehensive approach involving adequate funding and
1423 the strengthening of health system governance (Kutzin et al 2010).

1424

1425

1426

2.3. The role of VHI in addressing gaps in publicly financed coverage

VHI provides financial protection where it plays a substitutive role (a person's only source of coverage) and a complementary role (covering excluded services or user charges). It provides faster access to health services where it plays a supplementary role. However, with some important exceptions, VHI does not do well in addressing gaps in coverage in EU countries or indeed globally (see Box 2.3). In most countries around the world its share of private spending on health is minimal (see below) and the relationship between VHI and out-of-pocket payments as a share of total spending on health is extremely weak.

Box 2.3 VHI does not do well in addressing gaps in health coverage

In 2013, VHI accounted for over a third of all private spending on health in only 6 EU Member States – Croatia (38%), the Netherlands (38%), Germany (40%), Ireland (41%), Slovenia (48%) and France (59%) – and accounted for under 10% of private spending in 14 EU Member States (see Figure 2.5). Its share is especially low in countries with higher levels of out-of-pocket payments. Thus, while there is evidence of significant gaps in coverage in several EU countries, VHI does not systematically address these gaps. Gaps in publicly financed coverage (or perceptions about the quality of publicly financed coverage) are a necessary but not sufficient prerequisite for VHI market development.

International analysis suggests that if VHI is to address gaps in coverage it must (Sagan and Thomson 2015 in press):

- be easily accessible and affordable, including to older people and people in poor health
- cover a very high share of the population (over 80% in Slovenia, the Netherlands and France, over 50% in Croatia and close to 50% in Ireland)
- or play a significant substitutive role in countries where public spending dominates

Although VHI can and does play a role in enhancing the affordability of health care, the EU experience suggests that the conditions under which this is most likely to happen are not easy to replicate. They also involve a number of risks for policy, including excluding richer people from publicly financed coverage (as in Germany) and introducing very high user charges in the form of co-insurance across the board (as in France and Slovenia).

Promoting VHI through tax subsidies – in the hope that this will relieve pressure on the health budget – has not been shown to be a cost-effective or equitable way of enhancing access. As we noted in chapter 2, due to sometimes complex interactions between publicly and privately financed and delivered care – and poor policy design – the promotion of VHI can skew the distribution of public and private health care resources away from need.

1475 **Tools for monitoring and evidence of variation**

1476

1477

1478

1479

1480

1481

1482

1483


1484

1485

1486

The most common way of monitoring affordability issues is to look at data on unmet need due to cost (see Figure 2.4). These data are routinely available in the European Union. They show how unmet need due to cost was experienced by around 12 million people across the European Union in 2013 (2.4% of the EU population). It is also relatively high as a share of the total population in some EU countries.

Figure 2.4 Share (%) of the population reporting unmet need for health care due to cost, EU28, 2013



1487

1488

1489

1490

1491

Source: Authors based on EU-SILC (2015)

1492

1493

1494

1495

1496

1497

1498

1499

1500

1501

1502

At EU level, unmet need due to cost is a particular problem among older inactive people, unemployed people, retired people, the poorest 40% of the population, people aged over 75, people with lower educational status and women and girls (see Figure 2.5). In comparison, people aged 65 and over experience quite low levels of unmet need due to cost. EU-level data mask important differences across countries, however. Figure 2.6 shows how older people have very good access to health care in many countries – and do not, in fact, report any unmet need due to cost in the Netherlands, the United Kingdom and Slovenia – but experience much higher levels of unmet need due to cost than the general population in Poland, Bulgaria, Italy, Greece, Latvia and Romania.

1503

1504

1505

1506


1507

1508

Although the unmet need data currently collected through EU-SILC are of limited value for comparative purposes, as we noted in the introduction, and lack explanatory power, they are useful for identifying trends over time within a country. For example, Figure 2.7 shows how unmet need due to cost has increased quite substantially for the poorest quintile in 12 countries since 2008.

1509
1510
1511


Figure 2.5 Share (%) of the population reporting unmet need for health care due to cost by gender, age, education, income and labour market status, EU27, 2015-2013



1512
1513
1514
1515
1516

Source: Authors based on EU-SILC (2015)

1517 **Figure 2.6 Share (%) of the population reporting unmet need for health**
 1518 **care due to cost, total population vs older people, EU28, 2013**




1519
 1520
 1521 Source: Authors based on EU-SILC (2015)

1522
 1523 Note: Countries in two groups – older people experience lower (left) or higher
 1524 (right) levels of unmet need than the general population – ranked by difference in
 1525 percentage points between older people and the total population.

1526
1527
1528

Figure 2.7 Change in the share (%) of the poorest quintile perceiving an unmet need for a medical examination due to cost, 2008-2013



1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553

Source: Authors based on EU-SILC (2015)

Note: Countries are shown in three groups: on the left, countries with only one year of data; in the middle, countries in which unmet need has fallen since 2008; on the right, countries in which unmet need has increased since 2008. Countries ranked from high to low by the extent to which unmet has improved for the poorest quintile since 2008.


Estimates of financial hardship among people who use health services are important, because having to pay for health care at a given point in time may reduce affordability in the future. Financial hardship is usually measured by calculating how much a household spends on health care out-of-pocket and then assessing this against measures of poverty and capacity to pay. This type of analysis provides valuable information on the incidence and distribution of financial hardship caused by out-of-pocket payments by income level and other household characteristics. It also provides useful information on the drivers of financial hardship – that is, what

While this calculation is straightforward, the household survey data required are not routinely available. EU Member States are only required to conduct household budget surveys every five years (although some do this on an annual basis) and the number of questions relating to health spending is usually very low in this type of survey and the recall period is often very short, which means financial hardship due to health spending is likely to be systematically underestimated. The WHO

1554 Regional Office for Europe is currently conducting a regional study on financial
 1555 protection. Results for 15-20 countries will be available in 2016 and 2017.

1556
 1557 The Eurostat database can be used to calculate the share of total household
 1558 consumption spent on out-of-pocket payments for health, as shown in Figure 2.8.
 1559 However, these data are only available at five-year intervals and, more
 1560 importantly, they do not permit any disaggregation by income or type of
 1561 household. As a result, they can provide a rough picture of differences across
 1562 countries and over time but do not really capture the incidence, distribution or
 1563 drivers of financial hardship.

1564
 1565 **Figure 2.8 OOPs as a share (%) of total household consumption, EU28,**
 1566 **2012**
 1567



1568
 1569
 1570 Source: OECD health data (2014)

1571
 1572 The simplest proxy indicator for affordability and financial protection is the out-of-
 1573 pocket share of total spending on health (Figure 2.3). International analysis shows
 1574 the incidence of catastrophic and impoverishing out-of-pocket payments rises
 1575 sharply when out-of-pocket payments exceed 15% of total spending on health (Xu
 1576 et al 2010). OOPs vary enormously as a share of total spending on health across
 1577 EU countries, with two-thirds of countries having shares of over 15% and almost
 1578 one third having shares of over 25% (see Figure 1.4).

1579
 1580 Similarly, the VHI share of private spending on health can shed light on how well
 1581 VHI addresses gaps in publicly financed coverage. Figure 2.9 shows how VHI does
 1582 not do well in addressing gaps in publicly financed coverage in all but a handful of
 1583 countries. In many countries its share of private spending is minimal, particularly
 1584 in countries where the private share of total spending on health is high (see Figure
 1585 2.2).


1586
 1587 Data on patterns of service use are useful if they can be disaggregated by
 1588 coverage status (publicly covered, VHI coverage, uninsured), income quintile and
 1589 other individual characteristics. Unfortunately, such data are not available at EU
 1590 level.

1591
 1592 Qualitative assessment of health coverage is important in understanding where
 1593 affordability is likely to be an issue. Looking at which groups are excluded from

1594 entitlement, whether certain essential services are available only to those who are
 1595 eligible for specific schemes and the design of user charges policy is a useful
 1596 starting point for analysis.

1597

1598 **Figure 2.9 Per capita spending on health through VHI and OOPs (PPP),**
 1599 **EU28, 2013**



1600

Source: WHO (2015)

1601

1602

1603

1604

Note: Countries ranked from low to high by VHI as a share (%) of private spending on health

1605

1606

1607

Resonance for specific people

1608

1609

1610

1611

1612

1613

1614

1615

1616

1617

1618

Affordability is most likely to be problematic for poorer people and people in poor health, especially people with chronic conditions, who use health services and medicines on a regular and ongoing basis. In 2013, one in four people in the European Union (24.5%) – about 122 million people in total – was at risk of poverty or social exclusion. This number has risen since substantially since 2009, following a period of decline (see Table I.1). Women, young adults, unemployed people and less-educated people face the highest risks.

1619 **Policy responses**

1620

1621 Within the health sector, ensuring affordable access to health care requires the
1622 following actions (see also Box 2.4):

1623 ▪ Ensure most spending on health comes from collective public rather than
1624 private sources.

1625 ▪ Ensure out-of-pocket payments are as low as possible. The incidence of
1626 catastrophic and impoverishing spending on health rises as the out-of-pocket
1627 share of total spending on health rises.

1628 ▪ Identify and close gaps in publicly financed coverage of cost-effective services.

1629 ▪ Broaden the basis for entitlement to encompass everyone living in a country,
1630 regardless of legal status.

1631 ▪ Eschew discriminatory approaches such as entitlement linked to employment
1632 status or payment of contribution or situations in which people with different
1633 diagnoses are entitled to different benefits ('inequity by disease').

1634 ▪ Reduce or eliminate user charges so that they do not create financial barriers to
1635 cost-effective services or undermine financial protection.

1636 ▪ Ensure efficiency in spending public resources, paying attention to the scope of
1637 the benefits package, prioritising cost-effective health services, including
1638 elements of performance in provider payment and developing appropriate
1639 pricing strategies.

1640 ▪ Eliminate informal payments using a mix of policy instruments.

1641

1642 Outside the health sector, fiscal social protection policies are critical to addressing
1643 poverty and income inequality.

1644

1645 To support Member States, the European Union can adapt EU-SILC, its main source
1646 of comparable data, to include proxy measures of financial hardship; require
1647 countries to carry out household budget surveys more regularly; and ensure these
1648 surveys use a robust, standardised, extended health module to enable better
1649 estimation of financial hardship.

Box 2.4 Coverage policies for equitable access to health services

1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697

The basis for entitlement is living in a country rather than employment status, payment of contributions or income.

Everyone living in a country is in the same (risk) pool. This may be a virtual pool , achieved through risk-adjusted transfers to or among purchasing agencies.

Everyone living in a country is entitled to the same publicly financed benefits.

There are no incentives for providers to treat people differently.

The publicly financed benefits package covers the full spectrum of health services, from prevention to treatment, rehabilitation and palliative care.

The publicly financed benefits package includes evidence-based clinical pathways, including referral.

Before applying user charges, consideration should be given to the potential costs involved: the costs of increasing the complexity of entitlements; the costs of administering user charges and exemptions from user charges; the costs of creating barriers to cost-effective services and patterns of use; and the costs of any care foregone or delayed as a result of user charges.

If user charges are applied, they should be carefully designed to avoid creating barriers to cost-effective services and patterns of use and to avoid creating uncertainty about how much people have to pay for health care. Poorer people and people who regularly use health services (including medicines) require special protection. Some examples of good practice include:

- exempting poorer people, economically inactive people, people with chronic conditions, minors, pregnant women and new mothers from user charges
- exempting preventive services from user charges
- the use of (low) co-payments (a fixed rate per prescription or service) rather than co-insurance (a share of the medicine or service price), so that people know exactly how much they will have to pay for a prescription or physician visit or stay in hospital
- setting a ceiling or cap on user charges so that people know they will not have to pay more than a certain share of their income every year; Germany uses this policy and the share of annual income is set at 2% or 1% for people with chronic conditions

Entitlements should be defined as simply and transparently as possible to avoid confusing users and health workers.

1698 *[This page intentionally left blank]*

1699 **3. Services are relevant, appropriate and cost-effective**

1700

1701 **Chapter summary**

1702

1703 Promoting access does not mean making everything available to everyone at all
1704 times. In the context of limited resources, it is important to ensure that spending
1705 on health is as cost-effective as possible. While the publicly financed benefits
1706 package needs to be broad, covering the full spectrum of services from health
1707 promotion, disease prevention and early detection to disease management,
1708 treatment, rehabilitation and palliative care, it should also be relevant to the health
1709 needs of the population and defined and delivered in a way that is consistent with
1710 need and evidence, including evidence of cost-effectiveness. Otherwise, the right
1711 services may not be provided to the right people at the right time at least cost,
1712 with negative implications for quality, efficiency, equity and financial protection.

1713

1714 Evidence of the provision of non-cost-effective health services, of avoidable
1715 hospitalisations and of unwarranted variations in clinical practice is growing in EU
1716 Member States. International research on unwarranted clinical variations indicates
1717 that geography is the main determinant of health care use and spending at the
1718 population level, not need, and that higher-spending regions fail to achieve better
1719 outcomes. European analysis reveals significant room for improving efficiency by
1720 lowering the provision of non-cost-effective health services. Data on avoidable
1721 hospitalisations for ambulatory care-sensitive conditions such as asthma and
1722 diabetes also show substantial variation within and across countries. Both types of
1723 data highlight a social gradient, indicating that people living in more deprived areas
1724 may be subject to more unnecessary and potentially harmful overuse than others.

1725

1726 To address these issues, countries should adopt a comprehensive strategy mainly
1727 targeting health workers, but also patients and the public:

1728 ▪ Ensure the publicly financed benefits package covers the full spectrum of
1729 services, is correlated with population health needs and does not result in
1730 inequity by disease.

1731 ▪ Take steps to avoid over-medicalisation.

1732 ▪ Put in place systematic priority-setting processes to enable HTA-informed, cost-
1733 effective coverage decisions for both new *and* existing technologies.

1734 ▪ Develop clinical pathways, guidelines and systems of referral, adapt single-
1735 condition guidelines to meet the needs of people with multiple morbidities and
1736 monitor adherence to guidelines.

1737 ▪ Train and support health workers to deliver services in line with evidence.

1738 ▪ Ensure all patients have access to adequate and accessible information about
1739 treatment options and outcomes.

1740 ▪ Establish information systems to identify (and publicly report on) practice
1741 variations and patient outcomes and to support effective decision making by
1742 health professionals and patients. This should include decision aids for patients
1743 to help them assess the potential benefits and risks of different treatment
1744 options.

1745

1746 People should have access to a full spectrum of publicly financed health services:
1747 health promotion, disease prevention, early detection, disease management,
1748 treatment, rehabilitation and palliative care. However, as we noted in the
1749 introduction, promoting equitable access does *not* mean making everything
1750 available to everyone at all times. Rather, it aims to ensure three things:

- 1751
- 1752 ▪ The services available broadly correspond to the health needs of the
1753 population, including people with rare diseases. This notion of ‘relevance’
1754 (Maxwell 1992) refers to an optimal overall pattern and balance of services
1755 given the needs and desires of a specific population.
 - 1756
 - 1757 ▪ Services are delivered in way that is consistent with the needs of a particular
1758 individual and with evidence. This is often referred to as appropriate care (see
1759 the EXPH opinion on quality and patient safety).²
 - 1760
 - 1761 ▪ Services are defined and delivered in relation to cost-effectiveness, meaning
1762 that benefits should outweigh costs and, where alternatives are available, the
1763 most cost-effective option is chosen.
 - 1764

1765 Meeting these aims is an important dimension of access because public resources
1766 are limited and it is therefore wasteful – and unethical – from a societal
1767 perspective, to promote access to services that are ineffective or more costly than
1768 alternatives offering the same degree of benefit. The provision of non-cost-
1769 effective services is not only inefficient. It can also undermine quality of care and
1770 may diminish financial protection and equity if it causes people to use unnecessary
1771 services or draws resources away from cost-effective services.

1772

1773 Evidence of the provision of non-cost-effective health services, of avoidable
1774 hospitalisations and of unwarranted variations in clinical practice is growing in EU
1775 Member States. International research on unwarranted clinical variations indicates
1776 that geography is the main determinant of health care use and spending (at the
1777 population level), not need, and that higher-spending regions fail to achieve better
1778 outcomes.

1779

1780 Data on avoidable hospitalisations for ambulatory care sensitive conditions such as
1781 asthma and diabetes also show substantial variation within and across countries. In
1782 2012, the rate of hospital admission for uncontrolled diabetes ranged from under
1783 25 to over 150 per 100,000 people (Figure 3.1).

1784

1785 Both types of data highlight a social gradient, indicating that people living in more
1786 deprived areas may be more subject to unnecessary and potentially harmful over
1787 use than others.


1788

1789 There is significant evidence of variation across countries in the use of – for
1790 example – antibiotic drugs and in the effectiveness of basic but vital preventive
1791 programmes such as immunisation. In 2013, the share of children immunised
1792 against diphtheria, tetanus and pertussis ranged from 83% to 99% (Figure 3.2).

1793
1794
1795
1796


² http://ec.europa.eu/health/expert_panel/index_en.htm

1797 **Figure 3.1 Hospital admissions for uncontrolled diabetes (age-sex**
 1798 **standardised rates per 100,000 people), EU28, 2007 and 2012 or latest**
 1799 **available year**
 1800



1801 Source: OECD health data (2015)
 1802 Note: Countries ranked from low to high in latest available year; no data available for most EU
 1803 countries; data are for people aged 15 and over; data for Austria and Italy are for 2009 for the earlier
 1804 year; data for the UK and Germany for the later year are 2009 and 2010 respectively.
 1805
 1806
 1807

1808 **Figure 3.2 Share (%) of children immunised against DTP, EU28, 2008 and**
 1809 **2013**
 1810



1811 Source: OECD health data (2015)
 1812 Note: Countries ranked from low to high in 2013. DPT = diphtheria, tetanus, pertussis.
 1813
 1814

1815 In theory, ensuring services are relevant, appropriate and cost-effective can be
1816 achieved by using systematic and evidence-based approaches such as health needs
1817 assessment to define overall service availability at national and local levels and
1818 health technology assessment (HTA) to inform coverage decisions (the content of
1819 the publicly financed benefits package) and clinical practice. Health needs
1820 assessment is a systematic method of identifying the unmet health and health care
1821 needs of a population, so that resources can be effectively targeted. It may involve
1822 working with other agencies, local people and service users (Stevens and Gillam
1823 1998). HTA identifies safe, effective, patient-focused and cost-effective
1824 interventions (Velasco Garrido et al 2008). In reality, evidence-based approaches
1825 frequently fall short of expectations for a variety of reasons.

1826
1827 **Limited uptake of HTA to inform coverage decisions:** Some EU health
1828 systems use HTA evidence to inform coverage decisions although it tends to be the
1829 exception rather than the norm – limits to coverage more often focus on whole
1830 areas of service and usually those not provided by physicians such as dental care
1831 and physiotherapy. Countries are increasingly trying to use cost-effectiveness as a
1832 decision criterion (Sorenson et al 2008). However, HTA presents technical, financial
1833 and political challenges, which may explain why it is not as widely used as it might
1834 be, especially for disinvestment, and why it is mainly applied to new technologies.

1835
1836 **HTA focuses on new technologies rather than on disinvestment:** To date,
1837 only a handful of EU countries systematically uses HTA for disinvestment (de-listing
1838 of existing benefits) (Ettelt et al 2007).

1839
1840 **Evidence is ill-equipped to meet changing health and policy needs:** Since
1841 the early 1990s, evidence-based medicine has played an increasingly prominent
1842 role in health service delivery, resulting in the development of a vast set of
1843 guidelines to inform clinical practice. However, most guidelines focus on a single
1844 disease or condition and draw on evidence from trials in which people with multiple
1845 morbidities were excluded. As a result, they are frequently unsuited to – even
1846 inappropriate in – a context in which many people have more than one illness or
1847 condition – ‘multi-morbidity’ (De Maeseneer et al 2003). There is also the view that
1848 clinical evidence should be complemented by contextual and policy evidence,
1849 taking into account the history, expectations and goals of specific patients and the
1850 cost-effective use of resources.

1851
1852 **Evidence-based practice guidelines are lacking or ignored:** Evidence of large
1853 variations in delivering care to similar patients has stimulated efforts to optimise
1854 and, where appropriate, standardise treatment of specific conditions or groups of
1855 patients over the course of care using practice guidelines, protocols or care
1856 pathways. These tools have been shown to improve the quality of care provided by
1857 physicians and allied health professionals (Grimshaw et al 2004a, Grimshaw et al
1858 2004b, Thomas et al 2000). A small body of evidence suggests guidelines can also
1859 enhance efficiency and reduce costs, although care needs to be paid to
1860 implementation (Bahtsevani et al 2004, Legido-Quigley et al 2013).

1861
1862 In general, it is difficult to assess to what extent available guidelines are
1863 implemented, adhered to and influence outcomes. A recent survey mapping the
1864 use of practice guidelines in 29 (mainly EU) countries identified relatively few as
1865 being ‘leaders’ in the field (Belgium, England, France, Germany, the Netherlands)
1866 or having well-established programmes (Finland, Norway, Sweden), but noted
1867 recent albeit sometimes fragmented developments in a few other countries (the
1868 Czech Republic, Greece, Hungary, Ireland, Luxembourg, Malta, Spain) (Legido-
1869 Quigley et al 2013). This suggests considerable scope for action in EU and non-EU
1870 countries.

1871

1872 **Lack of processes to ensure access is based on severity of need:** Ensuring
1873 equitable access means treatment should be prioritised according to the severity of
1874 a person's condition or need for health care. This requires the use of effective
1875 referral systems and triage. Most health problems are self-limiting and appropriate
1876 use of basic diagnostic tools – starting with low-cost strategies such as history-
1877 taking and clinical examination, then moving onto simple technologies (lab tests or
1878 imaging) – can therefore address over 90% of all new health problems. For this
1879 reason it is most cost-effective for most people to enter the health system at the
1880 primary care level and then, when needed, to be referred to secondary care.

1881
1882 Referral systems aim to improve quality and efficiency in health service delivery by
1883 ensuring that people receive appropriate and well-coordinated care. Through
1884 referral, patients are guided to the professionals and facilities most suited to
1885 treating them. Referral systems can contribute to efficiency by minimising
1886 inappropriate care and duplication and by upholding the principle of subsidiarity –
1887 that is, that tasks should be carried out at higher levels if they cannot be
1888 performed effectively at lower levels (and vice-versa). In the absence of a referral
1889 system, hospitals and secondary care doctors would see too many self-limiting
1890 cases, eroding their ability to deal with complex cases, while family physicians
1891 would not see enough children (for example), eroding their ability to provide
1892 effective out-of-hours care to children; and sometimes a second opinion is called
1893 for to confirm or reject an initial diagnosis. As a result, effective referral systems
1894 benefit patients and health professionals.³

1895
1896 **Over medicalisation:** Some domains of daily life are increasingly subjected to
1897 medical definition and jurisdiction, often as a result of 'disease mongering', a
1898 process in which interested parties create public awareness of and demand for
1899 specific treatments through direct to consumer advertising, use of the news media
1900 and other strategies (Moynihan and Cassels 2005). Disease mongering has been
1901 defined as 'the selling of sickness that widens the boundaries of illness and grows
1902 the markets for those who sell and deliver treatments . . . [it leads to] aspects of
1903 ordinary life, such as menopause, being medicalised; mild problems portrayed as
1904 serious illnesses, as has occurred in the drug-company-sponsored promotion of
1905 irritable bowel syndrome, and risk factors, such as high cholesterol and
1906 osteoporosis, being framed as diseases' (Moynihan and Henry 2006). Disease
1907 mongering is problematic because it can turn healthy people into patients, it
1908 wastes limited resources and it may harm health.

1909
1910 **Inequity by disease:** This can occur when people with the same need but with a
1911 different diagnosis receive different levels of care. A good example includes the
1912 increasing tendency to prioritise the treatment of cancer. The UK government set
1913 up a Cancer Drugs Fund in 2010 to ring-fence funding for cancer drugs and enable
1914 the use of drugs normally deemed non-cost-effective. Similarly, in Belgium,
1915 patients with hemiplegia caused by a brain tumour are much better off than
1916 patients with the same condition caused by stroke because the government's
1917 cancer plan offers cancer patients access to all kinds of additional support (very
1918 often free of charge) that is not available to stroke patients. It will be important to
1919 monitor this phenomenon in the future (De Maeseneer et al 2012).

1920
1921 **Politics:** The examples highlighted in the last paragraphs reflect the role of
1922 interests, politics and the media in determining which patients obtain access to
1923 which services. Systematic, evidence-based approaches attempt to overcome the

³ For more information see the EXPH opinion on primary care, which includes a section on referral.
http://ec.europa.eu/health/expert_panel/opinions/docs/004_definitionprimarycare_en.pdf

1924 pitfalls of arbitrary or interest-driven decision-making, but other factors inevitably
1925 intervene, often in response to the limits imposed by those same approaches. This
1926 does not undermine the case for such approaches. It emphasises the importance of
1927 ensuring that efforts to allocate resources based on explicit criteria or to influence
1928 clinical practice pay careful attention to the views of the public, patients and health
1929 professionals in a transparent way.

1930

1931

1932 **Tools for monitoring and evidence of variation**

1933

1934 There is now a growing body of evidence on variations in clinical practice within
1935 and across countries, indicating potentially substantial amounts of waste and harm
1936 due to misuse, overuse and underuse of a wide range of health services. Four EU
1937 countries have established atlases of clinical practice variations (Spain, the United
1938 Kingdom, Germany and the Netherlands), there are national studies in other
1939 countries (Peiró and Maynard 2015) and the OECD has recently analysed variations
1940 in nine EU Member States (OECD 2014). Analysis from the five countries involved
1941 in the EU-funded European Collaboration for Health Optimization (ECHO)⁴ reveals
1942 significant scope for improving efficiency by lowering the provision of non-cost-
1943 effective health services.

1944

1945

1946 **Resonance for specific people**

1947

1948 The absence of relevant, appropriate and cost-effective care will ultimately affect
1949 all those in need of health services, but has particular resonance for the rising
1950 share of patients with multiple morbidities.

1951

1952

1953 **Policy responses**

1954

1955 Public reporting via atlases are a first step towards promoting change. Less is
1956 known about how to address the problem of unwarranted variations, which has
1957 proved to be intractable over a long period of time. However, countries should
1958 adopt a comprehensive strategy that mainly targets health workers, but also
1959 patients and the public:

1960 ▪ Ensure the publicly financed benefits package covers the full spectrum of
1961 services, is correlated with population health needs and does not result in
1962 inequity by disease.

1963 ▪ Take steps to avoid over-medicalisation.

1964 ▪ Put in place systematic priority-setting processes to enable HTA-informed, cost-
1965 effective coverage decisions for both new *and* existing technologies.

1966 ▪ Develop clinical pathways, guidelines and systems of referral, adapt single-
1967 condition guidelines to meet the needs of people with multiple morbidities and
1968 monitor adherence to guidelines.

1969 ▪ Train and support health workers to deliver services in line with evidence.

1970 ▪ Ensure all patients have access to adequate and accessible information about
1971 treatment options and outcomes.

1972 ▪ Establish information systems to identify (and publicly report on) practice
1973 variations and patient outcomes and to support effective decision making by

⁴ http://echo-health.eu/?doing_wp_cron=1443262769.6446959972381591796875

1974 health professionals and patients. This should include decision aids for patients
1975 to help them assess the potential benefits and risks of different treatment
1976 options.
1977

1978 *[This page intentionally left blank]*

1979 **4. Well-equipped facilities are within easy reach**

1980

1981

Chapter summary

1982

1983

Proximity to health facilities is determined by a number of interrelated factors, including the topography of the land, the density of the population and the quality of the transport infrastructure. The situation may be compounded by the maldistribution of facilities due to a failure of planning or official neglect, as is the case with Roma people in some countries in central Europe.

1984

1985

1986

1987

1988

1989

Geographical barriers present inevitable trade-offs. The provision of modern health services requires facilities with 24-hour cover of a range of specialties. An equitable distribution of services is not simply a matter of funding. It also requires a substantial number of staff with qualifications that cannot easily be substituted, as well as a sufficient workload to justify employment and ensure staff retain their skills.

1990

1991

1992

1993

1994

1995

1996

Although in many places the problems are obvious – for example, small islands, mountainous terrain or remote areas – those involved have typically developed their own solutions, influenced by the resources available and what is provided in the facilities that serve them. Few of these approaches have been evaluated systematically and evidence of the health impact of differences in access to facilities in Europe is limited.

1997

1998

1999

2000

2001

2002

Potential solutions lie in two broad areas:

2003

2004

- To engage in area-level planning with the aim of creating networks of dispersed facilities feeding into a central one, based on agreed clinical pathways.

2005

2006

2007

- To develop mechanisms to facilitate the transport of patients to health facilities or health professionals to patients.

2008

2009

2010

Both sets of policy responses require administrative structures that can take a population-wide perspective and have the managerial tools required for capacity planning. In the absence of geographical responsibility for health, instruments such as certificates of need for particular forms of advanced medical technology can be used.

2011

2012

2013

2014

2015

2016

2017

Ensuring policy responses are effective is challenging and there is a need to accept trade-offs. Where barriers are social rather than geographical – for example, those that lead to a relative lack of facilities in areas populated by poorer people or ethnic minorities – there is a need to document the extent of inequalities and to take action within the context of health planning systems.

2018

2019

2020

2021

2022

The European Union can support Member States by continuing work to develop reference networks.

2023

2024

2025

2026

2027 Facilities and equipment should be distributed so that they are in easy reach of
2028 everyone. However, this is a goal that is much easier to state than to achieve in
2029 practice. In many parts of Europe there are significant barriers to achieving
2030 equitable geographic access to appropriate facilities. These can be related to supply
2031 factors, with a number of considerations serving to increase pressure to centralise
2032 services in large facilities providing a high volume of care – notably, the challenge
2033 of providing 24-hour cover safely in certain specialties and evidence of a
2034 relationship between volume and outcome in some areas of care. For example,
2035 paediatric cardiac surgery is now organised on a national basis in England following
2036 revelations of sub-standard care in one facility and clear evidence of a volume-
2037 outcome relationship, while in Germany there are continuing concerns about the
2038 large number of low-volume and solo practitioners.

2039
2040 Other factors are related to demand. This is the case in isolated rural areas with a
2041 very low population density, such as northern Sweden and Finland. To a lesser
2042 extent, similar problems can arise around large cities, many of which have
2043 hospitals occupying the same land as they did several centuries previously, even
2044 though the distribution and composition of the population around the hospital may
2045 have changed beyond recognition. Particular challenges arise in places that are
2046 isolated by the presence of natural barriers. The most obvious examples are
2047 islands and mountainous areas.

2048
2049 Even where these geographical problems do not exist, facilities providing
2050 appropriate care may not be effectively distributed. The nature of health care has
2051 changed dramatically in the past century. The modern hospital was created around
2052 three major technological developments: operating theatres, laboratories and x-ray
2053 machines. The advent of minimally invasive surgery, interventional radiology,
2054 handheld or desktop analysers and ultrasound have challenged the traditional
2055 model. In addition, the growth of multi-morbidity and chronic disease means that
2056 many patients will be managed not as a series of isolated episodes requiring
2057 hospitalisation but as a continuum that spans primary, secondary, tertiary and
2058 social care.

2059
2060 These developments call for systems that can put in place co-ordinated or
2061 integrated models of service delivery that allow patients and carers to move
2062 seamlessly between different settings. The ability of health systems to respond
2063 effectively varies greatly, with many facing considerable organisational and
2064 financial barriers to change.

2065
2066

2067 **Tools for monitoring and evidence of variation**

2068
2069 Traditionally, indicators of health system capacity, and particularly those that
2070 relate to facilities, have been based on counting structures such as hospitals or
2071 hospital beds. However, these measures are largely meaningless. Definitions vary
2072 enormously, both among countries and over time, as when the Belgian authorities
2073 reclassified many small facilities that had been described as hospitals, recognising
2074 that in effect they were nursing homes.

2075
2076 More appropriate measures would look at the experience of people seeking care.
2077 There may be questions on unmet need for health care in individual surveys
2078 conducted within countries or comparing a few countries, as well as surveys of
2079 unmet need for specific conditions. The only comparable source of such data across
2080 Europe is EU-SILC (Arora et al 2015), which includes a question on unmet need for
2081 medical and dental examinations due to travelling distance. However, interpreting
2082 these data is challenging given the complex nature of the interaction between

2083 people and the health system. Thus, it may be relatively easy to make first contact
2084 with the health system then face significant barriers in progressing further.

2085
2086 Measurement is also complicated in countries that have adopted targets and have
2087 imposed either incentives to meet targets or penalties for failing to do so. The
2088 experience of England illustrates the pitfalls. During the 2000s, the imposition of
2089 targets led to numerous imaginative gaming strategies, allowing providers to meet
2090 the targets without necessarily conferring any benefit on patients (Wismar et al
2091 2008).


2092
2093 A further problem is that aggregate figures may obscure important differences.
2094 Thus, the population overall may be able to obtain access to care at nearby
2095 facilities but there may be barriers facing particular groups within the population
2096 (see below).

2097
2098 For all of these reasons, it is unlikely that any single indicator can be used to
2099 assess unmet need related to the distribution of health facilities. Instead, it is likely
2100 to require specific studies to understand the barriers facing different groups of
2101 people as they seek to obtain care at different levels of the health system and at
2102 different points in their trajectory through it.

2103
2104 EU-SILC data suggest that levels of unmet need attributable to travel distance are
2105 low in most Member States, at under 1% in all except Croatia (Figure 4.1). In
2106 about half of EU Member States reported rates were 1 in 1000 or less. However, as
2107 noted above, this indicator has many limitations and it is possible that the
2108 sampling strategy tends to exclude those in most need. Survey data from the EU-
2109 funded QUALICOPC study (Figure 4.2) confirm that problems with distance to
2110 facilities is mainly experienced among people living in the Member States that
2111 joined the European Union in 2004.


2112
2113

2114 **Figure 4.1 Share (%) of the population reporting unmet need for a medical**
 2115 **examination because it was too far to travel, EU28, 2013**
 2116



2117
 2118 Source: Authors based on EU-SILC (2015)

2119
 2120
 2121 **Figure 4.2 Share (%) of people that have to travel for more than 20**
 2122 **minutes to reach their nearest primary care facility, EU27, 2013**
 2123



2124
 2125 Source: QUALICOPC (2015)

2126
 2127 Note: No data are available for Croatia and France.

2128
 2129
 2130
 2131
 2132
 2133
 2134
 2135

2136 **Resonance for specific people**

2137

2138 In some cases it is straightforward to identify those groups who will be particularly
2139 disadvantaged by the distribution of health facilities. However, there will also be
2140 many problems that are not so obvious. The former include the delivery of health
2141 care in sparsely populated rural areas, especially where there are geographical
2142 barriers like mountains and stretches of water, and in locations experiencing
2143 severe deprivation. The less obvious barriers are often to do with social and
2144 economic disadvantages facing particular groups of people.

2145

2146 One group that faces particular barriers within the EU are the Roma. In some
2147 countries Roma people live in separate settlements or in rundown areas on the
2148 outskirts of larger settlements. A number of studies have documented how these
2149 places are underserved by health facilities and often have poor transport
2150 connections to the facilities that do exist. The situation is compounded by
2151 widespread discrimination, so that emergency services are often inaccessible. The
2152 title of a seminal report on the experiences of Roma people – *Ambulance Not on*
2153 *the Way* – conveys this issue very clearly (ERRC 2006).

2154

2155

2156 **Policy responses**

2157

2158 Working from first principles, there are two ways in which access to health facilities
2159 might be improved. The first is to design health systems in ways that allow the
2160 dispersal of facilities, for example through the creation of integrated networks
2161 allowing individuals to have rapid access to immediate or basic routine care and
2162 then be referred to more specialised facilities when required. A recent study
2163 includes two examples of area-wide approaches to planning, both of which involve
2164 creating networks of health facilities offering different levels of care (Northern
2165 Ireland and the region of Tuscany in Italy). Both are based on a comprehensive
2166 assessment of health needs in the population and the definition of appropriate
2167 clinical pathways. Both also involved investment in new facilities, including
2168 hospitals and peripheral clinics.

2169

2170 However, such approaches face considerable challenges. First, there may be
2171 problems with recruiting and retaining adequately trained staff in peripheral
2172 facilities, and in particular providing full-time staffing for emergencies. Second, this
2173 will often require a high level of co-ordination between different agencies coupled
2174 with measures to overcome fragmentation imposed by organisational and financial
2175 barriers to co-operation.

2176

2177 The second approach involves moving patients to a central facility or health
2178 professionals to the patient or a dispersed facility. This may call for investment in
2179 public transport, recognising that services have declined dramatically in many rural
2180 areas in recent years. In some places this may require public funding for helicopter
2181 or aircraft services (see Box 4.1). When health professionals move into the
2182 community it is inevitable that a lot of time will be taken up with travelling. This
2183 has a significant opportunity cost in terms of treating patients.

2184

2185 The advent of high-speed Internet holds out the possibility of innovative models of
2186 care delivery, although so far claims about benefits have far outweighed actual
2187 evidence of cost-effectiveness. For example, numerous systematic reviews of
2188 telemedicine have concluded that evidence of cost-effectiveness is lacking and
2189 published papers are subject to considerable publication bias (Nordheim et al 2014,
2190 Hasselberg et al 2014, Mistry et al 2014).

2191

2192

2193 **Box 4.1 Helicopter emergency medical services in a region of Spain**

2194

2195 Ensuring access to emergency services in case of serious illness or accident is not
2196 easy in very remote and isolated villages. Castilla-La Mancha is an autonomous
2197 community of Spain, between Madrid and Andalusia. Is one of the most sparsely
2198 populated European Regions, with an average population density of 26.16 per
2199 square kilometres (2,076,000 inhabitants; 79,463 k2). Of its 919 municipalities,
2200 only 297 have more than 1,000 inhabitants. 100 municipalities have less than 100
2201 inhabitants. Some of these villages are in mountain areas, at a distance of more
2202 than 1 hour and a half to the nearest hospital.

2203 The rural areas are equipped with Health Centres, multidisciplinary primary
2204 health teams, and road ambulances equipped for transport of patients or for
2205 advance treatment. Districts are equipped with Diagnostic and Treatment Centres
2206 or with General Hospitals depending on the covered population. But it is not
2207 possible, nor is convenient, creating this kind of services in all the villages.

2208 Since 2002, in order to improve emergency and urgency services in remote
2209 areas, the Regional Health Service put in place 4 Helicopters fully equipped as
2210 Mobile ICUs for treating severe patients: the "Helicopter Emergency Medical
2211 Service" (HEMS) can reach remote areas in 20', patients can be stabilised and
2212 treated while they are transported to the hospital. The emergency team (doctor
2213 and nurse), adequately trained, is connected to their colleagues at the Hospital
2214 Emergency service, and is able to transmit the relevant information on-line. The
2215 HEMS is able to operate 24 hours/ day, 365 days/ year. From 2002 this service has
2216 treated people affected by heart attack, strokes, traffic and train accidents, work
2217 injuries, etc. There have been built 225 landing sites at the rural areas of Castilla-
2218 La Mancha, making it possible to offer safe and quality health services to isolated
2219 people living in places with difficult access by road (mainly in the winter).

2220

2221 Effective policy responses are complicated because they will often require major
2222 changes to the organisation of health systems, in terms of governance and service
2223 delivery. Most will require the creation of some form of administrative structure
2224 that can take a population-wide perspective and has the managerial tools needed
2225 for capacity planning. The precise approach taken will depend on the nature of the
2226 health system. There are major differences in approaches to hospital planning in
2227 Europe (Thompson and McKee 2011). For example, where health services are
2228 provided by geographically defined bodies, such as county councils in Denmark or
2229 Sweden, it is relatively easy – at least in theory – to design service delivery in a
2230 way that reflects the health needs of the population and, over time, to realign it in
2231 accordance with changing needs (Saltman et al 2006). The situation is more
2232 challenging where those responsible for financing and delivering health services do
2233 not have a geographical responsibility. There are, however, instruments that can
2234 be used, such as certificates of need for particular forms of advanced medical
2235 technology.

2236

2237 The European Union can support Member States by continuing work in the area of
2238 reference networks.

2239

2240 **5. There are enough health workers, with the right skills, in the right**
2241 **place**

2242

2243

Chapter summary

2244

2245

2246

2247

2248

2249

2250

2251

2252

2253

2254

Health systems across Europe are facing shortages of health workers for a number of reasons. First, few countries are training adequate numbers of health professionals. Second, health workers are increasingly mobile in a globalised economy and in the context of the single market in Europe; those who feel they are not being adequately rewarded for what they are doing can easily move somewhere else. Third, there may be problems within countries, where it can be difficult to recruit and retain health workers in isolated rural areas with few employment opportunities for partners, limited leisure infrastructure or weak provision of education for children.

2255

2256

2257

2258

2259

The extent to which access to care is hindered by inadequate health workers is difficult to ascertain, even though the problem is widely accepted to be important. Systems of data collection are unable to answer the most important policy questions.

2260

2261

2262

2263

2264

2265

2266

2267

2268

2269

2270

To address these issues countries should:

- 2271 ▪ Put in place processes to train adequate numbers of health workers. Unfortunately, workforce planning has had a very poor record in most countries.
- 2272 ▪ Establish working conditions designed to retain staff in underserved countries and areas: not only remuneration commensurate with skills, but also attention to broader working conditions, including access to peer support and continuing professional development.
- 2273 ▪ Ensure an appropriate mix of skills is in place. This may require investment in additional administrative or care staff to relieve pressure on specialised health professionals (and, in a period of austerity, avoiding short-sighted cuts in staff); the development of new roles, with more advanced skills, such as specialist nurses; and task shifting, with delegation of certain roles to less specialised staff. Skill mix developments often require significant changes to the organisational structure of the health facility, recognising that new responsibilities require different reward systems and can challenge existing professional hierarchies. They must also take account of the widespread existence of financial incentives that serve to maintain the status quo.

2274

2275

2276

2277

2278

2279

2280

2281

2282

2283

2284

2285

2286

2287

2288

The European Union can support Member States through better data collection on health worker roles and functions, remuneration and working conditions; ensuring ethical international recruitment; promoting cooperation on health workforce policies through the Expert Group on European Health Workforce and Joint Action on health workforce planning and forecasting.

2289 Access to effective and appropriate health care requires that there are sufficient
2290 numbers of health workers, with the right combination of skills and expertise, in
2291 the places that they are needed. Within Europe there are significant problems with
2292 regard to all of these issues (Dubois et al 2005).

2293

2294 For decades, many European countries have been failing to train adequate
2295 numbers of health workers to meet their own needs. Instead, they have depended
2296 on importing health workers from other parts of the world, and in particular from
2297 some of the poorest countries where they are most needed (Buchan and Sochalski
2298 2004).

2299

2300 Historically, there have also been long-standing patterns of migration within
2301 Europe, such as the movement of doctors and nurses from Ireland to the United
2302 Kingdom and from Austria to Germany. These intra-European movements have
2303 increased with progressive European Union enlargements (Garcia Perez et al
2304 2007). Initially, this involved movement of health workers from Spain and Portugal
2305 to countries such as the United Kingdom but more recently there has been large-
2306 scale migration from some of the countries of Central and Eastern Europe to those
2307 in Western Europe. This has created major challenges for some of the countries
2308 that have lost large numbers of skilled health workers, such as Lithuania
2309 (Starkiene et al 2005).

2310

2311 Another problem is the failure to train health workers with the combination of skills
2312 that are needed in a rapidly changing health care environment. Ageing populations
2313 bring with them higher rates of multi-morbidity (Barnett et al 2012). This calls for
2314 more generalist physicians who can support those patients with problems spanning
2315 several different body systems, both in primary care and in hospitals. In practice,
2316 in many countries there has been a tendency to emphasise the training of
2317 specialists, encouraged by payment systems that offer disproportionate rewards to
2318 those with specialist skills, in particular where this involves undertaking specialised
2319 procedures.

2320

2321 There are also areas where more health workers with certain specialist skills are
2322 also required. Many countries struggle to recruit and retain adequate numbers of
2323 nurses with specialist skills in areas such as critical care, stoma care, and other
2324 forms of cancer care. There are some areas where all countries find it difficult to
2325 recruit and retain staff, such as mental health and the care of those with
2326 intellectual disabilities (Patel et al 2007). The problem extends beyond shortages of
2327 specific types of staff. Many countries have struggled to put in place mechanisms
2328 that will support the multi-professional team working required to care for patients
2329 with chronic conditions (Nolte and McKee 2008), especially where the payment
2330 system encourages individualism and fragmentation.

2331

2332 A third problem relates to the geographical distribution of health workers within
2333 countries. Some countries face the challenge of attracting and retaining staff in
2334 isolated rural areas and deprived urban areas where there is a high burden of
2335 disease, and associated workload, and where the quality of life for health workers
2336 and their families maybe poor.

2337

2338

2339 **Tools for monitoring and evidence of variation**

2340

2341 Although data on health workforce are widely available, their interpretation is often
2342 very problematic. Much work has been done to standardised definitions but there
2343 are still many blurred boundaries. There are several different sources of data but
2344 all have limitations. For example, while most doctors on a medical register will be
2345 providing direct patient care, a significant number may be involved in other

2346 activities, such as medical management, academic research, or the pharmaceutical
2347 industry among others. Others may be retired, taking a break from work for family
2348 reasons, or working abroad. Data can also be obtained from employers, but this
2349 typically captures only a subset of all possible employers. For example, it may
2350 exclude those providing care in private facilities. Such data may also vary as to
2351 whether it records the headcount or the whole time equivalent numbers, taking
2352 account of growing rates of part-time working. The problem is further complicated
2353 by the indistinct and often varying boundary between health and social care in
2354 many countries. Thus, a substantial number of nurses may be working in facilities
2355 that would be considered to lie within the health sector in one country within the
2356 social care sector in another.

2357
2358 Most data collection systems have failed to keep up with changing patterns of
2359 health care. They tend to focus on numbers of doctors, dentists, and nurses, even
2360 though modern health care requires the input of many other professional groups,
2361 such as specialist therapists and laboratory workers.

2362
2363 Routine data are even more problematic at finer levels of disaggregation. Thus,
2364 even the definition of medical specialties varies across Europe. Dermato-
2365 venerology is a distinct specialty in many countries, while others have separate
2366 groups of physicians who specialise either in dermatology or sexually-transmitted
2367 diseases. The situation is complicated further because of variation among countries
2368 in whether such specialists operate in hospitals or in ambulatory care facilities and
2369 who is included in the data gathering system (Box 5.1).

2370
2371 **Box 5.1 Definitions of medical specialists included in data from selected**
2372 **Member States**
2373

2374 *France:* Data refer to active physicians in metropolitan France and D.O.M.
2375 (overseas departments). Interns and residents are not included.

2376 *Germany:* Data are on the number of specialists who are actively practising
2377 medicine in public and private institutions and provide services directly to patients
2378 (head-count data).

2379 *The Netherlands:* Data are for professionally active and licensed physicians based
2380 on BIG register (a register of (para)medical professions) and the SSB database (a
2381 micro-integrated database of Statistics Netherlands with data from municipal
2382 register, tax register, social security, business register). Data on doctors in training
2383 are from the KNMG (Royal Dutch Society for the Advancement of Medicine).


2384 *United Kingdom:* Data do not include the private sector. In Northern Ireland, data
2385 exclude bank staff, research fellows, clinical assistants and hospital/medical
2386 practitioners. In Scotland the sum of GPs and specialists is greater than the total
2387 number of physicians due to some staff holding more than one post. There is
2388 currently no simple way of assigning such staff to one group only. Scottish data
2389 also exclude Ophthalmic Medical Practitioners.

2390 Source: WHO

2391
2392 In addition to routinely collected data, there are a number of ad hoc studies and
2393 surveys that provide some comparative data. These are often undertaken by
2394 European professional bodies to inform their policies and practice and many
2395 depend on the availability of committed individuals in each country to collect the
2396 data. Although they have the advantage of using standardised definitions and
2397 survey methods and, in many cases, providing information on the scope of practice
2398 of the professionals concerned, a disadvantage is that they do not cover all
2399 countries and are undertaken infrequently and at irregular intervals. An example is
2400 the European Primary Care Monitor.

2401
 2402 For all these reasons, the limited published data on the health workforce in Europe
 2403 are extremely difficult to interpret and comparisons must be made with great
 2404 caution. Recognising this, there is evidence of considerable variation (Figures 5.1
 2405 and 5.2), with an almost threefold difference in the density of physicians and an
 2406 almost fourfold difference in the density of nurses, although some of the figures at
 2407 the extremes of the range raise questions about the definitions in use. Data
 2408 collected by the OECD also show that there are very substantial differences in
 2409 health worker density within countries, where the definitions should be consistent
 2410 (Figure 5.3).

2411
 2412 **Figure 5.1 Density of physicians, EU28, most recent year**




2413
 2414 Source: WHO

2415
 2416 Note: Data since 2010 unavailable for Denmark, Finland, Slovakia and Sweden

2417
 2418
 2419

2420 **Figure 5.2 Density of nurses, EU28, 2012**




2421
2422
2423
2424
2425
2426
2427

Source: WHO

Note: Data since 2010 unavailable for Cyprus, Denmark, Greece, Netherlands, and Sweden

Figure 5.3 Physician density by territorial Level 2 regions, European OECD countries, 2011 (or nearest year)



2428 Source: OECD (2013)

2429 **Policy responses**

2430

2431 Policy responses to shortages of health workers are simple in theory but difficult to
2432 implement in practice. Many health workers have portable skills that are in demand
2433 in a wide range of high-income countries. Thus, it is clear that there is a global
2434 market for them. Following from this, responses can be considered under the
2435 headings of demand and supply.

2436

2437 If the price a country is willing to pay for health workers is substantially lower than
2438 elsewhere, this implies it has expressed a low level demand as a government or a
2439 society (this is separate from the demand that individuals may express). In such
2440 circumstances, the logical response is to raise the price that it will pay, by
2441 increasing salaries or by provision of non-monetary incentives, such as improved
2442 working conditions. Of course, there may be many obstacles to doing so, including
2443 affordability, but also political willingness and concerns about differentials with
2444 other workers whose skills can less easily be traded internationally.

2445

2446 The other response is to increase supply, with greater investment in training.
2447 However, this is unlikely to be effective unless attention is paid to the demand
2448 side, as otherwise the additional health workers will simply move abroad.

2449

2450 Potential responses to maldistribution of health workers within a country, especially
2451 shortages in rural areas, were examined in a comprehensive review conducted by
2452 the World Health Organization (Dolea et al 2010). It found that the quality of the
2453 evidence overall was weak and there were few evaluations using robust designs.
2454 Interventions for which there was some evidence of effectiveness included
2455 recruitment of students from rural areas, reorienting training to prepare health
2456 workers for practice in rural areas, financial incentives and support programmes for
2457 isolated practitioners, such as those linking them to peers for mutual support.

2458

2459 There is a growing body of evidence on skill mix, ensuring that patients are cared
2460 for by those with the most appropriate skills. The evidence mainly relates to nurses
2461 taking on roles traditionally associated with physicians and there are an increasing
2462 number of well-designed comparisons, including randomised controlled trials
2463 (Martinez-Gonzalez et al 2015). Many studies have methodological limitations and
2464 results cannot easily be extrapolated from one setting to another because of
2465 differences in nurses' roles and competencies. Nevertheless, findings show that
2466 specially trained nurses can provide care for patients with chronic diseases that is
2467 at least equivalent to care provided by physicians, in terms of process of care.

2468

2469 Research into which physician is most appropriate to manage patients show that
2470 general practitioners working in hospital emergency departments request fewer
2471 tests and get better results than junior doctors in training (Dale et al 1996). A
2472 recent trial in which severe head injuries were randomised to be managed at the
2473 site of injury by paramedics only or with additional input from a physician
2474 transported by helicopter produced results that tended to favour the latter (Garner
2475 et al 2015). However, skill mix developments often require significant changes to
2476 the organisational structure of the health facility, recognising that new
2477 responsibilities require different reward systems and can challenge existing
2478 professional hierarchies. They must also take account of the widespread existence
2479 of financial incentives that serve to maintain the status quo.

2480

2481 The European Union can support Member States through better data collection on
2482 health worker functions, remuneration and working conditions; ensuring ethical
2483 international recruitment; promoting cooperation on health workforce policies
2484 through the Expert Group on European Health Workforce and Joint Action on health
2485 workforce planning and forecasting.

2486 **6. Quality medicines and medical devices are available at fair prices**

2487

2488

2489

Chapter summary

2490

2491

2492

Medicines and medical devices contribute significantly to health and quality of life. They account for around 25% of total spending on health care and employ over a million people across the European Union. The efficient use of these vital resources is critical to guaranteeing equitable access to safe and high quality health services. Yet across and within EU countries, many people find it hard to access necessary medicines, supplies and diagnostic tests. In some countries, high out-of-pocket costs are a significant barrier to access and medicines are frequently the most important driver of financial hardship when using health services. In others, people face long waiting times for diagnostics due to lack or inappropriate use of equipment and staff.

2493

2494

2495

2496

2497

2498

2499

2500

2501

2502

The high price of many medicines is becoming an increasing problem for health systems in EU countries, threatening fiscal sustainability. Ironically, this is a problem the European Union has often debated in the context of international development – an issue for the world’s poorest countries. It is now a challenge for a wide range of its own Member States, as recent experiences with Hepatitis C and cancer drugs have shown. The lack of research and development (R&D) in areas of unmet need, such as antibiotics, is also a major concern. These issues call for an urgent re-think of the way in which investment for R&D for medicines is funded and rewarded. The outcome of the current funding model has been a lack of transparency, excessive profits and a failure to develop new drugs where they are most needed. It is time to consider de-linking pricing from R&D, as well as actions to ensure much greater transparency.

2503

2504

2505

2506

2507

2508

2509

2510

2511

2512

2513

2514

2515

Routinely available data on the use of medicines and medical devices are extremely limited. Interpretation of existing data is hindered by the absence of information on prices. Nevertheless, the extent of variation across countries suggests problems of underuse and overuse of medicines and diagnostic equipment.

2516

2517

2518

2519

2520

2521

To address these problems, countries should:

2522

2523

2524

2525

- Ensure fairer prices by identifying more efficient ways to fund R&D, requiring much greater transparency around costs and prices and developing joint procurement agreements for medicines and medical devices.

2526

- Define national policies on medical devices (in addition to medicines).

2527

2528

2529

- Systematically use HTA, including cost-effectiveness and cost-utility analysis, to inform coverage decisions and disinvestment for medicines *and* medical devices.

2530

2531

2532

- Encourage rational prescribing and use of medicines and medical devices through ‘wise lists’, algorithms, guidelines, capacity planning of big-ticket equipment and specialised medical equipment management units.

2533

2534

- Improve information systems and data collection at regional, national and EU level.

2535

2536

2537

The European Union can support Member States to develop more efficient R&D and pricing systems and better information and assessment strategies and by continuing to foster cooperation in HTA and e-health.

2538 **6.1. Medicines**

2539

2540 Antibiotics, vaccines, insulin, anti-psychotics and many other medicines have
 2541 changed the history of diseases and health care in the 20th century. The European
 2542 Union accounts for around a quarter of all pharmaceutical sales globally, and the
 2543 pharmaceutical industry employs over half a million people in EU countries, around
 2544 half of whom are in just three countries, Germany, the United Kingdom and Italy
 2545 (see Figure 6.1).


2546

2547 People living in EU countries have publicly financed entitlement to a wide range of
 2548 medicines. And yet there are thousands of people who cannot access the medicines
 2549 they need and there are many conditions for which effective medicines are lacking.
 2550 Ensuring access to medicines and addressing issues of underuse and overuse
 2551 involves tackling interrelated and challenging problems ranging from the way in
 2552 which research and development (R&D) is funded and rewarded to rational use and
 2553 disinvestment.

2554

2555 **Figure 6.1 Numbers of people employed in the pharmaceutical industry,**
 2556 **EU28, 2012 or latest available year**

2557



2558

2559

2560 Source: EFPIA (2014)

2561

2562 **R&D:** The current system of funding R&D through medicine prices encourages
 2563 pharmaceutical companies to focus on areas likely to be most profitable for them
 2564 rather than areas in which there is unmet need (see Box 6.1 and Box 6.2) (WHA
 2565 2015). The European Union could, however, find more effective ways of funding
 2566 R&D to meet health needs (Bloemen and Hammerstein 2012). An interesting line
 2567 of development would be to de-link prices and R&D costs (WHO 2012a; WHO
 2568 2012b). In 2010, Council Conclusions on the EU's role in global health asked
 2569 Member States to explore this option and to ensure that EU investments in health
 2570 research secure access to the knowledge and tools generated as a global public
 2571 good and generate socially essential medical products at affordable prices. These

2572 ideas were discussed in relation to low- and middle-income countries, but they are
2573 equally relevant to EU Member States.

2574

2575 **Authorisation:** Two key issues warrant attention. First, insufficient controls and
2576 unnecessary controls and barriers. Second, the conflicts of interest that arise when
2577 regulatory agencies are financed (at least in part) by pharmaceutical companies.
2578 For example, 83% of the budget of the European Medicines Agency (EMA) is
2579 financed directly by the industry.

2580

2581 **Pricing:** High prices are becoming an increasingly important barrier to access
2582 (WHO 2015). The Council of the European Union has noted with concern “that the
2583 prices of many new innovative medicines are very high in relation to the public
2584 health expenditure capacities of most Member States, and that this pricing
2585 situation could destabilise health systems in Member States already weakened by
2586 the financial crisis” (Council 2014). In the US a group of physicians and
2587 researchers are supporting a patient-driven initiative and petition to lower the high
2588 price of cancer drugs (Tefferi et al 2014).

2589

2590 High prices are usually linked to patent protection and are justified on the grounds
2591 of re-couping the costs of R&D. However, information about the real costs of R&D
2592 is lacking (EC 2009, Light and Warburton 2011, Light and Kantardjian 2013, DNDi
2593 2014). Some authors have found evidence to suggest “current pricing models are
2594 not rational but simply reflect what the market will bear” (Mailankody and Prasal
2595 2015).

2596

2597 Prices can be set based on cost or value. Patent protection was designed to
2598 guarantee fair compensation for R&D based on cost (CESCR 2005). When a
2599 medicine is protected by patent, prices should be as low as possible, covering costs
2600 (production and R&D) and a reasonable profit (return on investment) to promote
2601 continued investment. However, pharmaceutical companies have changed the way
2602 in which they negotiate prices with national health authorities, moving from a
2603 system based on costs to one based on value. Under this new system, prices are
2604 based on ‘what the market will bear’. At the same time, medicines have become
2605 financial products, and companies face tremendous pressure to obtain high profits
2606 in the short term.

2607

2608 Pricing needs to achieve a balance between static efficiency (lower prices today)
2609 and dynamic efficiency (high prices to maintain incentives for innovation). If,
2610 however, companies ask for the highest price the client is willing to pay (pricing
2611 per value), then patent protection should be removed, creating the conditions for
2612 effective competition through for-profit and non-profit generic companies (OECD
2613 2014).

2614

2615 The Communication from the Commission on effective, accessible and resilient
2616 health systems stated that Member States and the Commission should reflect
2617 further on how to reconcile the policy objectives of ensuring accessible health care
2618 for all EU citizens with the need for cost containment. Consideration should be
2619 given to improved cooperation on building mechanisms for increased transparency
2620 and better coordination to minimise any unintended effects that current national
2621 pricing systems may have in terms of accessibility throughout the EU (European
2622 Commission 2014).

2623

2624 Multilateral initiatives have been proposed in order to address this problem, like
2625 the one led by France and Italy in relation to Hepatitis C (see Box 5.3), or the
2626 agreement signed between the Netherlands, Belgium and Luxembourg to
2627 coordinate joint procurement of orphan drugs. At the same time, Council Subgroup

2628 3 of the Working Party on Public Health at Senior Level continues to work on the
2629 cost-effective use of medicines.

2630

2631 Another important issue is that price negotiations may require two important
2632 features in the negotiation process. First, a maximum price that Member States
2633 (on average) are willing to pay for the specific medicine (ideally in relation to its
2634 cost plus fair profit). This is a contentious issue in many countries. Second, real
2635 bargaining power requires the willingness and ability of negotiators to say 'no' in
2636 cases where prices are too high in relation to the benefits produced. Again, this is
2637 not in line with current practice or the political and social attitude towards
2638 reimbursement decisions in many countries.

2639

2640 During the crisis various Member States approved reduction of prices for different
2641 group of medicines. In some cases there have been used reference prices. In other
2642 cases there have been achieved agreements with the pharmaceutical industry to
2643 limit the total expenditure (or the annual growth). There have been specific
2644 confidential negotiations for new expensive medicines (i.e. hepatitis C treatments),
2645 with different arrangements. Each country is developing different measures,
2646 depending on the context and political balances.

2647

2648 **Procurement:** Usually there are different procurement mechanisms for hospital
2649 medicines and ambulatory medicines. Joint procurement mechanisms have been
2650 established in some countries or regions, to obtaining better prices. The EU has
2651 created the Joint Procurement Agreement for the purchasing of vaccines. The
2652 possibility to use this mechanism for other products should be discussed,
2653 acknowledging purchasing power differences between Member States. If joint
2654 procurement of medicines results in a single price for medicines throughout
2655 Europe, this may result in unaffordability in some Member States even though the
2656 average price may be lower than currently the case. Hence, clear ideas about how
2657 to deal with such differences between Member States – which may require agreed
2658 upon solidarity payments from higher income Member States to lower income
2659 Member States need to be installed.

2660

2661 All these mechanisms have to be evaluated periodically in order to redesign the
2662 systems, improving efficiency. In particular, the dynamic properties of mechanisms
2663 have to be carefully assessed. Extreme competition in price today may create
2664 concentrated market structures in the future.

2665

2666 **Distribution:** Health systems have to guarantee geographical distribution through
2667 wholesalers and pharmacies 365 days per year 24 hours per day. There are
2668 different ways of organizing distribution. Important efficiencies can be obtained
2669 while ensuring safety and quality. Other problems, like drug fakes, non-controlled
2670 prescription and dispensation through internet, etc, that can affect access to
2671 quality and safety medicines.

2672

2673 **Coverage:** Member States decide what medicines are included in the package of
2674 benefits, and to what extent medicines are funded with public resources. The
2675 majority of Member States apply user charges to ambulatory medicines. Cost-
2676 effectiveness analysis and HTA are good methods to accept or reject reimbursing of
2677 a new medicine, or to disinvest in ineffective ones, according to the therapeutic
2678 value of the product. EUnetHTA can play an important role in this field.
2679 Determining the social value of a new product is different from defining pricing
2680 rules for new products. During the crisis some countries decided to de-list
2681 medicines from the package of benefits. It is not clear if the decision has been
2682 taken on a cost-effective analysis bases or only to reduce public spending.

2683

2684 Millions of people in EU cannot afford to pay medicines that they need. Medicines
2685 that are not publicly financed and reimbursed, or that have too-high user charges
2686 are not accessible for patients because of their economic situation. Financial
2687 protection should be ensured and not eroded by health systems.
2688

2689 **Prescribing:** It is possible to improve prescription through adequate continuous
2690 training, using helping mechanisms (e-prescription, algorithms, "wise lists"), and
2691 prioritising the use of generics and biosimilars. Improving prescription of medicines
2692 is not just a question of cost, it is mainly a question of quality and safety, and
2693 preventing negative side effects like antimicrobial resistance.
2694

2695 **Use of medicines:** Patients do not always not take their medicines in the most
2696 effective way. It could be that the patients do not understand the dosage. Other
2697 patients could forget. Some patients do not believe that the use of generic and
2698 biosimilars is effective. Older people can have difficulties if the pharmacist changes
2699 the pill that he is used to have. It is important to take time to explain the patient
2700 how and why he has to take the medicine and to monitor adherence to treatment.
2701 Self-management of complex polypharmacy is a challenge.
2702

2703 **Disinvestment:** It is necessary to evaluate periodically the list of medicines
2704 authorised according to its safety, and efficacy, and to control adverse effects.
2705 Successive innovation leads to the presence of products with distinct effectiveness
2706 for the same clinical need. The use of electronic health records (databases), and
2707 patient registries, could help in this field of management (analysing diagnoses,
2708 dosage, outcomes, etc.) and contribute to improved prescription and efficiency.
2709
2710

2711 **Box 6.1 Antibiotics**

2712

2713 The failure of the current model of drug discovery and development is most
2714 obvious with respect to antibiotics. There have been almost no new antibiotics
2715 since the 1970s and there are none at all in the current development pipeline. The
2716 existing economic model of drug development does not make investment in new
2717 antibiotics by profit-maximising corporations worthwhile. This model is based on
2718 the production of medicines that will be used by as many people and for as long as
2719 possible. Medicines such as those used to treat high blood pressure, a common
2720 disorder requiring lifelong treatment, were ideal. In contrast, courses of antibiotics
2721 typically last for a few days and should be prescribed as sparingly as possible to
2722 avoid the risk of resistance emerging.

2723

2724

2725 **Box 6.2 Macular degeneration**

2726

2727 In recent years manufacturers have decided that the profit margin on a range of
2728 injected generic medicines, such as Phenytoin, do not justify their continued
2729 manufacture despite demonstrable clinical need (Fox et al 2014). The development
2730 of medicines effective against wet macular degenerative disease, a common cause
2731 of blindness, has highlighted a new problem.

2732 Ranibizumab (Lucentis) and Bevacizumab (Avastin) are monoclonal
2733 antibody fragments derived from the same parent monoclonal antibody and acting
2734 through the same mechanism to prevent blood vessel growth. The intellectual
2735 property rights to both are owned by Roche, although Novartis has the rights to
2736 market Ranibizumab in Europe. Bevacizumab is only licensed for use in certain
2737 cancers and Roche has consistently refused to undertake the necessary clinical
2738 trials or to apply for marketing authorisation for its use in eye disease.

2739 Given the resistance by the manufacturer to conduct trials comparing the
2740 two drugs, public funders, including the English National Institute for Health
2741 Research, have funded them, although it has since been revealed that Novartis and
2742 clinicians with close ties to the company lobbied hard to prevent recruitment to the
2743 trial (Cohen 2015). The trials have shown that the two drugs are equally effective,
2744 but Bevacizumab is 10 to 20 times as expensive as Ranibizumab.

2745 Novartis has subsequently successfully lobbied to change guidance from the
2746 UK's medical regulator that would have supported doctors who prescribe medicines
2747 where the manufacturer had refused to seek authorisation for a particular
2748 indication and the published evidence showed that they are effective (Cohen
2749 2015). As a result, in many parts of the United Kingdom, treatment for this form of
2750 preventable blindness is effectively rationed on grounds of cost, despite a much
2751 cheaper and equally effective alternative being available. In contrast, the Italian
2752 Competition Authority fined the two companies a total of €180 million for
2753 maintaining an artificial distinction between the two drugs (Autorità Garante della
2754 Concorrenza e del Mercato 2014).

2755

2756

2757 **Box 5.3 Hepatitis C**

2758

Controversy about impaired access to innovative medicines on grounds of cost has
been reignited by the case of Sofosbuvir, a treatment for Hepatitis C that is highly
effective in eliminating infection and preventing progress to cirrhosis. In some
European countries it is sold for about €25,000 per course (prices have been
negotiated under confidentiality clauses). This means that it is, in effect, unaffordable
for most of those affected in several European countries. Generic versions of
Sofosbuvir can be produced for under \$300 per course (Hill et al 2014). Several
organisations have argued that the manufacturing process is not innovative, an

argument accepted by the Indian Patent Office, which has refused to issue a patent, opening the way for large scale generic manufacture.

In recent years, other new medicines with very high prices have been authorised in Europe, for example, for cancer treatment. The case of Hepatitis C (HCV) is “new” because it affects a large number of people. Current estimates are that between 7.3 and 8.8 million persons are infected with HCV in the European Union (EASL 2014), and the treatment seems to be very effective, safe and without adverse effects.

The case of HCV offers a unique opportunity to discuss the issue of price fixing for new pharmaceutical products, balancing the role of dynamic incentives for R&D investment and extreme value appropriation by companies introducing new products. The pricing of new medicines is a vital issue for the financial sustainability of health systems in the European Union and around the world. It is not a question of discussing the price of a particular product. It is a question of addressing problems created by a pricing process that gives firms strong bargaining power in setting prices with the argument of rewarding innovation.

2759
2760

2761 **Tools for monitoring and evidence of variation**

2762

2763 Routinely available data are limited to expenditure and consumption only, with
2764 substantial variation in both types of indicator across countries. Figure 6.2 shows
2765 that pharmaceutical spending per person is more than double in Belgium compared
2766 to Denmark. However, data on total or public expenditure on medicines are not
2767 particularly useful given differences in consumption (Figure 6.3) and prices across
2768 countries. Looking at the out-of-pocket share of spending on pharmaceuticals gives
2769 a better idea of access issues across countries. Figure 6.4 shows how the out-of-
2770 pocket share varies from under 2% in Luxembourg and the Netherlands to over
2771 15% in Lithuania, Latvia and Hungary.

2772

2773 The lack of policy-relevant data on medicines is surprising and should be addressed
2774 as a priority. The types of data that would be useful include expenditure data
2775 broken down by region, consumption data for outpatient and hospital settings at
2776 national and regional level, survey data on ability to obtain and pay for medicines,
2777 comparable information on drug prices across countries, the extent to which health
2778 care providers adhere to 'wise lists' at national and regional level and the division
2779 of value generated between supply (pharmaceutical companies) and demand
2780 (health systems and patients).

2781

2782

2783 **Policy responses**

2784

2785 Promote dialogue between Member States and stakeholders to reward R&D
2786 investment without excessive prices. Prices should cover the costs of R&D and
2787 production and allow for a reasonable profit, guaranteeing a fair reward for
2788 industry innovation, ensuring access for patients and contributing to the financial
2789 sustainability of health systems.

2790

2791 Enforce transparency around the costs of pharmaceutical companies and the price
2792 of medicines. The use of mandatory licenses in cases where patents are used to set
2793 prices at a level well above production cost (including R&D) should not be
2794 excluded.

2795

2796 Link products that have benefited from EU funds such as Horizon 2020 to socially
2797 responsible licensing.

2798

2799 Support the use of cost-effectiveness analysis in coverage decisions and
2800 disinvestment.

2801

2802 Develop joint procurement agreements for public purchasing of medicines
2803 (vaccines, emergency circumstances, others).

2804

2805 Promote the use of 'wise lists', algorithms and guidelines to enhance efficiency in
2806 the prescribing of all medicines and especially antibiotics.

2807

2808 Improve information systems and data collection at regional, national and EU level.


2809

2810

2811

2812 The European Union can support Member States in the following ways:
2813
2814 Promote joint action to develop a strategy to ensure equitable access to new
2815 medicines and new innovative treatments and fairer prices.
2816
2817 Promote transparency to ensure that patents serve the social purpose for which
2818 they were created. This requires detailed knowledge of costs and prices. Without
2819 this information there is a risk of patent misuse. Evaluate the possibility of
2820 withdrawing patents in cases of misuse.
2821
2822 Consider setting up a European Parliament committee to analyse the prices of new
2823 medicines. The committee should be guaranteed transparency around costs and
2824 prices.
2825
2826 Review the impact of the Supplementary Protection Certificate in ensuring access
2827 to medicines (De Boer 2015).
2828
2829 Link products that have benefited from EU funds such as Horizon 2020 to socially
2830 responsible licensing.
2831
2832 Explore models to separate the cost of R&D from prices (Council Conclusions May
2833 10, 2010) and extend these to EU countries (not just low-income countries).
2834
2835 Evaluate and promote the use of joint procurement mechanisms.
2836
2837 Decouple the financing of EU regulatory agencies (the European Medicines Agency,
2838 EMA) from the pharmaceutical industry. Currently, 83% of the EMA's budget comes
2839 from the industry via authorisation fees). Introduce stricter control over conflicts of
2840 interest.
2841
2842
2843


2844 **Figure 6.2**



Source: OECD Health Statistics 2014; Eurostat Database
Includes medical non-durables (resulting in an over-estimation of around 5-10%) in Ireland, Greece, Slovak R, Italy, Portugal, Netherlands, Lithuania

2845
2846 Source: OECD health data (2015)

2847
2848 **Figure 6.3**




Source: ECDC (2013), Surveillance of antimicrobial consumption in Europe 2011
Data include hospital sector in Lithuania, Slovak R, Cyprus, Data not including non-reimbursed medicines in Spain, Romania

2849
2850 Source: OECD health data (2015)

2851
2852 **Figure 6.4**

Figure... Private Out-of-pocket spending on Pharmaceuticals as a share of total health spending, 2012 (or nearest year)



Source: OECD Health Statistics 2014; Eurostat Statistics Database
The Netherlands do not account for fixed deductible payable patients (350€ per year) as oop spending, resulting in an underestimation of the share of oop payments.

2853
2854 Source: OECD health data (2015)
2855

2856 **6.2. Medical devices**

2857

2858 Medical devices include a huge range of products ranging from contact lenses and
2859 software to stents, prostheses, ophthalmic lasers, pacemakers, defibrillators,
2860 clinical laboratory equipment, surgical equipment, scanning equipment and e-
2861 health technologies. These devices can have a substantial impact on health
2862 outcomes, quality of life and health care expenditure. In addition, the industry
2863 employs over half a million people in Europe and had total sales of €100 billion in
2864 2013. In spite of the crisis, the European market for medical devices grew on
2865 average by 4% a year between 2008 and 2013 (MedTech 2014).

2866

2867 The EU regulatory framework for medical devices was reviewed in Directive
2868 2007/47/EC (EU 2007), followed by an exploratory process on the future of
2869 medical devices initiated in 2009. The Poly Implant Prothèse breast implant
2870 scandal prompted a European Parliament Resolution calling on Member States and
2871 the Commission to implement specific actions. In 2012, the Commission adopted a
2872 proposal for a Regulation on medical devices and in vitro medical devices (EP 2012,
2873 EC 2012). The proposal has been discussed in the European Parliament and in the
2874 Council of Ministers and negotiations between them are expected to start soon
2875 (Council 2015).

2876

2877 Access issues around medical devices are similar to those around medicines.
2878 However, there is even less transparency where medical devices are concerned,
2879 and more needs to be known about their certification, distribution and use. In 2010
2880 the World Health Organization established a global atlas of medical devices, which
2881 it updated in 2014 (WHO 2014).

2882

2883 Important access issues concern:

2884

2885 **Geographical distribution, supply and efficiency in use:** There are wide
2886 variations in the distribution and use of medical devices within and across
2887 countries. Although there are no European guidelines regarding the appropriate
2888 rate of use of different devices, the available information suggests there are likely
2889 to be significant problems of under-use and over-use. So-called big-ticket
2890 equipment needs to be limited in supply to ensure efficiency and quality. If
2891 facilities are lacking or equipment is not being operated efficiently, people may
2892 have to wait too long, resulting in delayed diagnosis, unnecessary suffering,
2893 complications, economic losses and other negative effects.

2894

2895 **Maintenance and life-cycle substitution:** High technology requires careful
2896 instalment and supervision, regular maintenance and attention to replacement as
2897 new devices become available.

2898

2899 **Reprocessing:** The practice of reprocessing and re-using medical devices
2900 designed for single use merits attention.

2901

2902 During the crisis some countries cut medical device budgets, affecting the
2903 availability of supplies ranging from prostheses to CT scans. However, the crisis
2904 also created opportunities for countries to negotiate better prices, organise joint
2905 procurement schemes, assess rates of prescribing and use and improve the supply
2906 of clinical and epidemiological information.

2907

2908 **Tools for monitoring and evidence of variation**

2909

2910 There is barely any comparable information on medical devices. The only routinely
2911 available data focus on big-ticket technologies, mainly the availability and use of
2912 scanning equipment (see Annex 3). There are no data on the prices, cost-


2913 effectiveness and use of or waiting times for other medical devices that have an
 2914 important impact on health outcomes and health care expenditure – notably,
 2915 pacemakers, prostheses, contact lenses, computer software, etc.
 2916

2917 Figure 6.5 indicates the extent of variation across EU Member States in the
 2918 availability of MRI scanning equipment, with a ten-fold difference in the number of
 2919 MRI units between Italy and Hungary. There are three- to twelve-fold differences
 2920 for other scanning equipment (CT, radiation therapy, PET, etc).
 2921

2922 Figure 6.6 indicates a huge difference in the number of MRI scans per 1,000
 2923 population. A difference of this magnitude is difficult to justify on clinical or
 2924 epidemiological grounds in countries with similar levels of economic development.
 2925 It suggests problems of overuse and underuse which are likely to be linked to lack
 2926 of control over the location of scanning equipment and incentives for overuse
 2927 created by the procurement, pricing and provider payment mechanisms in place.
 2928

2929 **Figure 6.5 MRI units per million population, EU28, 2012 or latest available**
 2930 **year**

Figure... Magnetic Resonance Units (2012 or rearest year)
 Per million population




Source: OECD Health Statistics 2014; Eurostat Statistics Database.
 Equipment outside hospital is not included in Denmark, Germany, Belgium, Portugal

2931
 2932
 2933 Source: OECD health data (2015)
 2934

2935
 2936
 2937
 2938
 2939
 2940
 2941
 2942
 2943
 2944
 2945
 2946

2947 **Figure 6.6 MRI units per million population, EU28, 2012 or latest available**
 2948 **year**

Figure... Magnetic Resonance Image exams (2012 or nearest year)
 Per 1000 population



Source: OECD Health Statistics; Eurostat Statistics Database.
 Exams outside the hospital are not included in Denmark, UK, Portugal, Ireland, Cyprus, Romania

2949
 2950
 2951 Source: OECD health data (2015)
 2952
 2953

2954 **Policy responses at national level**

2955

2956 Countries can take a wide range of steps to ensure equitable access to medical
2957 devices, address problems of under- and over-use and improve efficiency in the
2958 use of resources. These include measures to:

2959

2960 ▪ Define national policies on medical devices.

2961

2962 ▪ Establish regulatory agencies and national health technology units. Promote use
2963 of HTA for medical devices.

2964

2965 ▪ Ensure careful planning of facilities and big-ticket equipment.

2966

2967 ▪ Improve procurement processes and pricing systems.

2968

2969 ▪ Create specialised medical equipment management units at national, regional
2970 and hospital level to ensure appropriate use and maintenance.

2971

2972 ▪ Improve the prescribing and rational use of devices and introduce systematic
2973 assessment of variations in use and cost-effectiveness.

2974

2975 ▪ Use devices efficiently (functioning hours) to optimise investment.

2976

2977 ▪ Promote cost-effective ICT solutions to provide services in remote areas.

2978

2979

2980 **Policy responses at EU level**

2981

2982 Approve the new directives on medical devices and in vitro diagnostic medical
2983 devices.

2984

2985 Promote effective coordination between national authorities in implementing the
2986 directives.

2987

2988 Reinforce the capacity of EUnetHTA.

2989

2990 Stimulate cooperation between Member States in the development of e-health
2991 solutions.

2992

2993 Support Member States in the development of information systems and
2994 assessment methods.

2995

2996 Reinforce information systems at EU level to monitor the medical devices sector,
2997 including monitoring of infrastructure, procurement, prices, maintenance,
2998 utilisation and clinical evaluation, adverse effects, serious incidents and traceability
2999 throughout the supply chain.

3000

3001 Promote R&D in medical devices and optimal utilisation strategies.

3002

3003 **7. People can use services when they need them**

3004

3005

Chapter summary

3006

3007

3008

3009

3010

3011

3012

3013

3014

3015

3016

People may find it difficult to use health services when they need them due to: lack of information about services, especially if information is not provided in the patient's language; low levels of literacy in general and health literacy in particular; factors affecting the convenience of services for the general population, such as the absence of an effective appointments system (recognising that not all have access to the internet) or the limited availability of out-of-hours services, home visits, repeat prescriptions by telephone and email or mobile phone contact with providers; the extent to which services are equipped to meet the needs of people with disabilities; and long waiting times.

3017

3018

3019

3020

Although it is extremely hard to find comparable and robust data in any of these areas, the available data consistently highlight the potential for these types of barriers to exacerbate underlying inequalities in access to health services.

3021

3022

3023

3024

3025

3026

3027

3028

Comparative data on health literacy – available for eight countries only – suggest inadequate health literacy is a widespread problem affecting the general population. They also indicate a clear socio-economic gradient, with lower levels of health literacy concentrated among people with poor health status, high health care use, low socio-economic status, lower education and older age (over 75 years). The evidence base for strategies to improve health literacy is weak and needs to be strengthened.

3029

3030

3031

3032

3033

3034

3035

3036

3037

3038

3039

3040

Waiting time data are notoriously problematic, both in terms of definitions and the scope for manipulation. Data on self-reported unmet need due to waiting lists also need to be interpreted with caution, especially since they do not account for financial hardship experienced by people who seek privately financed alternatives when waiting times for publicly financed treatment are excessive. Many national waiting time initiatives have been criticised for failing to prioritise access to treatment based on severity of illness and, in some instances, for creating perverse incentives to prioritise patients with relatively minor needs. Nevertheless, attempting to specify and adhere to maximum waiting times and efforts to provide the public with reliable information on waiting times can play a role in enhancing transparency, accountability and other dimensions of health system performance.

3041

3042

3043

3044

3045

3046

3047

3048

3049

3050

3051

EU-wide data show how 95% or more of all health facilities are accessible to people using wheelchairs in Sweden, Finland, Spain, Greece, Cyprus and the United Kingdom, in contrast to less than 60% in Austria, Germany, Slovakia and Luxembourg⁵ – perhaps a reflection of the dominance of solo office-based practice in these countries. Individual health facilities can and should take a wide range of relatively straightforward steps to make existing services more easily accessible to the general population and to meet the needs of people with disabilities. Countries should also do more to ensure that people have good information about health services in their own language and have access to translation or interpretation services when required.

3052

3053

3054

3055

3056

The European Union can support Member States by harmonising the definition of and collection of waiting time indicators and setting and enforcing standards for accessibility in health facilities for people with disabilities.

⁵ No data were available for Denmark, Croatia and France.

3057 This chapter focuses on five factors that may make it difficult for people to use
 3058 health services when they need them: service information; health literacy; service
 3059 convenience; meeting the needs of people with disabilities; and waiting times.

3060
 3061

Service information

3062
 3063

3064 Patient organisations report that 19 out of 28 EU Member States provide an
 3065 interactive, 24-hour, web- or telephone-based health care information service that
 3066 is publicly available throughout the country (Björnberg 2015). However, such
 3067 services are not reported to be effective in 6 out of the 19 countries, either
 3068 because people do not know about it or because it is hard to access (see Table
 3069 7.1).

3070

**Table 7.1 Availability and effectiveness of interactive, 24-hour web- or
 telephone based health care information service, EU28, 2014**

3071
 3072
 3073

Status of service	EU Member State
Service exists	Austria, Estonia, Finland, France, Italy, Latvia, Lithuania, Portugal, Spain, Sweden, UK
Service exists but few members of the public know about it, or it is hard to access	Belgium, Malta, Netherlands, Poland, Slovakia, Slovenia
Service does not exist	Bulgaria, Croatia, Cyprus, Czech Republic, Greece, Hungary, Ireland, Luxembourg, Romania

3074

Source: Björnberg (2015)

3075

3076

Languages

3077

3078

3079 A more important consideration may be whether information about health services
 3080 is routinely provided in people’s languages and the availability of translation and
 3081 interpretation services. Unfortunately, European efforts to capture the quality of
 3082 the user experience – for example, the Euro Health Consumer Index produced by
 3083 the Health Consumer Powerhouse – do not focus on this or on other factors
 3084 relevant to people who may be especially vulnerable where access to health
 3085 services is concerned.

3086

3087

Health literacy

3088

3089

3090 Traditional indicators of health literacy have been criticised for focusing on reading
 3091 skills, being too clinically focused and not assessing important aspects such as
 3092 understanding and the ability to assess and use information for health promotion,
 3093 disease prevention and self-management of health conditions. More comprehensive
 3094 definitions of health literacy encompass its dynamic interaction with the wider
 3095 health, education and social systems (Nutbeam 2000; Rudd 2004; Institute of
 3096 Medicine 2004; WHO 2013).


3097

3098 Recent research in Europe is adopting a population health perspective going
 3099 beyond individual and clinical dimensions to include interdependencies between

3100 health understanding, health attitudes and behaviour, the social determinants of
 3101 health and the design and delivery of health services (Sorensen et al 2012;
 3102 Kickbusch et al 2013). This research defines health literacy as ‘people’s knowledge,
 3103 motivation and competences to access, understand, appraise and apply health
 3104 information in order to make judgments and take decisions in everyday life
 3105 concerning health care, disease prevention and health promotion to maintain or
 3106 improve quality of life during the life course’ (Sorenson 2012).

3107
 3108 Survey results from Europe and north America show that around half of all patients
 3109 cannot understand basic health care information, which indicates that health
 3110 literacy is not simply a minority problem. The first European survey of health
 3111 literacy, carried out in 2011, found that 48% of all respondents had an inadequate
 3112 or problematic level of health literacy (Figure 7.1). However, this share varied
 3113 across countries, ranging from around 29% in the Netherlands to around 60% in
 3114 Bulgaria and Spain.

3115
 3116 **Figure 7.1 Levels of health literacy in eight EU Member States, 2011**



3117
 3118
 3119 Source: HLS-EU Consortium (2012)

3120
 3121 Note: Data for Germany are for one region only (North Rhine-Westphalia)

3122
 3123
 3124 Low health literacy can increase the risk of medical errors and reduce the success
 3125 of treatment. It is also likely to be a determinant of inequalities in health, because
 3126 low levels of health literacy tend to be concentrated among people with poor health
 3127 status, high health care use, low socio-economic status, lower education and older
 3128 age (over 75 years) (HLS-EU Consortium 2012).

3129
 3130
 3131

3132 **Service convenience**

3133

3134 The term ‘convenience’ covers a wide range of issues around how easily patients
 3135 are able to make use of available health services and how well services are
 3136 organised to be as accessible as possible for everyone. The issue of accessibility for
 3137 people with disabilities is discussed in more detail below. Here, the focus is on the
 3138 population as a whole and people’s ability to access non-emergency services
 3139 beyond normal working hours; have health professionals visit them at home if they
 3140 are unable to travel; obtain repeat prescriptions by telephone or some other means
 3141 so that they do not have to return to the physician’s practice or health centre;
 3142 communicate with the health system in ways that are convenient for them, such as
 3143 by email or mobile phone; and use non-emergency services without registration.

3144

3145

3146 **Meeting the needs of people with disabilities**


3147

3148 People with temporary or permanent disabilities may face a range of barriers to
 3149 accessing facilities. Figure 7.2 shows how the number of primary care facilities
 3150 accessible to people using wheelchairs varies from 100% in Sweden to less than
 3151 60% in Austria, Germany, Slovakia and Luxembourg.

3152

3153 **Figure 7.2 Share of primary care practices accessible to people using**
 3154 **wheelchairs, EU28, 2013**

3155



3156

3157

3158 Source: QUALICOPC (2015)

3159 Note: No data available for Denmark, Croatia and France

3160

3161

3162 **Waiting times**


3163

3164 If services are not readily available due to capacity or funding constraints or
 3165 inefficient use of resources, people may be required to wait for treatment.
 3166 Although not all waiting has negative outcomes – some people on waiting lists
 3167 decide they would prefer not to be treated – there is no doubt that having to wait
 3168 can involve stress, anxiety and pain and some people may die before being
 3169 treated. Long waiting times can also lead to financial hardship for people who seek

3170 private alternatives and may be damaging for public perceptions about the health
 3171 system.

3172
 3173 There is large variation in the extent to which waiting times for treatment are a
 3174 problem in EU Member States. Among European OECD countries, long waiting
 3175 times are not seen as an issue in Belgium, France, Germany and Luxembourg
 3176 (OECD 2013). Among the very limited number of European OECD countries
 3177 reporting waiting times, the average waiting time from specialist assessment to
 3178 treatment for coronary bypass in 2014 ranged from 33 days in the Netherlands to
 3179 over 400 days in Poland (Figure 7.3).

3180
 3181 **Figure 7.3 Average waiting time (days) from specialist assessment to**
 3182 **treatment for coronary bypass, OECD countries for which data are**
 3183 **available, 2006-2014**
 3184



3185
 3186 Source: OECD (2015)
 3187

3188 According to patient organisations, most patients would not wait for more than
 3189 three months for elective surgery in 18 out of 28 EU Member States (see Table
 3190 7.2). Comparing this information to reported unmet need due to waiting lists
 3191 suggests there is no clear link between patient organisation-reported waiting times
 3192 and self-reported unmet need due to waiting lists. The three countries in which
 3193 more than 4% of those surveyed reported unmet need due to waiting lists
 3194 (Finland, Estonia and Poland), as shown in Figure 7.4, experience very different
 3195 levels of waiting time, as shown in Table 7.2. It is possible that patients in some
 3196 countries resolve waiting time issues by paying privately for treatment, either
 3197 through voluntary health insurance or out-of-pocket.
 3198
 3199


3200 **Table 7.2 Extent of waiting time problems for elective surgery, EU28, 2014**
 3201

Extent of waiting time problem	EU Member State
The vast majority of patients (over 90%) would get the operation within three months	Belgium, Bulgaria, Denmark, Finland, France, Germany, Luxembourg, Netherlands
Most patients (over 50%) would get the operation within three months	Austria, Czech Republic, Estonia, Greece, Hungary, Italy, Lithuania, Romania, Sweden, UK
Most patients (over 50%) would typically wait more than three months	Croatia, Cyprus, Ireland, Latvia, Malta, Poland, Portugal, Slovakia, Slovenia, Spain

3202 Source: Björnberg (2015)

3203
 3204
 3205
 3206
 3207

Figure 7.4 Share (%) of the population reporting unmet need for a medical examination due to waiting lists, EU28, 2013



3208
 3209
 3210 Source: Authors based on EU-SILC (2015)

3211
 3212 Waiting time indicators are problematic for several reasons (Pope et al 1991). First,
 3213 their interpretation, although superficially simple, is actually quite complex
 3214 (Cromwell 2004). Second, they assume that everyone on the waiting list is actually
 3215 in need of care, which is not necessarily the case. Third, they may fluctuate in line
 3216 with supply, so that the threshold for placing someone on a waiting list may vary
 3217 according to the anticipated capacity for treatment. Put another way, there may be
 3218 little point in placing someone on a waiting list if there is no prospect of their being
 3219 treated within a reasonable period.

3220
 3221
 3222 **Policy responses**
 3223

3224 Health literacy is recognised as a key dimension of population health improvement
 3225 in the World Health Organization’s Health 2020 policy framework. Unfortunately,
 3226 the European evidence base on the most effective strategies to use for improving
 3227 population health literacy remains underdeveloped, particularly in the area of the
 3228 prevention and control of communicable diseases (Barry et al 2013b).

3229

3230 Many actions to make existing services more easily accessible can be taken without
3231 detailed evidence but rather by applying basic principles. Individual health facilities
3232 can take steps to improve accessibility by strengthening the transport
3233 infrastructure, including public transport networks; extending hours of operation to
3234 fit in with patients' working lives; introducing measures for people with disabilities,
3235 such as wheelchair access, clear signage for those with impaired eyesight and
3236 hearing loops for people with hearing problems; and taking account of the very low
3237 levels of literacy among some groups of patients (Dani et al 2007).
3238

3239 Other measures include outreach activities, such as locating services in peripheral
3240 clinics or using telemedicine. It is essential, however, for these types of strategies
3241 to be evaluated before use. For example, numerous systematic reviews of
3242 telemedicine have concluded that evidence of cost-effectiveness is lacking and
3243 published papers are subject to considerable publication bias (Nordheim et al 2014,
3244 Hasselberg et al 2014, Mistry et al 2014).
3245

3246 Strategies to reduce long waiting times used in EU Member States include targets
3247 backed up by heavy sanctions for hospital managers, including job loss (England);
3248 maximum waiting times organised by the national purchasing agency and
3249 negotiated with providers (Estonia); waiting time guarantees set in law (Sweden);
3250 waiting time guarantees accompanied by access to treatment in the private sector
3251 or abroad (Denmark and Sweden); financial incentives targeting regional
3252 purchasers (Denmark and Sweden); using private sector capacity (England); and
3253 allocating additional funds to tackle long waits in problem specialties (England,
3254 Estonia). Box 7.1 gives examples of maximum waiting times in selected countries.
3255

3256 Many national waiting time initiatives have been criticised for failing to prioritise
3257 access to treatment based on severity of illness and, in some instances, for
3258 creating perverse incentives to prioritise patients with relatively minor needs. For
3259 this reason, the Danish government recently announced plans to abolish the one-
3260 month guarantee and replace it with a differentiated guaranteed based on severity.
3261

3262 Nevertheless, attempting to specify and adhere to maximum waiting times and
3263 efforts to provide the public with reliable information on waiting times can play a
3264 role in enhancing transparency, accountability and other dimensions of health
3265 system performance. The waiting time guarantee in Denmark enabled nearly half a
3266 million people to obtain treatment in private hospitals between 2002 and 2009,
3267 which may have helped to limit out-of-pocket spending and financial hardship for
3268 the patients concerned (Denmark HiT 2012). At the same time, it is possible that
3269 poorly designed and implemented initiatives will exacerbate inequities in the use of
3270 health services.
3271

3272 The European Union can support Member States by harmonising the definition of
3273 and collection of waiting time indicators and setting and enforcing standards for
3274 accessibility in health facilities for people with disabilities.
3275
3276

3277 **Box 7.1 Examples of maximum waiting times in selected EU Member**
3278 **States**

3279

3280 **Estonia**

3281 Maximum wait for a specialist outpatient visit: 6 weeks

3282 Maximum wait for inpatient treatment / day surgery: 8 months

3283 Maximum wait for cataract surgery: 1.5 years

3284 Maximum wait for large joint replacement: 2.5 years

3285

3286 **Denmark**

3287 Maximum wait from diagnosis to treatment: 1 month

3288

3289 **Sweden**

3290 Maximum wait for contact with the health system: same day

3291 Maximum wait to see a GP: 7 days

3292 Maximum wait to see a specialist: 3 months

3293 Maximum wait from diagnosis to treatment: 3 months

3294

3295 Source: European Observatory HiT reports for Estonia, Denmark and Sweden,

3296 available from www.healthobservatory.eu

3297

3298

3299 **8. Services are acceptable to everyone**

3300

3301

Chapter summary

3302

3303

3304

3305

3306

3307

3308

3309

People need to be willing to use services, especially in primary care, which is the first point of contact with the health system for many people. When they use health services, their experience should be as positive as possible because user experience shapes expectations and can influence health care-seeking behaviour in the future. Services that fail to be acceptable to people are likely to be under used, with negative implications for health, efficiency in the use of health system resources and equity in use.

3310

3311

3312

3313

3314

3315

3316

3317

3318

3319

User experiences may be sub-optimal due to not having enough time with the provider, communication failures, lack of involvement in care decisions, lack of respect and lack of privacy. These factors may reflect fear on the part of the user; social, demographic and cultural differences between user and provider, potentially resulting in discrimination on the grounds of age, gender, race, ethnicity, religion or other individual characteristic; lack of user participation or consultation; lack of informational continuity (good health records) and service continuity (especially for out-of-hours services); poor management; and poor training of staff (communication skills, cultural competence).

3320

3321

3322

3323

3324

3325

3326

3327

3328

3329

3330

Comparable data on overall user experience of the health system are not available in the European Union. Routinely collected data on the quality of patient-provider interactions are limited to a handful of countries (see Annex 3). The EU-funded QUALICOPC study is the only reliable source of comparable data on aspects of patient-provider interaction across all Member States. The study shows variation across countries, but its results are difficult to interpret. In general, there is a clear socioeconomic gradient in the quality of interaction between patients and physicians. Poorer people, people with less education and people in lower-paid jobs receive less information, explanation and emotional support than others and are less involved in treatment decisions.

3331

3332

Policy responses lie in the following areas:

3333

3334

- Strengthen the development of culturally sensitive and appropriate services (cultural competence).

3335

- Improve the communication skills of health workers.

3336

- Develop e-health systems for better informational and service continuity.

3337

3338

3339

- Conduct regular national surveys of user experience of the health system, building on the experience of regular user surveys carried out in countries such as Denmark, Spain, Sweden and the United Kingdom.

3340

3341 People need to be willing to use services, especially in primary care, which is the
 3342 first point of contact with the health system for many people. When they use
 3343 health services, their experience should be as positive as possible because user
 3344 experience shapes expectations and can influence health care-seeking behaviour in
 3345 the future. Services that fail to be acceptable to people are likely to be under used,
 3346 with negative implications for health, efficiency in the use of health system
 3347 resources and equity in use.

3348
 3349 User experiences may be sub-optimal due to not having enough time with the
 3350 provider, communication failures, lack of involvement in care decisions, lack of
 3351 respect and lack of privacy. These factors may reflect fear on the part of the user;
 3352 social, demographic and cultural differences between user and provider, potentially
 3353 resulting in discrimination on the grounds of age, gender, race, ethnicity, religion
 3354 or other individual characteristic; lack of user participation or consultation; lack of
 3355 informational continuity (good health records) and service continuity (especially for
 3356 out-of-hours services); poor management; and poor training of staff
 3357 (communication skills, cultural competence).

3358
 3359


3360 **Tools for monitoring and evidence of variation**

3361

3362 Comparable data on overall user experience of the health system are not available
 3363 in the European Union. Routinely collected data on the quality of patient-provider
 3364 interactions are limited to a handful of EU Member States (see Annex 3). The only
 3365 routinely collected data available across all Member States are for unmet need due
 3366 to fear of the doctor, as shown in Figure 8.1. In general, this is a very minor
 3367 source of unmet need, although there is some variation across countries.

3368

3369 **Figure 8.1 Share (%) of the population reporting unmet need for a medical**
 3370 **examination due to fear of doctor, hospital, examination or treatment,**
 3371 **EU28, 2013**



3372


3373 Source: Authors based on EU-SILC (2015)

3374

3375 The EU-funded QUALICOPC study is the only reliable source of comparable data on
 3376 aspects of patient-provider interaction across all 28 Member States. Figure 8.2
 3377 ranks countries on the quality of this interaction in primary care. It shows some
 3378 variation across countries. These data are hard to interpret, however, as we know
 3379 very little about the reasons why patients report lower levels of quality.

3380


3381 **Figure 8.2 Quality of interaction between patient and primary care**
 3382 **physician (score), EU28, 2013**



3383
 3384 Source: QUALICOPC (2015)
 3385 Note: A higher score indicates better interaction based on factors such as
 3386 politeness, attentiveness, eye contact, understandability and asking questions; no
 3387 data available for Croatia and France.

3388
 3389 The same study reports on the share of patients feeling they have been
 3390 discriminated against in the past year because of their gender, age or ethnic
 3391 background by health workers in the primary care practice they visit or by other
 3392 patients (Figure 8.3). Although this ought to provide some explanation in theory, in
 3393 practice the association between these two sets of results is weak ($R^2 = 0.19$).

3394 **Figure 8.3 Share (%) of people feeling discriminated against by health**
 3395 **workers or other patients in their primary care practice, EU28, 2013**
 3396



3397
 3398 Source: QUALICOPC (2015)
 3399 Note: No data available for Croatia, France and Slovakia.

3400
 3401 Continuity of care – the extent to which a series of health services is experienced
 3402 as connected, coherent and consistent with a patient's health needs and personal
 3403 circumstances (Haggerty et al 2003) – is an important factor in determining the
 3404 quality of patient-provider interaction. While the benefits to patients of always
 3405 seeing the same physician (relational continuity) are limited, the benefits of

3406 informational continuity cannot be overstated, especially the presence of good
3407 health records. Continuity of out-of-hours services is also critical.

3408

3409

3410 **Resonance for specific people**

3411

3412 Studies find a clear socioeconomic gradient in the quality of interaction between
3413 patients and physicians. Poorer people, people with less education and people in
3414 lower-paid jobs receive less information, less explanation, less emotional support
3415 and are less involved in treatment decisions.

3416

3417

3418 **Policy responses at national level**

3419

3420 Policy responses lie in the following broad areas: strengthening the development of
3421 culturally sensitive and appropriate services (cultural competence); improving the
3422 communications skills of health workers; and developing e-health systems for
3423 better informational continuity and service continuity.

3424

3425 Culturally competent health services require a range of actions, including the
3426 definition of agreed standards and frameworks for practice, the development of
3427 supportive policies and organisational structures, the provision of education and
3428 training for staff, the effective use of cultural mediation to support providers and
3429 the recruitment of staff from ethnic or cultural minorities.

3430

3431 Countries should increase efforts to conduct regular national surveys of user
3432 experience of the health system, building on the experience of regular user surveys
3433 carried out in countries such as Denmark and Sweden.

3434

3435

3436

3437 **Access for Roma, undocumented migrants and people with mental health**
3438 **problems**

3439

3440 **Chapter summary**

3441

3442 Some groups of people experience particular difficulties in accessing health
3443 services. This chapter focuses on barriers to access among three underserved
3444 population groups in Europe: Roma people, undocumented migrants and people
3445 with mental health problems. The literature shows that these groups experience
3446 substantial problems in accessing health services due to legal, financial and
3447 administrative barriers, fragmentation and lack of flexibility in the organisation of
3448 services, complex needs, lack of knowledge about health services, fear and
3449 mistrust, cultural, language and communication barriers and experience of stigma
3450 and discrimination.

3451

3452 Effective policy responses to bridge the gap between need and health service use
3453 for these underserved groups of people include the following:

3454

3455 ▪ Guarantee their entitlement and access to health services.

3456

3457 ▪ Provide them with a combination of mainstream and specialised outreach
3458 health services.

3459

3460 ▪ Deliver interventions to enhance knowledge about health services and improve
3461 health literacy.

3462

3463 ▪ Develop services that are culturally competent to meet the needs of diverse
3464 populations.

3465

3466 ▪ Train health service providers to reduce barriers to service uptake.

3467

3468 The European Union can support Member States by funding research into cost-
3469 effective approaches to improving access for underserved people and research on
3470 the benefits of improved access for these people; promoting the dissemination of
3471 good practice; and advocating the implementation of effective policy responses.

3472 Population groups that experience particular difficulties in accessing health services
3473 include: people living in poverty, the homeless, long-term unemployed, those
3474 without health insurance, with poor education, poor health literacy, people living in
3475 rural isolated areas, older people, people with mental disorders and disabilities,
3476 ethnic minorities, migrants, asylum seekers and refugees and members of traveller
3477 and Roma communities.

3478

3479 Barriers to access may be associated with health policies and the organisation of
3480 the health system, including legal restrictions on entitlement to health services for
3481 certain population groups as well as financial barriers. In most EU countries, for
3482 example, there are legal restrictions on entitlements to access for asylum seekers
3483 and undocumented migrants with access to emergency services available in most,
3484 but not all countries. Other barriers include special requirements for referral to
3485 specialist care e.g., mental health services. Fees for service users and the costs of
3486 medicines create inequity in access for many marginalised groups due to their
3487 generally lower socioeconomic status. Barriers due to language, communication,
3488 sociocultural factors, lack of trust, discrimination and poor health literacy may also
3489 be experienced by vulnerable groups.

3490

3491 The stressful and poor living conditions of vulnerable and socially excluded groups
3492 and the lack of responsiveness of health services in meeting their complex health
3493 and social needs can result in costly patterns of service use (Carr et al 2014). This
3494 includes a high reliance on acute services such as Accident and Emergency as
3495 opposed to utilisation of primary care, and underutilisation of specialist or
3496 outpatient care have also been reported. There are low referral and attendance
3497 rates for disease prevention among vulnerable groups, including lower coverage
3498 and uptake of screening and immunisation, and difficulties in accessing services
3499 related to preventive reproductive health, prenatal care and mental health
3500 services. Efforts to improve the accessibility and uptake of health services will
3501 contribute to reducing costs associated with the treatment of illness and will
3502 improve the health of vulnerable groups.

3503

3504 Studies analysing policies and rights conclude that legal entitlements to health care
3505 including emergency care, child immunisations, antenatal care and mental health
3506 services, vary considerably across EU Member States (see Table 2.1). However, it
3507 is important to note that legal entitlements do not always correspond with access
3508 to care as there are country differences in implementation of rights at regional and
3509 individual level among health care providers and employers. Similar barriers
3510 among different health systems, including communication difficulties, cultural
3511 misunderstandings, referral difficulties and delayed or disrupted care, have been
3512 reported (Dauvrin et al 2012). The particular barriers experienced by underserved
3513 population groups will be explored in the following paragraphs.

3514

3515 An earlier study of differences in access to health care worldwide identified three
3516 broad categories of groups (Healy and McKee 2004). These are; i) indigenous
3517 populations, such as Native Americans, Australian Aborigines, and New Zealand
3518 Maori; ii) migrants, and especially those with cultural characteristics that differ
3519 from the majority population and those lacking documentation; iii) others defined
3520 by shared characteristics, including location (e.g. rural dwellers), legal status (e.g.
3521 prisoners), functioning (e.g. physical or mental disability, or age (older people),
3522 among others. In this report we examine the barriers faced by groups representing
3523 each of these three categories in Europe: Roma, undocumented migrants, and
3524 people with mental health problems.

3525

3526 Much research and many policy responses to inequalities in access to care have
3527 focused on groups defined by single characteristics, such as those listed in the
3528 previous paragraph. However, many people have multiple characteristics that,

3529 while individually important, have even more important consequences when
3530 combined. This recognition has given rise to an area of study termed
3531 intersectionality (Bauer 2014).⁶ So far, most research on inequalities in access to
3532 health care using an intersectionality perspective has been undertaken in North
3533 America, but similar studies are required to provide a more comprehensive
3534 understanding of the determinants of inequalities in Europe.

3535

3536

3537 **Roma**

3538

3539 Roma are Europe's largest ethnic minority, numbering 10-12 million and
3540 comprising up to 12% of the population in some countries. They have long been
3541 known to face barriers to health care, including distance to health facilities,
3542 unwillingness of health professionals to treat them, fear and mistrust of health
3543 professionals and lack of access to statutory health insurance schemes. In the last
3544 decade more and more attention has been drawn to Roma in Europe as a
3545 vulnerable and marginalised population group. The Roma population is an
3546 extremely diverse group that includes several subgroups (Hajioff and McKee 2000;
3547 Jarcuska et al 2013). Depending on the place they currently reside they will be
3548 referred to as Roma, Romani, Gypsies or Travellers.

3549

3550 The European Commission (2014) published a 'Roma Health Report' which
3551 highlighted how Roma still experience a lower life expectancy, up to 20 years
3552 fewer. In addition, infant mortality rates are significantly higher in some Roma
3553 populations and they are generally more likely to suffer from infectious diseases
3554 and communicable diseases (European Commission 2004, 2014). These findings
3555 can be explained partly by worse living-conditions (Eurofound 2012) and risk
3556 factors. However, the lower health status of Roma can also be explained by their
3557 limited access to care and levels of unmet need (ERRC 2006).

3558

3559 A series of household surveys designed to assess the living conditions of Roma was
3560 conducted between May and June 2011 by the UNDP, the World Bank, and the
3561 European Commission in 12 European central and eastern European countries.
3562 Primary sampling units were drawn randomly from settlements where, according to
3563 census data, Roma were more than 50% of the population. Non-Roma populations
3564 were sampled from those living in close proximity to the Roma settlements. That
3565 study found that Roma were significantly less likely to have health insurance than
3566 non-Roma in all countries except Slovakia and Serbia, with the greatest differences
3567 in Montenegro, Bosnia and Herzegovina, Croatia, Bulgaria, and Romania. Even
3568 after adjusting for employment status and income, the gap between Roma and
3569 non-Roma remained significant in Montenegro, Croatia, Bosnia and Herzegovina,
3570 Bulgaria, Romania and Moldova.


3571

3572 Further analysis of these data shows that Roma report higher levels of unmet need
3573 than non-Roma in each one of the countries studied (Figure U.1).

3574

⁶ Initially developed by feminist scholars researching the experiences of African Americans, intersectionality seeks to understand the complex challenges faced by those defined by the interaction of different social locations. These interactions occur within the context of connected systems and structures of power, such as laws, policies, religious institutions, and the media. Thus, from an intersectionality perspective, human lives cannot be reduced to single characteristics and social categories such as gender, sexuality, ethnicity, and class are socially constructed, fluid, and flexible while social locations are shaped by interacting social processes and structures that are influenced by time and place.

3575 **Figure U.1 Unmet need for health care among Roma and their non-Roma**
 3576 **neighbours, 2011**



3577
 3578 Source: EU-SILC (2015)

3579
 3580 Both higher unmet need and lower access can be explained by the barriers that
 3581 Roma experience in their search for care. Some of these barriers, such as lack of
 3582 financial resources and geographical remoteness, are relatively common and are
 3583 also prevalent barriers for other vulnerable groups (ERRC 2006; Jarcuska et al
 3584 2013). However, the European Roma Rights Centre (2006) identified barriers which
 3585 are particularly critical for the Roma population. One such barrier is the systematic
 3586 exclusion of Roma from health-insurance schemes (ERRC 2006). Not only are the
 3587 insurance contributions usually unaffordable for this population, they often lack the
 3588 necessary documents and identification required to join an insurance scheme. A
 3589 recent study by Kühlbrandt et al (2014) has shown that in almost all central and
 3590 east European countries Roma are significantly less likely to be insured than Non-
 3591 Roma, with the biggest differences being found in Montenegro, Bosnia and
 3592 Herzegovina, Croatia Bulgaria and Romania. The absence of personal documents
 3593 and citizenship is not only problematic in obtaining an insurance but also in
 3594 receiving fundamental rights and social benefits such as pensions, social
 3595 assistance, and basic care (ERRC 2006).

3596
 3597 In addition to actual lower access, information of how to access relevant care is
 3598 mostly absent in Roma communities (ERRC 2006). This is true for Roma in their
 3599 native country as well as for those who migrated to another country in Europe. In
 3600 both cases Roma often live outside the mainstream society and have little
 3601 knowledge about their rights or the possibilities to gain access to medical care.
 3602 Apart from the lack of knowledge on health services, (il)literacy and language
 3603 differences also hinder Roma in accessing and obtaining health care.

3604
 3605 The barriers mentioned above are enforced by the direct and indirect discrimination
 3606 by health care providers and government policies (European Commission 2004). In
 3607 2012 a survey in 11 EU-Member States revealed that the proportions of Roma who
 3608 felt discriminated ranged from 25% in Romania to 60% Czech Republic, Greece,
 3609 Italy and Poland (FRA 2012). Discrimination can occur in an indirect way by
 3610 excluding Roma from the labour market, education or even denying them

3611 citizenship (ERRC 2006) and forcing them to migrate to neighbouring countries
3612 where they often remain permanent illegal. More overt forms of discrimination
3613 have also been reported, including the denial of emergency aid, refusal to treat
3614 Romani patients, segregation in hospital facilities and even extortion of money
3615 from Romani patients by health care providers have been documented (ERRC
3616 2006; European Commission 2014).

3617
3618 In response to these problems several European countries have implemented new
3619 policies to address the situation of the Roma in their country (ERRC 2006).
3620 Outreach programmes using trained members of the Roma and Traveller
3621 communities are documented in the literature (Carr et al 2014). Examples include
3622 the Pavee Point Primary Health Care Project in Ireland (Murphy 1999) and the
3623 Roma health mediators programme in Eastern Europe and Finland (Open Society
3624 Institute 2005). In 2005, a new platform called 'Decade of Roma Inclusion' was
3625 launched. In its statement 14 European countries declared to: "work toward
3626 eliminating discrimination and closing the unacceptable gaps between Roma and
3627 the rest of society." (Decade of Roma Inclusion 2005). These countries have
3628 developed different projects to achieve Roma inclusion, which include strategies
3629 such as immunisations campaigns targeted specifically at the Roma communities,
3630 health education, communication-training for personnel working with Roma
3631 (European Commission 2014), and the use of Roma health mediators (see also Box
3632 U.1). Since the launching of this platform, much attention has been given to the
3633 health-improvement of the Roma-community in Europe. Meanwhile, the European
3634 Council continues to stimulate the European Member States to develop and
3635 implement policies that improve Roma-integration and inclusion (European
3636 Commission 2014).

3637
3638

3639 **Box U.1 Mediators in care for Roma**

3640

3641 In 1987, a non-governmental organisation implemented the 'Health Promotion
3642 among Navarre Ethnic Minorities'- programme (Jarauta et al 2010). This
3643 programme targeted the deplorable health of the Roma-community by using
3644 mediators from within the Roma-community. They received extensive training in
3645 the health needs of Roma, aspects of personal empowerment, the functioning of
3646 health care services and other services used by the Roma, etc... . The mediators
3647 function as an intermediary between the Roma community and policy, by assessing
3648 their needs and expectations, developing a local strategy for that particular
3649 community and the implementation of the plan. The programme succeeded in
3650 achieving higher levels of primary health care coverage, better maternal and child
3651 care, increasing participation of Roma in various health care and prevention
3652 programs and increased school attendance of Roma-children. Since its success
3653 similar programs were implemented in e.g.: Belgium, France and Romania
3654 (European Commission 2014).

3655

3656

3657 **Undocumented or irregular migrants**

3658

3659 Undocumented or irregular migrants are regarded as one of the most socially
3660 marginalised groups in Europe. Policies exist at a European level to improve health
3661 care for migrants in general; however, the actual implementation of these in
3662 practice is highly variable (Cuadra 2011). In the EU context, 'undocumented
3663 migrants' or 'irregular migrants' refers to "third country nationals without a valid
3664 permit authorizing them to reside in EU Member States" (Cuadra 2011), covering
3665 rejected asylum seekers, those who have violated the terms of their visas, as well
3666 as those who have entered the country illegally. It is estimated that 1% of the
3667 entire population in the EU and circa 10% of the foreign-born population is
3668 undocumented (Duvell 2010 cited in Cuadra 2011).

3669

3670 **Box U.2 Access to health care by undocumented migrants in the UK**

3671

3672 In 2014 the United Kingdom government imposed major restrictions on the ability
3673 of undocumented migrants to access health care. This was despite evidence that,
3674 even before this, they faced many obstacles because of difficulties in navigating
3675 the system. As a consequence, when they were treated, it was often at a late stage
3676 in their illness. A number of qualitative studies seeking to understand their
3677 experiences have highlighted the scale of the challenges they face (Poduval et al
3678 2015, Britz and McKee 2015). They also show that the claims by politicians that
3679 migrants come to the United Kingdom purely to obtain health care, a phenomenon
3680 pejoratively termed health tourism, has no basis in evidence. Moreover, these
3681 studies raise serious questions about the risk posed to the population in general as
3682 a result of late diagnosis of communicable disease.

3683

3684 In the Council of Europe Resolution 1509 (2006) on Human Rights of Irregular
3685 Migrants - Article 13.2 states that as a minimum right, emergency care should be
3686 available for irregular migrants and that Member States should seek to provide
3687 more holistic health care, in particular for vulnerable groups such as pregnant
3688 women, children, people with a disability, older migrants etc. However, these
3689 human rights obligations appear to be only partially met, or not at all in the
3690 majority of Member States. A comparative study of national policies regarding the
3691 right to access to health care for undocumented migrants in the 27 EU Member
3692 States found that there are wide differences in the entitlement to health care in the
3693 EU (Cuadra 2011) (see Table 2.1). However, the authors comment that there are
3694 gaps in the implementation of these policies in practice, whereby health care staff

3695 may refuse access where they do not know the rules or may grant access in spite
3696 of restrictive regulations. These variations were found to be independent of the
3697 system of financing or the number of undocumented migrants present in the
3698 country, but were rather related to categories or types of undocumented migrants
3699 and country level strategies for controlling migration.

3700

3701

Box U.3 Access to health care for undocumented people in Belgium

3702

3703

Since 1996, a royal decree organises the access for Undocumented People to "urgent medical care" in Belgium. Originally, this system was organised in the framework of the Public Centres for Social Welfare, run by the local authorities. Undocumented People had access to care providers (physicians, nurses,) where they received "free care" for "urgent" health conditions. They also had access to those medicines that were integrated in the official reimbursement-scheme of the health insurance system. The providers had to fill in administrative documents in order to be paid by the Public Centres, that then had to ask for reimbursement at the federal government.

3712

Certainly at the primary care level and in the emergency departments, care providers tried to help Undocumented People, broadening the scope of "urgent medical care" to follow-up of chronic conditions, prevention, family planning, pregnancy. The system was quite complex, required a lot of instruction for the stakeholders at the different levels and created frustration as reimbursement was sometimes delayed. Moreover, it was not always easy to assess the entitlement to free "urgent medical care" for different groups of "Undocumented People": asylum seekers, political refugees. The strategy to "distribute" the undocumented people over all the cities and villages in Belgium, required an important effort in terms of information sharing, competency building and development of skills. After more than 10 years the system was optimised, in this sense that the Undocumented People who had free access to "urgent medical care", had to first collect a "medical card" at the Public Centre for Social Welfare. The administrative overhead and frustration at the level of care providers and administrative staff was huge and contrasted with the limited amount of the budget spent for the reimbursement (+/- 41 million euros a year). Moreover, the "medical card" had frequently to be renewed, not all groups of undocumented people were included, and there was a need for an official address (domiciliation).

3730

Recently, a proposal to integrate the system for medical care for Undocumented People in the broader social insurance system was developed and one of the sickness funds was asked to provide membership for Undocumented People so that they could access health care as other citizens do. The transition from a selective approach to a more universal strategy is under assessment.

3735

3736

Measures adopted by the Spanish government in 2012 have resulted in further restrictions in access to health care for undocumented migrants (Council of Europe 2014 - report of the European Committee of Social Rights) with a loss of health coverage previously granted (MINECO 2013). The Spanish Government has recently announced a partial coverage for primary care consultations. In contrast, Sweden passed a law in July 2013 which has broadened access to health services for undocumented migrants, leading to improved access to a range of primary and secondary health services and with no evidence of an increase in migration following the health care reforms) It would appear that the problems that undocumented migrants experience are related to both the laws governing access and to the variable implementation of these laws in practice. As international and national migration policies are becoming more restrictive, urgent attention is needed to avoid worsening the current situation.

3749

3750

The stressful environments in which undocumented migrants live and work are not conducive to good health, particularly mental health. Mental health is one of the

3751

3752 most frequently reported health needs of undocumented migrants in EU countries
3753 (PICUM 2010) and findings also indicate that infectious diseases such as HIV, TB
3754 and chronic Hepatitis B rates may be relatively high, while access to screening,
3755 immunisation and treatment is relatively low (Chauvin et al 2009, 2015). Effective
3756 public health care needs to reach all, including those without documentation. The
3757 lack of reliable data on the health of undocumented migrants remains a problem,
3758 especially those not seeking care, and leads to their invisibility in health service
3759 planning (Mladovsky 2007; PICUM 2015).

3760
3761 The literature on health and access to health care for undocumented migrants in
3762 the EU is limited, although increasing, in part because of increasing restrictions on
3763 entitlement to care being imposed in several countries. A scoping review by
3764 Woodward et al (2014) identified several studies, which were mainly qualitative in
3765 approach, that described poor self-reported health among undocumented migrants
3766 with increased stress and mental health problems being reported. Access to health
3767 care was described as variable and unpredictable depending on choices of health
3768 care workers. Barriers to health care access were found at primary, secondary and
3769 tertiary level. Primary care access was often delayed with the continuum of care
3770 disrupted /delayed for pregnant undocumented migrants. Hospital referrals were
3771 limited and several studies raised concerns about mental health services access
3772 (Strassmayr et al 2012).

3773
3774 Preserving the health advantage of newly arrived migrants has been identified as
3775 an important preventive strategy (Mladovsky 2007), however, there is a paucity of
3776 research on access to prevention and health promotion for undocumented migrants
3777 in Europe. Particularly vulnerable undocumented migrant groups include children,
3778 pregnant women and detainees. Studies describe the lack of, or delays in antenatal
3779 care (van den Muijsenbergh 2007, PICUM 2014, Mladovsky 2007) with women
3780 facing payment barriers at hospitals and lack of referrals to gynaecologists.
3781 Delayed health care seeking and practical financial and administrative barriers to
3782 health service access among undocumented migrant children and their parents is
3783 frequently reported (PICUM 2014, 2015). Access to dental, HIV, and TB services
3784 are also reported as limited. The Platform for International Cooperation on
3785 Undocumented Migrants (PICUM) argue that for services to be accessible in
3786 practice, there needs to be a clear separation or 'firewall' between service provision
3787 and immigration enforcement so that the personal information of undocumented
3788 service users is not shared with immigration authorities.

3789
3790 Major access barriers reported in the literature include:

- 3791 ▪ Lack of awareness of legal entitlements among undocumented migrants and
3792 health care providers.
- 3793 ▪ Fear of being reported to the authorities was cited as an important barrier to
3794 care seeking.
- 3795 ▪ Financial obstacles limited access to secondary care, with access to primary
3796 care also affected. Costs prevented undocumented migrants from accessing
3797 care and medicines.
- 3798 ▪ Cultural and language barriers were described as reducing undocumented
3799 migrants' ability to negotiate treatment options, compounded by limited socio-
3800 cultural skills among providers, potentially compromising quality of care.
- 3801 ▪ The complexity of the social needs and health problems of undocumented
3802 migrants lead to difficulty in providing adequate treatment and reduced quality
3803 of care.

3804

3805 Access appears to be improved by the presence of voluntary health organisations,
3806 which play a role in referring undocumented migrants to accessible primary and
3807 secondary care providers and provision via outreach clinics. Some NGOs also
3808 provide advocacy and legal support. However, there is concern that the
3809 responsibility for delivery should not rest solely with non-governmental
3810 organisations. Closer cooperation between governments and NGOs is needed,
3811 including user involvement in the design and provision of accessible services.

3812
3813

3814 **People with mental health problems**

3815

3816 Mental health problems are estimated to account for up to 30% of the burden of ill-
3817 health across Europe as measured by Years Lived with Disability (WHO 2014), with
3818 suicide being one of the ten most common causes of premature death (European
3819 Commission 2010). In any one year, some 38% of the EU's population experience
3820 a mental disorder (Wittchen et al 2011) and the rate remains persistently high.
3821 Access to mental health care for those who need it is critical, yet the gap between
3822 need and utilisation of mental health care services is wide in many countries in
3823 Europe (Alonso et al 2007). There is a need to improve access for the treatment of
3824 common and severe mental disorders, and the delivery of early intervention,
3825 prevention and mental health promotion adapted to the needs of diverse
3826 population groups, especially those who are vulnerable and socially disadvantaged
3827 (WHO 2013). On foot of the economic crisis in Europe, mental health care budgets,
3828 already operating from a low base, have been cut in many countries, giving rise to
3829 serious concerns regarding the adequate provision of mental health care.

3830

3831 People with mental disorders are at greater risk for poorer physical health and
3832 have higher levels of disability and earlier mortality, as they die on average 20
3833 years earlier (Brown et al 2010). There is also evidence that people with severe
3834 mental disorders and comorbid physical health problems are less likely to receive
3835 standard level of health care for metabolic, cardiovascular, viral, respiratory and
3836 other disorders (De Hert et al 2011). On average 26% of people with mental
3837 disorders in Europe are provided with treatment, which compares with over 75%
3838 for those with physical illnesses (Wahlbeck and Huber 2009). Health professionals
3839 have more difficulties when diagnosing and treating physical health problems in
3840 people affected by mental disorder and stigma and discrimination are recognised
3841 as being detrimental to the provision of good quality care. Specific strategies are
3842 needed to improve the access to appropriate health services for people with mental
3843 disorders, including improving the prevention and early detection of mental health
3844 problems, and the effective delivery of mental health promotion and primary
3845 prevention for both children and adults (Campion et al 2012, Barry et al 2013a).

3846

3847 People who experience social exclusion and marginalisation are more likely than
3848 the rest of the population to experience mental health problems (Friedli 2009)
3849 and are also more likely to be over-represented in psychiatric hospital admissions
3850 (Priebe et al 2012). However, it is not clear what actions have been taken by
3851 governments in different Member States to address social exclusion as a
3852 determinant of mental health or how much priority has been given to targeted
3853 mental health promotion and strategies to improve access to appropriate health
3854 services. If mental health services are organised separately from other health care
3855 services, gaps arise in the provision of comprehensive services to people with
3856 multiple and complex problems, including mental and physical health needs,
3857 addiction and social needs such as homelessness (Canavan et al 2012). The
3858 integration and co-ordination of services across the health and social care sectors
3859 is of vital importance, as is ensuring good coordination between primary health
3860 care and mental health services. The co-occurrence of mental disorders with
3861 substance use disorders has given rise to the integration of specialised mental

3862 health and addiction treatment in several European countries (Wahlbeck 2010).
3863 Although the evaluation of integrated care models for people with mental health
3864 problems and /or addictions is limited, existing evidence is encouraging concerning
3865 their positive outcomes (Wahlbeck 2010).

3866
3867 The EU-funded PROMO project (DG Sanco: 2007-2010), assessed and described
3868 services in 14 EU capital Member States in order to identify good practice in mental
3869 health care for socially marginalised groups in Europe (Priebe et al 2012). The
3870 focus was on the delivery of health and social care for people with mental health
3871 problems who belong to one of the six following groups: long-term unemployed;
3872 homeless; street sex workers; asylum seekers/refugees; undocumented migrants;
3873 travelling communities. The quality of care provision was investigated and the
3874 components of good practice identified. The relevant policies and legislation in the
3875 participating countries were also identified and reviewed.

3876
3877 The most important barriers to care for these socially marginalised groups across
3878 all 14 countries were grouped into seven categories:

- 3879 ▪ Limited entitlements and administrative barriers to obtaining health care,
3880 particularly for asylum seekers and undocumented migrants, but also for the
3881 other groups who may be without health insurance.
- 3882 ▪ Complexity of needs and limited ability to engage, because marginalised people
3883 often live in poor socio-economic circumstances, inadequate housing, and social
3884 isolation, having chaotic life styles and lack information on health services.
- 3885 ▪ Language barriers and cultural differences between clients and staff in services,
3886 with a shortage of resources for trained interpreters (and a reluctance to use
3887 them where available) and often very different explanatory models for mental
3888 health problems.
- 3889 ▪ Lack of flexibility in the organisation of services and administrative procedures.
- 3890 ▪ Poor co-ordination and collaboration among services in the same area.
- 3891 ▪ Negative attitudes and discrimination towards some of the marginalised groups
3892 (particularly travelling communities, street sex workers, and the homeless).
- 3893 ▪ Clients from marginalised groups often mistrust or fear staff in services, which
3894 may be associated with previous negative experiences.

3895
3896 The collected evidence from this project suggested four components of good
3897 practice that apply across all marginalised groups:

- 3898 ▪ Establishing outreach programmes for marginalised groups to identify, engage
3899 with and help individuals with mental health problems.
- 3900 ▪ Facilitating access to general health services that include expertise and
3901 treatment programmes for mental disorders (providing different aspects of
3902 health care in one service and reducing the need for further referrals).
- 3903 ▪ While practice in mental health care for socially excluded and vulnerable groups
3904 varies substantially across Europe, there are some common barriers to good
3905 care for these groups. PROMO identified components of good practice, based on
3906 what is already in place or has been suggested as improvements, that apply
3907 across health and social care systems in Europe. These practices may guide
3908 future policies to improve mental health care for socially marginalised groups.
3909 In addition to sufficient financial and human resources, this requires the
3910 appropriate organisation of both individual services and the way services are
3911 co-ordinated, training programmes for staff in different services, the provision
3912 of information material, and improving the attitudes of health and social care
3913 professionals towards socially excluded groups.
- 3914 ▪ Disseminating information on health services available to marginalised groups
3915 to both the marginalised groups themselves and other services.

3916
3917

3918 **Box U.4 Good practice for different marginalised people with mental**
3919 **health problems**
3920

3921 *Homeless people*

- 3922 ▪ Reducing administrative barriers to access mental health care (especially for
- 3923 those without insurance or without a permanent address).
- 3924 ▪ Including mental health expertise in outreach teams for appropriate
- 3925 assessments and referrals.
- 3926 ▪ Training mental health professionals to use a flexible and non-intrusive
- 3927 approach.
- 3928 ▪ Training staff in frontline services for homeless people, including
- 3929 accommodation/housing services, to increase awareness of mental health
- 3930 problems.

3931
3932 *Asylum seekers/refugees*

- 3933 ▪ Funding of and facilitating access to competent interpreting services.
- 3934 ▪ Providing culturally appropriate mental health care services.
- 3935 ▪ Developing good collaboration between mental health services and other
- 3936 organisations involved in the care for asylum seekers/refugees such as migrant
- 3937 organisations, not-for-profit organisations, asylum authorities and social
- 3938 welfare organisations.
- 3939 ▪ Clear information for mental health services on the entitlements of asylum
- 3940 seekers and refugees to care.

3941
3942 *Street sex workers*

- 3943 ▪ Including mental health expertise in the outreach services for sex workers.
- 3944 ▪ Establishing effective collaboration between specialised outreach services and
- 3945 mental health services to facilitate access to care.

3946
3947 *Undocumented migrants*

- 3948 ▪ Funding of and facilitating access to competent interpreting services.
- 3949 ▪ Providing clear information to migrant organisations on available services and
- 3950 on the entitlements of undocumented migrants to use them.

3951
3952 *Long-term unemployed*

- 3953 ▪ Training staff in unemployment agencies (e.g job centres) to be aware of the
- 3954 prevalence and implications of mental disorders.
- 3955 ▪ Establishing close collaboration of unemployment agencies (e.g. job centres)
- 3956 with mental health and social care services.
- 3957 ▪ Providing long-term and flexible training and employment schemes to
- 3958 accommodate the specific needs of people with mental disorders.

3959
3960 *Travelling communities*

- 3961 ▪ Providing a specialised point of entry into health care either with mental health
- 3962 expertise (eg cultural mediators, specialised health care staff) or close
- 3963 collaboration with a mental health service.
- 3964 ▪ Fostering cooperation between mainstream mental health services and non-
- 3965 governmental organisations specialising in care for travelling communities.

3966
3967 **Policy responses**
3968

3969 It is clear from this brief review that entitlement to health care does not always
3970 translate into access or uptake of services. The literature on barriers to access for
3971 underserved population groups shows that there is some consistency across the
3972 groups in relation to the main barriers experienced. There is also some consistency
3973 regarding examples of good practice in reducing inequalities in health access.
3974 These include strategies to:

3975

3976 ▪ Guarantee access for underserved groups, incorporated explicitly into health
3977 policies and supported by adequate resources and service user involvement in
3978 the design and planning of services to meet their specific needs.

3979

3980 ▪ Underserved groups should use 'mainstream' services, which should be
3981 organised in such a way as to ensure uptake among these groups.

3982

3983 ▪ Establish outreach services for underserved and socially excluded groups with
3984 trained peer health workers who will help bridge the gap between specific
3985 needs of excluded groups and mainstream health service provision.

3986

3987 ▪ Increase knowledge related to access and health literacy for vulnerable and
3988 underserved groups, supported by the provision of services and material
3989 developed for specific ethnic and linguistic groups, taking into account levels of
3990 education and literacy.

3991

3992 ▪ Develop culturally competent health services that will meet the health needs of
3993 diverse population groups, through the use of qualified interpretation services,
3994 multilingual staff, cultural mediators and other organisational supports and
3995 practices, that will provide culturally accessible, acceptable and effective
3996 services.

3997

3998 ▪ Train health care providers to enable the participation of services users in the
3999 planning and delivery of services. Includes, advocacy, informal support and
4000 advice in empowering both providers and patients in reducing barriers to
4001 service uptake.

4002

4003 Further research is needed to determine the most effective and efficient
4004 approaches to improving access to health service for underserved population
4005 groups, including research to inform policy decisions about the optimal balance of
4006 specialised and mainstream services and the effectiveness of different outreach
4007 service models for different groups.

4008

4009 The provision of effective prevention and health promotion services for these
4010 groups is important to ensure tailored support and interventions are provided
4011 before health problems emerge and become severe and intractable.

4012

4013 Accessible and good quality health care for vulnerable underserved population
4014 groups needs to be defined and developed in a participatory way based on the
4015 active involvement of group members in determining levels of needs and the
4016 planning and delivery of appropriate models of service provision. A combination of
4017 research-based information and user participation is critical.

4018

4019 **Ensuring equitable access: EU and Member State responsibilities and**
4020 **responses**

4021
4022 **Chapter summary**
4023

4024 The EU Charter, the EU Treaty and the International Covenant on Economic, Social
4025 and Cultural Rights all establish a right of access to core health services for
4026 everyone, especially vulnerable and marginalised groups of people, with an
4027 equitable distribution based on need. Interpretation of these documents suggests
4028 there should be progressive realisation of the right to health, requiring countries to
4029 move forward and, by implication, not to adopt measures that are regressive. In
4030 addition, core obligations constitute a universal floor, not a ceiling. This has
4031 particular resonance in light of health system responses to the financial and
4032 economic crisis in Europe.

4033
4034 Assuring this right is primarily the responsibility of Member States. Nevertheless,
4035 the European Union has a mandate to complement national policies towards
4036 improving public health, preventing physical and mental illness and diseases and
4037 removing sources of danger to physical and mental health.

4038
4039 Overall, there is need for *better monitoring* to identify the magnitude of access
4040 problems in a timely manner, to measure changes over time and across groups of
4041 people and to enhance international comparability. There is also a need for *more*
4042 *policy analysis* to enable a deeper understanding of the causes of access problems
4043 and to identify cost-effective policy responses.

4044
4045 The indicators routinely used to monitor access in the European Union are limited
4046 in scope and relevance (see Annex 3): very few are available across all 28 Member
4047 States, almost none is available at sub-national level and only a handful can be
4048 broken down by population sub-group. Stronger and more accountable health
4049 systems call for a new generation of data collection in which indicators are robust,
4050 comparable across countries and relevant to European and national contexts; data
4051 are collected and disseminated in a timely and visible manner; and disaggregated
4052 at sub-national levels and by sub-groups in the population.

4053
4054 For inspiration, the European Union should look to the United States, where the
4055 National Center for Health Statistics provides a wealth of up-to-date information
4056 and analysis for the nation as a whole and across its 50 states.⁷ To match the
4057 quantity and quality of data available to health policy makers in the United States,
4058 the European Commission will need to:

- 4059
- 4060 ▪ Develop a robust framework of indicators relevant to access issues that can be
tailored to national contexts.
 - 4061 ▪ Harmonise data collection and classification across national statistical offices
4062 and ensure adequate funding for national data collection, especially during
4063 economic downturns.
 - 4064 ▪ Safeguard privacy in data collection, particularly where record linkage is
4065 required.
 - 4066 ▪ Gather information from hard-to-reach groups, who may experience the worst
4067 barriers to access.
 - 4068 ▪ Co-ordinate initiatives across countries.

⁷ <http://www.cdc.gov/nchs/>

4069 The most important areas requiring better data collection, and those where the
4070 information gaps are largest, are unmet need (better comparability across
4071 countries), utilisation of health services (disaggregated by region and population
4072 groups), user experience of the health system, financial protection and links
4073 between access barriers and health outcomes. Improving the availability and
4074 transparency of data on pharmaceutical costs and prices and finding a more
4075 efficient way to fund R&D should also be priorities, so that people living in the
4076 European Union can benefit from access to needed medicines and medical devices
4077 that are fairly priced.

4078
4079 The causes and consequences of poor access to health services are diverse.
4080 Because of this, monitoring, policy analysis and actions to improve access need to
4081 be tailored to a specific context. In this report we have identified actions in eight
4082 policy areas, at national and EU level. The actual policy responses required in a
4083 given context will depend, to a large extent, on the current state of the health
4084 system.

4085
4086 Evidence on unmet need clearly indicates the magnitude of financial barriers to
4087 access: cost is the single most important factor behind self-reported unmet need.
4088 Ensuring health services are affordable for everyone should therefore be a priority
4089 for the Member States. Improving affordability requires identifying and addressing
4090 gaps in publicly financed coverage to keep out-of-pocket payments as low as
4091 possible. It also has particular resonance when it comes to access to medicines,
4092 especially (but not only) new and innovative medicines, which are increasingly
4093 priced beyond the reach of many countries, including countries in the European
4094 Union.

4095
4096 The report has pointed out that promoting access does not mean making
4097 everything available to everyone at all times. Rather, it involves efforts to ensure
4098 access to health services that are relevant to people's need, appropriate and as
4099 cost-effective as possible. This is an area that will require added attention as
4100 evidence of unwarranted variation in clinical practice increases and if health
4101 budgets do not grow in line with population health needs. The report has also
4102 emphasised the importance of service availability – well-equipped facilities within
4103 easy reach; enough health workers, with the right skills, in the right place; and
4104 stimulating research and development in areas of significant clinical need, such as
4105 antibiotics.

4106
4107 A final area the report has covered is user experience. Whether people have the
4108 information and skills needed to navigate complex health systems; whether they
4109 can obtain appointments with ease and treatment without excessive waits;
4110 whether they are treated with respect and dignity, are able to avail of services in
4111 their own language and are sufficiently involved in decisions about their treatment
4112 – these are questions that are often overshadowed by issues of affordability and
4113 availability and yet they may have a critical impact on access to health care,
4114 especially for systematically underserved groups of people.

4115
4116 In covering all of these different areas, the report has aimed to show how ensuring
4117 equitable access to health services is a multi-dimensional challenge. There are very
4118 few simple or quick fixes. It is also a permanent challenge, requiring sustained
4119 effort on many fronts. Better monitoring, context-specific policy analysis and
4120 research targeting hard to reach groups of people can contribute to this effort.
4121 However, real progress will only be made – and felt – when Member States are
4122 ready to act in response to what the available data already clearly demonstrate.

4123
4124
4125

4126 This report has tried to illustrate the extent of variation in access to health care
4127 between countries in the European Union. Demographic changes, increasing
4128 migration, ethnic diversity and the high price of some medicines are creating new
4129 challenges for EU health systems. More inclusive and accessible health systems are
4130 needed to prevent inequities in health from growing.

4131
4132 The focus of this chapter is on the roles and responsibilities of the European Union
4133 and its Member States in ensuring equitable access to health services. It focuses
4134 on the need for a new generation of data collection for effective, accessible,
4135 resilient and accountable health systems; summarises the policy responses
4136 identified in previous chapters; and comments on the challenges and opportunities
4137 these actions entail.

4138
4139

4140 **The roles and responsibilities of the European Union and its Member** 4141 **States**

4142

4143 As noted in Chapter 1, the right to access health services is set out in the European
4144 Union's Charter of Fundamental Rights, which states that:

4145

4146 Everyone has the right of access to preventive health care and the right
4147 to benefit from medical treatment under the conditions established by
4148 national laws and practices. A high level of human health protection
4149 shall be ensured in the definition and implementation of all the Union's
4150 policies and activities. (Article 35)

4151

4152 The Charter does not specify where responsibility lies for ensuring these rights. For
4153 this it is necessary to look to the Treaty on the Functioning of the European Union,
4154 which makes clear that the competence of the European Union is strictly limited
4155 with respect to the first part of Article 35 of the Charter:

4156

4157 Union action shall respect the responsibilities of the Member States for
4158 the definition of their health policy and for the organisation and delivery
4159 of health services and medical care. The responsibilities of the Member
4160 States shall include the management of health services and medical
4161 care and the allocation of the resources assigned to them. (Article
4162 168.7)

4163

4164 The Treaty also notes that Union action to ensure health protection:

4165

4166 ...shall complement national policies, shall be directed towards
4167 improving public health, preventing physical and mental illness and
4168 diseases, and obviating sources of danger to physical and mental
4169 health. Such action shall cover the fight against the major health
4170 scourges, by promoting research into their causes, their transmission
4171 and their prevention, as well as health information and education, and
4172 monitoring, early warning of and combating serious cross-border
4173 threats to health. (Article 168.1)

4174

4175 EU Member States have other obligations under international agreements. The
4176 primary instrument in this respect is the International Covenant on Economic,
4177 Social and Cultural Rights. The Covenant has been interpreted by the Committee
4178 on Economic, Social and Cultural Rights, an international body tasked with
4179 monitoring compliance with Covenant, giving rise to a body of jurisprudence and
4180 authoritative interpretation of international human rights law that identifies the
4181 rights of individuals and the obligations of those who should secure their rights.
4182 Several principles flow from this body of material.

- 4183
4184 *All states, no matter how poor, should offer a minimum core level of provision,*
4185 *which should include at least the following obligations:*
- 4186 ▪ To ensure the right of access to health facilities, goods and services on a non-
4187 discriminatory basis, especially for vulnerable or marginalised groups
 - 4188 ▪ To provide essential drugs, as from time to time defined under the [Word
4189 Health Organization] Action Programme on Essential Drugs
 - 4190 ▪ To ensure equitable distribution of all health facilities, goods and services
4191 [based on need]
 - 4192 ▪ To adopt and implement a national public health strategy and plan of action, on
4193 the basis of epidemiological evidence, addressing the health concerns of the
4194 whole population
- 4195 Right of access to core health services, with an equitable distribution based on
4196 need, therefore lies at the heart of Member States' responsibilities.
4197
- 4198 *There should be progressive realisation of the right to health.* This requires
4199 countries to move forward towards the right to health and, by implication, *not to*
4200 *adopt measures that are regressive.* This has particular resonance in light of health
4201 system responses to the financial and economic crisis in Europe. In addition, each
4202 state should make progress "to the maximum of its available resources", which
4203 implies an explicit comparison of what is being provided and available resources. If
4204 states claim they cannot provide health care to the level seen elsewhere, they are
4205 obliged to demonstrate why. And if states are able to move beyond their core
4206 obligations, they have a legal obligation to do so: core obligations constitute a
4207 universal floor, not a ceiling. One clear implication of this principle is that when
4208 budget cuts cannot be avoided, they should be implemented selectively, with great
4209 care to ensure that cuts first target areas in which they will do least damage to
4210 equitable access to health services and to population health.
4211
- 4212 *Interventions should be cost-effective to maximise the benefit from available*
4213 *resources,* derived from non-discrimination. The Committee has noted that
4214 'expensive curative health services which are often accessible only to a small,
4215 privileged fraction of the population, rather than primary and preventive health
4216 care benefiting a far larger part of the population' are an '[i]nappropriate health
4217 resource allocation [that] can lead to discrimination that may not be overt'. In
4218 countries with relatively generous entitlement for the whole population, the same
4219 principle applies, but the divide is not so much between privileged and poor as
4220 between different illnesses. Non-discrimination therefore takes a broader
4221 perspective.
4222
- 4223 *There should be shared responsibility among states.* When the Committee
4224 elaborated states' core obligations arising from the right to health, it explicitly
4225 referred to international assistance: 'For the avoidance of any doubt, the
4226 Committee wishes to emphasise that it is particularly incumbent on State parties
4227 and other actors in a position to assist, to provide 'international assistance and co-
4228 operation, especially economic and technical' which enable developing countries to
4229 fulfil their core and other obligations'. Thus, there is an obligation on richer states
4230 to prioritise equitable access to health care in their international assistance
4231 programmes.
4232
- 4233 *There is an imperative for participatory decision-making,* derived from the principle
4234 of non-discrimination. The Committee believes that national public health
4235 strategies and plans of action that states are required to adopt and implement
4236 'shall be devised, and periodically reviewed, on the basis of a participatory and

4237 transparent process'. Thus, the health concerns of the whole population should not
4238 simply be assessed from epidemiological data but should incorporate people's
4239 expressed priorities.

4240

4241 *The needs of vulnerable or marginalised groups should be addressed explicitly*, the
4242 last derived from non-discrimination. Participation in the process of developing and
4243 monitoring national plans must specifically include marginalised populations in a
4244 meaningful way. Where particular health concerns disproportionately affect
4245 vulnerable or marginalised populations, it may be incumbent on the state to
4246 include interventions in its benefit package, even where the interventions needed
4247 are not considered cost-effective overall. This presents an explicit trade-off
4248 between the different objectives of a health system, in which improving access for
4249 disadvantaged groups may receive more weight than improving access for more
4250 advantaged groups.

4251

4252 In summary, the EU Charter, the EU Treaty and the International Covenant all
4253 establish a right to health care. They indicate that its assurance is primarily the
4254 responsibility of Member States. Nevertheless, the European Union has a mandate
4255 to complement national policies towards improving public health, preventing
4256 physical and mental illness and diseases, and obviating sources of danger to
4257 physical and mental health. The following section indicates areas and ways in
4258 which this might be possible.

4259

4260

4261 **A new generation of data collection for effective, accessible, resilient and** 4262 **accountable health systems**

4263

4264 Ensuring equitable access to health services across and within countries in the
4265 European Union requires action at EU and national levels:

4266

4267 ▪ *Better monitoring* to identify the magnitude of access problems in a timely
4268 manner, to measure changes over time and across groups of people and to
4269 enhance international comparability.

4270

4271 ▪ *More policy analysis* to enable a deeper understanding of the causes of access
4272 problems and to identify cost-effective policy responses.

4273

4274 The tables in Annex 3 list the indicators that are routinely used to monitor access
4275 in the European Union. On one hand, these indicators have the advantage of being
4276 consistently defined and collected over several years. On the other hand, it is
4277 evident that they are limited in scope and relevance. For example, none of these
4278 indicators is available at sub-national level, only a handful can be broken down by
4279 population sub-group and, with the exception of health expenditure data and
4280 unmet need data from EU-SILC, none are available across all 28 Member States.

4281

4282

4283

4284 **Goals, principles and governance for better monitoring and analysis**

4285

4286 If the European Union is serious about promoting effective, accessible and resilient
4287 health systems, there is an urgent need to invest in improving the health
4288 information infrastructure. Stronger and more accountable health systems call for a
4289 new generation of data collection based on the following principles:

4290

4291 ▪ Indicators that are robust, comparable across countries and relevant to
4292 European and national contexts.

4293

4294 ▪ Data collected and disseminated in a timely and visible manner.

4295

4296 ▪ Data disaggregated at sub-national levels, so that it is possible to identify
4297 regions requiring particular attention; analysis shows that variations within
4298 countries are sometimes greater than variations across countries.

4299

4300 ▪ Data disaggregated by sub-groups in the population, so that it is possible to
4301 identify differences between groups of people based on socio-economic status,
4302 health status, age, gender, ethnicity, residence in urban vs rural areas or other
4303 relevant characteristics.

4304

4305 The governance of this new data collection system will require greater involvement
4306 by the European Commission in the way in which relevant data are identified and
4307 collected, in line with the European Union's mandate to ensure a high level of
4308 human health protection. For inspiration, the Commission can look to the United
4309 States, where the National Center for Health Statistics provides a wealth of up-to-
4310 date information and analysis for the nation as a whole and across its 50 states.⁸

4311

4312 To match the quantity and quality of data available to health policy makers in the
4313 United States, the Commission will need to engage in a number of areas:

4314

4315 *Develop a robust framework of indicators relevant to access issues that can be*
4316 *tailored to national contexts.* This is something the EU Social Protection Committee
4317 identified as a key priority in 2013. Since then it has been working on a Joint
4318 Assessment Framework for Health, which includes indicators measuring access to
4319 health services.

4320

4321 *Harmonise data collection and classification across national statistical offices.* The
4322 Commission has been reluctant to require national statistical offices to adhere to
4323 EU standards, seeing its role as co-ordinating rather than imposing standards.
4324 However, this stance no longer seems appropriate in an era in which the
4325 Commission and EU Member States are committed to systematic assessment of
4326 health system performance. International and national statistical offices need to
4327 use standard definitions and make sure that indicators capture the same
4328 dimensions in a consistent fashion across countries and account for cultural
4329 differences.

4330

4331 *Safeguard privacy in data collection, especially where record linkage is required.*
4332 Monitoring access more effectively means developing national information systems
4333 that allow countries to link patient records across datasets using unique patient
4334 identifiers (see below). Few countries are able to link records at present, but the
4335 need to do so is growing and, as it grows, the need to safeguard patient rights also
4336 increases.

⁸ <http://www.cdc.gov/nchs/>

4337
4338 *Gather information from hard-to-reach groups, who may experience the worst*
4339 *barriers to access.* Vulnerable or marginalised groups of people are often least
4340 likely to participate in surveys targeting the general population, making them
4341 invisible to researchers and health systems. None of the European Union’s survey
4342 instruments that can offer insights into access – EU-SILC, SHARE (Survey of
4343 Health, Ageing and Retirement in Europe), Health interview and Health
4344 Examination Surveys – is likely to adequately capture the experience of people who
4345 are systematically underserved by the health system. This failure wastes
4346 resources. The Commission should develop specific methods to improve data
4347 collection among hard-to-reach groups of people, some of whom may actively
4348 avoid contact with researchers and bureaucrats.

4349
4350 *Ensure adequate funding for national data collection.* At the start of the crisis,
4351 Greece stopped collecting SHARE data due to the severe fiscal constraints it faced
4352 – a move that has undermined its ability to monitor the effects of the crisis on a
4353 vulnerable group of people. The European Union could draw on structural funds to
4354 provide matching funding for national statistical offices that agree to adhere to EU-
4355 defined standards and to enable Member States to invest in vital data collection
4356 when it is most needed.

4357
4358 *Ensure national data collection results are easily accessible.* Some countries – the
4359 Netherlands, for example – charge individuals and institutions relatively large sums
4360 of money to access routinely collected household budget survey data, while others
4361 (the United Kingdom) make it freely available and easily downloadable, at least to
4362 anyone based in a university. The Commission could address this by requiring
4363 more data to be made available centrally, through Eurostat.

4364
4365 *Co-ordinate initiatives across countries.* Some EU health systems are making rapid
4366 progress in the design and use of access measures such as surveys of user
4367 experiences and outcomes. Reaping the benefits of these innovations, and making
4368 them more internationally comparable, requires an international framework.

4369
4370 EU Member States should not see the collection of EU-wide data as a burden. A
4371 stronger system of data collection will benefit individual Member States by
4372 enhancing their ability to identify and respond to problems. It will also benefit the
4373 European Union as a whole.

4374
4375

4376 ***The content of better monitoring and analysis***

4377

4378 There are many areas that could be strengthened. Here, we focus on what we
4379 regard as the most important and those where the information gaps are largest.

4380

4381 *Unmet need:* Throughout the report we have highlighted both the importance and
4382 the limitations of EU-SILC data on unmet need. These critical data are less useful
4383 than they could be because they lack international comparability and explanatory
4384 power. Additional research is needed to understand how the survey question is
4385 understood by different people in different countries.

4386

4387 *Utilisation of health services, disaggregated:* Countries should be required to collect
4388 standardised administrative data on the use of health services, to help identify and
4389 interpret evidence of unmet need. Administrative data on utilisation need to be
4390 linked to data on individual characteristics, including socio-demographic
4391 information and measures of deprivation within geographically defined
4392 communities. Such systems are currently rare within Europe, but should be

4393 encouraged to become the norm in the next few years, accompanied by
4394 appropriate safeguards.

4395

4396 *User experience of the health system:* Data on user experience would also help to
4397 identify and interpret evidence of barriers to access. Some countries are beginning
4398 to invest in regular national surveys – notably Denmark and Sweden – and now is
4399 the time for the Commission to build on their experience and facilitate better
4400 collection of this important indicator across more countries.

4401

4402 *Financial protection:* A limitation of unmet need data is that they do not tell us
4403 about financial hardship patients experience when using health services, which
4404 might be significant enough to present a financial barrier to access in the future.
4405 Two routes need to be explored. First, EU-SILC should be adapted to include proxy
4406 measures of financial hardship. In 2014, suggestions were made to and considered
4407 by the EU Social Protection Committee’s Joint Assessment Framework for Health.
4408 Second, the Commission should invest in better and more regular collection of
4409 household budget survey (HBS) data – for example, developing a standardised
4410 health module with a detailed set of questions on households’ use of and spending
4411 on health services and requiring countries to use this at regular intervals. At
4412 present, the minimum requirement for household budget surveys is one every five
4413 years. HBS can be used to estimate the extent to which people are pushed into (or
4414 further into) poverty by out-of-pocket spending on health and the extent to which
4415 out-of-pocket payments prevent people from spending on other essential items
4416 such as food, shelter and utilities (gas, electricity etc). The WHO Regional Office for
4417 Europe is currently working to provide new and more robust estimates of financial
4418 protection in a range of EU Member States, but the lack of appropriate data is an
4419 obstacle.

4420

4421 *Links between access barriers and health outcomes:* More research is needed into
4422 how typical indicators of access – for example, health workforce shortages, time
4423 spent with health professionals, waiting times etc – affect health outcomes.

4424

4425

4426 **Actions to ensure equitable access: a summary of national and EU policy**
4427 **responses**

4428

4429 The causes and consequences of poor access to health services are diverse.
4430 Because of this, monitoring, policy analysis and actions to improve access need to
4431 be tailored to a specific context. Here, we identify a broad set of actions in the
4432 eight policy areas covered in the report. For each area we summarise actions to be
4433 taken at national level, by the Member States, and supporting actions to be taken
4434 at EU level, by the European Union. The actual policy responses required in a given
4435 context will depend, to a large extent, on the current state of the health system.

4436

4437

4438

4439

4440

4441

4442

4443

4444

4445

4446

4447

4448

4449

1 Financial resources are linked to health need

National policy responses	EU support
<ul style="list-style-type: none"> ▪ Link the availability of public funding for health to population health needs, especially during economic downturns. ▪ Countries with low levels of public spending on health should allocate a higher share of the government budget to the health sector. ▪ Ensure public funding is used effectively, rather than simply driving up the prices of technology or highly specialised staff. ▪ Introduce and improve sub-national resource allocation formulas. ▪ Move away from provider payment that links payment solely to inputs. 	<ul style="list-style-type: none"> ▪ Routinely collect data on sub-national health care expenditure patterns. ▪ Identify regions in need of additional public spending on health. ▪ Ensure unmet need is accounted for in country-specific recommendations made as part of the European Semester. ▪ Help countries develop secure systems of record linkage, including unique patient identifiers.

2 Services are affordable for everyone

National policy responses	EU support
<ul style="list-style-type: none"> ▪ Ensure most health system funding comes from public rather than private sources. ▪ Keep out-of-pocket payments as low as possible. ▪ Identify and close gaps in publicly financed coverage of cost-effective services. ▪ Broaden the basis for entitlement to encompass everyone living in a country. ▪ Eschew discriminatory approaches such as entitlement linked to employment status or payment of contribution or situations in which people with different diagnoses are entitled to different benefits. ▪ Improve user charges so they do not create financial barriers to cost-effective services or undermine financial protection. ▪ Ensure efficient use of public resources. ▪ Address informal payments using a 	<ul style="list-style-type: none"> ▪ Prohibit discriminatory approaches such as entitlement linked to employment status or payment of contributions. ▪ Adapt EU-SILC to include proxy measures of financial protection. ▪ Require countries to carry out household budget surveys on more frequently than every five years and develop a standardised health module to enable better estimation of financial protection.

mix of policy instruments.

- Social protection policies are critical to addressing poverty and income inequality.

3 Services are relevant, appropriate and cost-effective

National policy responses

EU support

- | | |
|--|--|
| <ul style="list-style-type: none">▪ Ensure the publicly financed benefits package covers the full spectrum of services, is correlated with population health needs and does not result in inequity by disease.▪ Take steps to avoid over-medicalisation.▪ Put in place systematic priority-setting processes to enable HTA-informed, cost-effective coverage decisions for both new and existing technologies.▪ Develop clinical guidelines and referral systems, adapt guidelines to meet the needs of people with multiple morbidities and monitor adherence to guidelines.▪ Train and support health workers to deliver services in line with evidence.▪ Ensure all patients have access to adequate and accessible information about treatment options and outcomes.▪ Establish information systems to identify (and publicly report on) practice variations and patient outcomes and to support effective decision making by health professionals and patients. | <ul style="list-style-type: none">▪ Support the strengthening of activities currently carried out by EUnetHTA. |
|--|--|

4 Well-equipped facilities are within easy reach

National policy responses	EU support
<ul style="list-style-type: none">▪ Engage in area-level planning to create networks of dispersed facilities feeding into a central one, based on agreed clinical pathways.▪ Develop mechanisms to facilitate the transport of patients to health facilities or health professionals to patients.▪ Both responses require administrative structures that can take a population-wide perspective and have the managerial tools required for capacity planning.▪ In the absence of geographical responsibility for health, instruments such as certificates of need for advanced medical technology can be used.	<ul style="list-style-type: none">▪ Continue work to develop European reference networks (ERNs).

5 There are enough health workers, with the right skills, in the right place

National policy responses	EU support
<ul style="list-style-type: none">▪ Put in place processes to train adequate numbers of health workers.▪ Establish working conditions designed to retain staff in underserved countries and areas: remuneration commensurate with skills and attention to broader working conditions, including access to peer support and continuing professional development.▪ Ensure an appropriate mix of skills is in place. This may require investment in additional administrative or care staff to relieve pressure on specialised health professionals, the development of new roles, such as specialist nurses, or task shifting, with delegation of certain roles to less specialised staff.	<ul style="list-style-type: none">▪ Improve data collection on health worker functions, remuneration and working conditions.▪ Ensure ethical international recruitment.▪ Promote cooperation on health workforce policies through the Expert Group on European Health Workforce and Joint Action on health workforce planning and forecasting.

6 Quality drugs and devices are readily available

National policy responses	EU support
<ul style="list-style-type: none"> ▪ Ensure fairer prices by identifying more efficient ways to fund R&D, requiring much greater transparency around costs and prices and developing joint procurement agreements for medicines and medical devices. ▪ Define national policies on medical devices. ▪ Systematically use HTA, including cost-effectiveness analysis, to inform coverage decisions and disinvestment for both medicines and medical devices. ▪ Encourage rational prescribing and use of medicines and medical devices through 'wise lists', algorithms, guidelines, capacity planning of big-ticket equipment and specialised medical equipment management units. ▪ Improve information systems and data collection at regional, national and EU level. 	<ul style="list-style-type: none"> ▪ Develop more efficient R&D and pricing systems. ▪ Improve information and assessment strategies. ▪ Foster cooperation in HTA and e-health.

7 People can use services when they need them

National policy responses	EU support
<ul style="list-style-type: none"> ▪ Ensure people have good information about health services in their own language and have access to translation or interpretation services when required. ▪ Strengthen the evidence base for strategies to improve health literacy. ▪ Specify and adhere to maximum waiting times; differentiate waiting times by severity of illness; provide the public with reliable information on waiting times. ▪ Individual health facilities can and should take a wide range of relatively straightforward steps to make existing services more easily accessible to the general population and to meet the needs of people with disabilities. 	<ul style="list-style-type: none"> ▪ Harmonise definition and data collection for waiting time indicators. ▪ Set and enforce standards for disabled access in all health facilities.

8 Services are acceptable to everyone

National policy responses	EU support
<ul style="list-style-type: none">▪ Strengthen the development of culturally sensitive and appropriate services (cultural competence).▪ Improve the communications skills of health workers.▪ Develop e-health systems for better informational and service continuity.▪ Conduct regular national surveys of user experience of the health system, building on the experience of regular user surveys carried out in countries such as Denmark, Spain, Sweden and the United Kingdom.	<ul style="list-style-type: none">▪ Support the sharing of good practice regarding methods to assess user experience.

4450

4451 **Challenges and opportunities**

4452

4453 In discussing ways of ensuring equitable access to health care, this report has
4454 focused on eight policy areas, identifying key issues, highlighting evidence of
4455 variation within and across countries where available and suggesting policy
4456 responses at national and EU level.

4457

4458 Evidence on unmet need clearly indicates the magnitude of financial barriers to
4459 access: cost is the single most important factor behind self-reported unmet need.
4460 Ensuring health services are affordable for everyone should therefore be a priority
4461 for the Member States. Improving affordability requires identifying and addressing
4462 gaps in publicly financed coverage to keep out-of-pocket payments as low as
4463 possible. It also has particular resonance when it comes to access to medicines,
4464 especially (but not only) new and innovative medicines, which are increasingly
4465 priced beyond the reach of many countries, including countries in the European
4466 Union.

4467

4468 The report has pointed out that promoting access does not mean making
4469 everything available to everyone at all times. Rather, it involves efforts to ensure
4470 access to health services that are relevant to people's need, appropriate and as
4471 cost-effective as possible. This is an area that will require added attention as
4472 evidence of unwarranted variation in clinical practice increases and if health
4473 budgets do not grow in line with population health needs. The report has also
4474 emphasised the importance of service availability – well-equipped facilities within
4475 easy reach; enough health workers, with the right skills, in the right place; and
4476 stimulating research and development in areas of significant clinical need, such as
4477 antibiotics.

4478

4479 A final area the report has covered is user experience. Whether people have the
4480 information and skills needed to navigate complex health systems; whether they
4481 can obtain appointments with ease and treatment without excessive waits;
4482 whether they are treated with respect and dignity, are able to avail of services in
4483 their own language and are sufficiently involved in decisions about their treatment
4484 – these are questions that are often overshadowed by issues of affordability and
4485 availability and yet they may have a critical impact on access to health care,
4486 especially for systematically underserved groups of people.

4487

4488 In covering all of these different areas, the report has aimed to show how ensuring
4489 equitable access to health services is a multi-dimensional challenge. There are very
4490 few simple or quick fixes. It is also a permanent challenge, requiring sustained
4491 effort on many fronts. Better monitoring, context-specific policy analysis and
4492 research targeting hard to reach groups of people can contribute to this effort.
4493 However, real progress will only be made – and felt – when Member States are
4494 ready to act in response to what the available data already clearly demonstrate.

4495

4496 **Annex 1 Informal care and its impact on access to health services**

4497

4498 Although this report is concerned primarily with access to formal care, it is
4499 important to recognise that a large amount of care in Europe is delivered by
4500 informal carers, such as family and friends of those in need. While there are major
4501 gaps in the available data on access to formal care in Europe, the situation is even
4502 worse for informal care. Obtaining such evidence is important for several reasons.
4503 First, the absence of informal carers may mean that individuals with need for care
4504 can only obtain it in formal settings, such as hospitals or care homes that are both
4505 more expensive and, in many cases, less acceptable to the individuals concerned,
4506 as many of those in need would prefer to be cared for in the familiar setting of
4507 their own home. Second, a failure to support informal carers may lead to them
4508 becoming patients in their own right.

4509

4510 The most important source of evidence on the situation in Europe is the EU-funded
4511 ANCIEN project (Pickard et al 2011). To understand the role of informal care, the
4512 researchers first developed a typology of long-term care in European countries,
4513 based on two dimensions. The first is organisational depth, characterised by an
4514 absence of means testing, clear entitlements, availability of cash benefits, quality
4515 assurance mechanisms and integration. The second is financial generosity,
4516 characterised by a high share of GDP being spent on long-term care and low user
4517 charges. The position of many countries is intuitive, with the post 2004 Member
4518 States being relatively less generous, although they vary in organisational depth.
4519 However, there is also considerable variation among the pre-2004 Member States
4520 on both measures.

4521

4522 Across the European Union, there are large differences in the share of the
4523 population receiving informal care, from 21% of those over 65 in France to 43% in
4524 the Czech Republic, and from 41% to 60% among those over 85 in the same
4525 countries. There are also large differences in the share of the population providing
4526 informal care, from just over 10% of those aged over 18 in Denmark to almost
4527 19% in Lithuania. While those providing care are most likely to be female in all
4528 countries, there are marked differences among countries in the age distribution of
4529 carers and their relationship to those they are caring for.

4530

4531 There are also substantial differences in the support offered to informal carers. In
4532 some countries either carers or those in need of care are entitled to financial
4533 support. In the Netherlands, those in need of care may be given a personal health
4534 budget that can be spent largely as they wish and, while this has provided greater
4535 autonomy for some in need of care, there have also been many examples of abuse,
4536 with exploitation of vulnerable individuals. A pilot study of a similar initiative in
4537 England achieved at best mixed results.

4538

4539 The support available to those in need of care or their carers is often means tested,
4540 as in France, Spain and Finland, but not always and, in Belgium, a federal
4541 allowance is means tested while another, paid in Flanders, is not. Another form of
4542 support, respite care, whereby those receiving care may enter a residential facility
4543 for a few weeks to relieve their carer, is also available in many countries but its
4544 extent, and the mechanisms involved, including financial arrangements, are poorly
4545 documented.

4546

4547 In summary, the volume of informal care provided in Europe is substantial but
4548 evidence on the extent of need, both met and unmet, is still very limited.

4549

4550 *[This page intentionally left blank]*


4551 **Annex 2 Trends in unmet need for health care in each EU Member State**

4552

4553 **Trends in unmet need for health care due to cost, distance or waiting time**
 4554 **by country**


4555 Note: Data are from EU-SILC (2015). Most figures are scaled from 0-8% but some
 4556 have a larger scale.

Austria




4557

Belgium




4558

Bulgaria




4559

Czech Republic




4560
4561

Croatia




4562

Cyprus




4563
4564

Denmark




4565

Estonia




4566
4567

Finland




4568

France




4569
4570

Germany




4571

Greece




4572
4573

Hungary




4574


Ireland



4575
4576




4577




4578

Lithuania




4579

Luxembourg




4580
4581

Netherlands




4582

Malta




4583
4584

Portugal




4585

Poland




4586
4587

Romania




4588

Slovakia




4589
4590

Slovenia




4591

Spain




4592
4593

Sweden



4594

United Kingdom



4595
4596
4597

Annex 3 Indicators for monitoring access in Europe

A = age; E = education; I = income; LS = labour market status; MS = Member States; NUTS = Nomenclature of Territorial Units for Statistics; SES = socio-economic status

Table A3.1 Financial resources are linked to health need

Indicator	Data source	No of countries	Gender, age	SES	Sub-national
Public spending on health as share of GDP	Eurostat	28 EU MS	-	-	-
Public spending on health as share of government spending	Eurostat	28 EU MS	-	-	-
OOP as share of total spending on health	Eurostat	28 EU MS	-	-	-
Public spending on health per capita PPP	Eurostat	28 EU MS	-	-	-

Table A3.2 Services are affordable for everyone

Indicator	Source	No of countries	Gender, age	SES	Sub-national
Consultation skipped due to cost	OECD	3 EU MS	-	-	-
Medical tests, treatment or follow-up skipped due to cost	OECD	4 EU MS	-	-	-
Prescribed medicines skipped due to cost	OECD	4 EU MS	-	-	-
OOP % of total current expenditure on inpatient care, day care, basic medical and diagnostics, home health care, prescribed medicines, over the counter medicines, other medical non-durables, glasses, orthopaedic appliances, hearing aids, medico-technical devices, other medical durables	OECD/Eurostat	27	-	-	-
Medical examination skipped due to cost	Eurostat	32	Gender, age	A, E, LS, I	-
Dental examination skipped due to cost	Eurostat	34	Gender, age	A, E, LS, I	-

Access to health services

Table A3.3 Services are relevant, appropriate and cost-effective

Indicator	Source	No of countries	Gender, age	SES	Sub-national
Immunisation diphtheria, tetanus and pertussis – share of children	OECD	24	-	-	-
Immunisation measles – share of children	WHO	36	-	-	-
Immunisation hepatitis B – share of children	WHO	28	-	-	-
Immunisation influenza – share of aged 65+	Eurostat	31	-	-	-
Breast cancer screening – share of 50-69	Eurostat	17	-	E	-
Cervical cancer screening – share of 20-69	Eurostat	17	-	E	-

Table A3.4 Well-equipped facilities are within easy reach

Indicator (density per population)	Source	No of countries	Gender, age	SES	Sub-national
Hospitals	OECD	21	-	-	-
Hospitals publicly owned / not-for-profit private / for-profit private	OECD	15 / 14 / 16	-	-	-
General hospitals	OECD	22	-	-	-
Total hospital beds / curative (acute care) / long-term care / psychiatric / other	OECD	24 / 24 / 18 / 24 / 22	-	-	-
Beds in publicly owned hospitals / not-for-profit private / for-profit private	OECD	18 / 15 / 15	-	-	-
Hospital beds	Eurostat	20	-	-	NUTS

Table A3.5 There are enough health workers, with the right skill mix, in the right place

Indicator (worker density per population)	Source	No of countries	Gender, age	SES	Sub-national
Total number of physicians	OECD	22	-	-	-
Generalist practitioners / specialist practitioners	OECD	18 / 24	-	-	-
Obstetricians and gynaecologists / psychiatrists / medical specialists / surgical specialists	OECD	24	-	-	-
Other specialists	OECD	19	-	-	-
Midwives / nurses / caring personnel	OECD	17 / 18 / 14	-	-	-
Dentists / pharmacists / physiotherapists	OECD	18 / 21 / 23	-	-	-
Hospital employment	OECD	21	-	-	-
Medical graduates	OECD	23	-	-	-

Access to health services

Dentist / pharmacist / midwife / nursing graduates	OECD	22	-	-	-
Doctors, nurses and midwives, dentists, pharmacists, physiotherapists	Eurostat	20	-	-	NUTS

Table A3.6 Quality medicines and medical devices are readily available

Indicator (density per population)	Source	No of countries	Gender, age	SES	Sub-national
CT scanners total / in hospitals / in ambulatory settings	OECD	20 / 19 / 17	-	-	-
MRI units total / in hospitals / in ambulatory settings	OECD	19 / 20 / 17	-	-	-
PET scanners total / in hospitals / in ambulatory settings	OECD	20 / 20 / 16	-	-	-
Gamma cameras total / in hospitals / in ambulatory settings	OECD	20 / 19 / 16	-	-	-
Digital subtractions angiography units total / in hospitals / in ambulatory settings	OECD	18 / 18 / 15	-	-	-
Mammographs total / in hospitals / in ambulatory settings	OECD	18 / 15 / 12	-	-	-
Lithotriptors total / in hospitals / in ambulatory settings	OECD	15 / 16 / 12	-	-	-

Access to health services

Table A3.7 People can use services when they need them

Indicator	Source	No of countries	Gender, age	SES	Sub-national
Waiting time more than 4 weeks for an appointment with a specialist	OECD	5	Age standardised	-	-
Medical exam skipped due to travelling distance	Eurostat	33	Gender, age	I, LS, E	-
Medical exam skipped due to lack of time	Eurostat	34	Gender, age	I, LS, E	-
No unmet needs to declare for medical examinations	Eurostat	34	Gender, age	I, LS, E	-
Medical exam skipped due to not knowing any good doctor	Eurostat	32	Gender, age	I, LS, E	-
Medical exam skipped due to waiting time (waiting list)	Eurostat	34	Gender, age	I, LS, E	-
Medical exam skipped due to fear of doctors/treatment	Eurostat	34	Gender, age	I, LS, E	-
Medical exam skipped due to decision to wait to see if problem got better	Eurostat	34	Gender, age	I, LS, E	-
Medical exam skipped due to other reasons	Eurostat	34	Gender, age	I, LS, E	-
Dental exam skipped due to travelling distance	Eurostat	34	Gender, age	I, LS, E	-
Dental exam skipped due to lack of time	Eurostat	34	Gender, age	I, LS, E	-
No unmet needs to declare for dental examinations	Eurostat	34	Gender, age	I, LS, E	-
Dental exam skipped due to not knowing any good doctor	Eurostat	32	Gender, age	I, LS, E	-
Dental exam skipped due to waiting time	Eurostat	34	Gender, age	I, LS, E	-
Dental exam skipped due to fear of doctors/treatment	Eurostat	34	Gender, age	I, LS, E	-
Dental exam skipped due to decision to wait to see if problem got better	Eurostat	34	Gender, age	I, LS, E	-
Dental exam skipped due to other reasons	Eurostat	34	Gender, age	I, LS, E	-

Table A3.8 Services are acceptable to everyone

Indicator	Source	No of countries	Gender, age	SES	Sub-national
Patients reporting spending enough time with any / regular doctor during consultation	OECD	2 / 7	Gender, age standardised	-	-
Patients reporting easy-to-understand explanations by any doctor / regular doctor	OECD	2 / 7	Gender, age standardised	-	-
Patients reporting having the opportunity to ask questions to any doctor / regular doctor	OECD	1 / 7	Gender, age standardised	-	-
Patients reporting being involved in decisions about care by any doctor / regular doctor	OECD	2 / 7	Gender, age standardised	-	-

LIST OF ABBREVIATIONS

ANCIEN project	Assessing Needs of Care in European Nations
BIG register	Registration of healthcare professionals (The Netherlands)
CESCR	Committee on Economic, Social and Cultural Rights
CT scan	Computerised Tomography scan
DNDi	Drugs for Neglected Diseases initiative
DOM	Départements d'Outre-Mer (overseas territories) (France)
DTP	Diphtheria, Tetanus and Pertussis
EASL	European Association for the Study of the Liver
EC	European Commission
ECHI	European Community Health Indicators
ECHO project	European Collaboration for Health Optimisation
EFPIA	European Federation of Pharmaceutical Industries and Associations
EHIS	European Health Interview Survey
EMA	European Medicines Agency
EP	European Parliament
ERN	European Reference Network
ERRC	European Roma Rights Centre
EU	European Union
EUnetHTA	European network for Health Technology Assessment
EU-SILC	European Union Survey on Income and Living Conditions
EXPH	Expert Panel on effective ways of investing in Health
GDP	Gross Domestic Product
GP	General Practitioner
HBS	Household Budget Survey
HCHS	Hospital and Community Health Services (UK)
HCV	Hepatitis C Virus
HEMS	Helicopter Emergency Medical Service (Spain)

HiT	European Observatory on Health Systems and Policies reports on Health Systems in Transition
HLS-EU	European Health Literacy Survey
HTA	Health Technology Assessment
ICT	Information and Communication Technology
ICU	Intensive Care Unit
IMF	International Monetary Fund
KNMG	Koninklijke Nederlandsche Maatschappij tot bevordering der Geneeskunst - Royal Dutch Society for the Advancement of Medicine (The Netherlands)
MINECO	Ministry of Economy and Competitiveness (Spain)
MRI	Magnetic Resonance Imaging
MS	Member States
NGO	Non-Governmental Organisation
NHS	National Health Service (England)
OECD	Organisation for Economic Co-operation and Development
OJEU	Official Journal of the European Union
OOP	Out-Of-Pocket payment
PET scan	Positron Emission Tomography
PHAMEU Project	Primary Health Care Activity Monitor for Europe
PICUM	Platform for International Cooperation on Undocumented Migrants
QUALICOPC project	Quality and Costs of Primary Care in Europe
R&D	Research & Development
SHA	Strategic Health Authority (England)
SHARE	Survey of Health, Ageing and Retirement in Europe
SSB	Social Statistical Database (The Netherlands)
UK	United Kingdom
UNESCO	United Nations Educational, Scientific and Cultural Organisation
VHI	Voluntary Health Insurance

WHA	World Health Assembly
WHO	World Health Organisation

[This page intentionally left blank]

REFERENCES

- Alonso, J., Codony, M., Kovess, V., Matthias, C., Angermeyer, M. C. et al. (2007) Population level of unmet need for mental healthcare in Europe. *British Journal of Psychiatry*, 190, 299-306.
- Arora V, Karanikolos M, Clair A, Reeves A, Stuckler D, McKee M. Data Resource Profile: The European Union Statistics on Income and Living Conditions (EU-SILC). *International journal of epidemiology*. 2015; doi:10.1093/ije/dyv069.
- Autorità Garante della Concorrenza e del Mercato. Pharmaceuticals and antitrust: the Italian Competition Authority fines Roche and Novartis over Eur 180 million for cartelizing the sales of two major ophthalmic drugs, Avastin and Lucentis. Rome: Autorità Garante della Concorrenza e del Mercato; 2014.
- Babinska, I., Geckova, A. M., Jarcuska, P., Pella, D., Marekova, M., Stefkova, G., et al. (2014). Does the Population Living in Roma Settlements Differ in Physical Activity, Smoking and Alcohol Consumption from the Majority Population in Slovakia? *Central European Journal of Public Health*, 22, S22-S27.
- Bahtsevani, C., G. Uden and A. Willman (2004). "Outcomes of evidence-based clinical practice guidelines: a systematic review." *Int J Technol Assess Health Care* 20(4): 427-433.
- Bandura, A. (1977)
- Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. *Lancet*. 2012 Jul 7;380(9836):37-43.
- Barry MM, Clarke AM, Jenkins R, Patel V. (2013a) The effectiveness of mental health promotion interventions for young people in low and middle income countries: A systematic review. *BMC Public Health*, 13, 835.
- Barry, M.M., D'Eath, M., Sixsmith, J. (2013b). Interventions for improving population health literacy: insights from a rapid review of the evidence. *Journal of Health Communication: International Perspectives*, 18 :1507-1522.
- Bauer GR. *Soc Sci Med*. 2014 Jun;110:10-7. Incorporating intersectionality theory into population health research methodology: challenges and the potential to advance health equity.
- Bensing J: Doctor-patient communication and the quality of care. *Soc Sci Med* 1991, 32:1301-1310.
- Berkman, N., Sheridan, S., Donahue, K., Halpern, D., Crotty, K. (2011) Low health literacy and health outcomes: an updated systematic review. *Ann Intern Med*, 155(2), 97-107.
- Bernheim SM, Ross JS, Krumholz HM, Bradley EH: Influence of patients' socioeconomic status on clinical management decisions: a qualitative study. *Ann Fam Med* 2008, 6(1):53-59.
- Björnberg A (2015), Euro Health Consumer Index 2014 Report, Stockholm: Health Consumer Powerhouse.

- Bloemen S, Hammerstein D (2012). Time for the EU to lead on innovation. EU policy opportunities in biomedical innovation and the promotion of public knowledge goods. Health Action International, Trans Atlantic Consumer Dialogue. Netherlands, April 2012.
- Bostock, S., Steptoe, A. (2012) Association between low functional health literacy and mortality in older adults: longitudinal cohort study. *Br Med J*, 344, e1602.
- Bradshaw J A taxonomy of social need in McLachlan G (ed.) Problems and progress in medical care. Seventh series NPHT/Open University Press. 1972.
- Britz and McKee 2015 Charging migrants for health care could compromise public health and increase costs for the NHS. *J Public Health*. doi:10.1093/pubmed/fdv043
- Brown, S., Kim, M., Mitchell, C. and Inskip, H. (2010). Twenty-five year mortality of a community cohort with schizophrenia. *British Journal of Psychiatry*, 196: 116-121. doi:10.1192/bjp.bp.109.067512
- Buchan J, Sochalski J. The migration of nurses: trends and policies. *Bull World Health Organ*. 2004 Aug;82(8):587-94.
- Buck D and A Dixon (2013) Dixon and Buck (2013) Improving the allocation of health resources in England: How to decide who gets what, London: The King's Fund
- Bussing R, Zima BT, Gary FA, Wilson Garvan C. Barriers to Detection, Help-Seeking, and Service Use for Children with ADHD Symptoms. *JBHS&R* 2003;30 (2):176-189.
- Campion, J., Bhui, K., Bhugra, D. (2012). European Psychiatric Association (EPA) guidance on prevention of mental disorder. *European Psychiatry* 27: 68-80.
- Canavan, R., Barry, M. M., Matanov, A., Barros, H., Gabor, E., Greacen, T., 2012
- Carr, S., Lhussier, M., Forster, N., Goodall, D., Geddes, L., Pennington, M., Bancroft, A., Adams, J. and Michie S. (2014). Outreach programmes for health improvement of Traveller Communities: a synthesis of evidence. *Public Health Research* Vol 2 (3), doi:10.3310/phr02030
- CESCR (2000) General Comment N° 14. The right to the highest attainable standard of health. E /C.12/2000/4
- CESCR (2001). Human rights and intellectual property. Statement by the Committee on Economic, Social and Cultural Rights. 29 Nov 2001. E/C 12/2001/15
- CESCR 2005
- Chamberlain and O'Neill Understanding social class differences in health: a qualitative analysis of smokers' health beliefs *Psychology and Health*, 1998, Vol. 13, pp. 1105-1119.
- Chan, M. Opening remarks on creating synergies between intellectual property rights and public health, delivered at a joint technical symposium by WHO, WIPO and WTO on Access to Medicines: lessons from procurement practices. Geneva. Switzerland, 16, July, 2010. http://www.who.int/dg/speeches/2010/access_medicines_20100716/en/
- Chauvin, P., Parizot, I., Simonnot, N. (2009). Access to Healthcare for cities. *BMC Health Services Research*, 12: 222.

Chauvin P, Simonnot N, Vanbiervliet F, Vicart M, Vuillermoz C. (2015). Paris: Doctors of the World – Médecins du Monde International Network, May 2015. Accessible at: <https://mdmeuroblog.wordpress.com/resources/publications/new-report-2015/>

Cohen D. Attacks on publicly funded trials: what happens when industry does not want to know the answer. *BMJ*. 2015;350:h1701.

Cohen D. Why have UK doctors been deterred from prescribing Avastin? *BMJ*. 2015;350:h1654.

Council Conclusions 2010 May 10

Council 2014

Council of Europe Resolution 1509 (2006) on Human Rights of Irregular Migrants – Article 13.2.

EU (2010) Council of the European Union. Council conclusions on the EU role in Global Health, 10 may 2010.

Council of Europe (2014). European Social Charter. European Committee of Social Rights. Conclusions XX-2 (2013) (SPAIN). January 2014.

Cromwell DA. Waiting time information services: an evaluation of how well clearance time statistics can forecast a patient's wait. *Soc Sci Med*. 2004 Nov;59(9):1937-48.

Cross, T., Bazron, B., Dennis, K. and Isaacs, M. (1989) *Towards a Culturally Competent System of Care: A Monograph on Effective Services for Minority Children Who Are Severely Emotionally Disturbed*. Volume 1, Washington, DC: Georgetown University.

Cuadra, C.B. (2011) Right of access to health care for undocumented migrants in EU: a comparative study of national policies. *European Journal of Public Health*, 22(20), 267-271.

Dahlgren, G. and Whitehead, M. (1991) *Policies and strategies to promote social equity in health*, Stockholm: Institute of Futures Studies.

Dale J, Lang H, Roberts JA, Green J, Glucksman E. Cost effectiveness of treating primary care patients in accident and emergency: a comparison between general practitioners, senior house officers, and registrars. *Bmj*. 1996 May 25;312(7042):1340-4.

Dani KA, Stobo DB, Capell HA, Madhok R. Audit of literacy of medical patients in north Glasgow. *Scottish medical journal*. 2007 May;52(2):21-4.

Dauvrin, M., Lorant, V., Sandhu, S. et al. (2012). Health care for irregular migrants: pragmatism across Europe: a qualitative study. *BMC Research Notes* 5: 99.

De Boer 2015

De Hert, Correll, C.U., Bobes, J., Cetkovich-Baskmas, M., Cohen, D., Asai, I., et al., (2011). Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. *World Psychiatry*, 10 (1): 52-77.

De Maeseneer JM, Mieke L van Driel, Larry A Green, Chris van Weel. Translating research into practice 2: the need for research in primary care. *The Lancet* 2003;362:1314-1319.

De Maeseneer J, Boeckxstaens P. James MacKenzie Lecture 2011 : multimorbidity, goal-oriented care, and equity. *Br J Gen Pract.* 2012; (62) (600) : e522-4.
<http://www.ncbi.nlm.nih.gov/pubmed/22782000>

De Maeseneer J, Roberts RG, Demarzo M, et al. Tackling NCDs: a different approach is needed. *Lancet* 2012;379(9829):1860-1.

Decade of Roma Inclusion (2005). Decade Declaration. Retrieved 27 April, 2015, Available from: <http://www.romadecade.org/article/decade-declaration/9240>

Declaration on the TRIPS Agreement and Public Health (Doha Declaration) adopted on 14 November 2001 at the Fourth Ministerial Conference of the WTO.

DNDi 2014

Dolea C, Stormont L, Braichet JM. Evaluated strategies to increase attraction and retention of health workers in remote and rural areas. *Bull World Health Organ.* 2010 May;88(5):379-85.

Drieskens S., Charafeddine R., Demarest S., Gisle L., Tafforeau J. & Van der Heyden J. (2015) Health Interview Survey, Belgium, 1997 - 2001 - 2004 - 2008 - 2013: Health Interview Survey Interactive Analysis. Brussels: WIV-ISP.

du Monde European Observatory on Access To Healthcare.

Dubois C-A, Nolte E, McKee M. Human resources for health in Europe: McGraw-Hill International; 2005.

Duvell, F. (2010). Foreword in: Lund Thomsen T., Bak Joorgensen, M., Meret, S. et al. (Eds) Irregular Migration in a Scandinavian Perspective. Maastricht: Shaker Publishing, 3-8.

EASL (2014) European Association for the Study of the Liver. Clinical Practice Guidelines: Management of hepatitis C virus infection. *Journal of Hepatology* 2014; 60: 392-420

EFPIA (2014), The pharmaceutical industry in figures: key data 2014

Elgin C, Öztunali O. Shadow Economies around the World: Model Based Estimates. Bogazici University, Working Papers 5, 2012

ERRC - European Roma Rights Center. Ambulance not on the way : the disgrace of health care for Roma in Europe. Budapest, Hungary: European Roma Rights Centre; 2006.

ERRC - European Roma Rights Centre (2006), 'Ambulance not on the way – the disgrace of healthcare for Roma in Europe', Retrieved 23 April, 2015, Available from: <http://www.errc.org/cms/upload/media/01/E6/m000001E6.pdf>

Ettelt, S., E. Nolte, S. Thomson and N. Mays (2007). The systematic use of cost-effectiveness criteria to inform reviews of publicly funded benefits packages. A report commissioned by the Department of Health. London, London School of Hygiene and Tropical Medicine.

Eurofound (2012). Living conditions of the Roma: Substandard housing and health. Retrieved 23 April, 2015, Available from: <http://www.eurofound.europa.eu/pubdocs/2012/02/en/1/EF1202EN.pdf>

Eurofound (2014), Access to healthcare in times of crisis, Publications Office of the European Union, Luxembourg.

European Commission (2004). Left out: Roma and access to health care in Eastern and Southeastern Europe, Retrieved 23 April, 2015, Available from:

http://www.opensocietyfoundations.org/sites/default/files/leftout_20070423.pdf

European Commission (2009). Communication from the Commission. Executive Summary of the Pharmaceutical Sector Inquiry Report

EC 2012

European Commission (2014). Report on the implementation of the EU framework for National Roma Integration Strategies. Retrieved 27 April, 2015, Available from:

http://ec.europa.eu/justice/discrimination/files/roma_implementation_strategies2014_en.pdf

EC 2014

European Commission (2014). Roma Health Report: Health status of the Roma population. Retrieved 24 April, 2015, Available from:

http://ec.europa.eu/health/social_determinants/docs/2014_roma_health_report_en.pdf

EP 2012

EU 2007

European Union. Consolidated Versions of the Treaty on European Union and the Treaty on the Functioning of the European Union (2008/C 115/01): Office for Official Publications of the European Communities; 2008.

European Union. Charter of Fundamental Rights of the European Union. Brussels: European Union; 2010.

Eurostat (2014). Living Conditions in Europe. Retrieved 8 June, 2015. Available from:

<http://ec.europa.eu/eurostat/documents/3217494/6303711/KS-DZ-14-001-EN-N.pdf/d867b24b-da98-427d-bca2-d8bc212ff7a8>

Eurostat (2015)

<http://ec.europa.eu/eurostat/2015>.

falling back? HNP Discussion Paper, Washington DC: The World Bank.

female immigrants. 5th European Congress on Tropical Medicine and International Health, Amsterdam. Tropical Medicine and International Health, 12: 18–19.

Fesus, G., Ostlin, P., McKee, M., & Adany, R. (2012). Policies to improve the health and well-being of Roma people: The European experience. Health Policy, 105(1), 25-32.

Figueras J, McKee M. Health Systems, Health, Wealth And Societal Well-Being: Assessing The Case For Investing In Health Systems: Assessing the case for investing in health systems: McGraw-Hill International; 2011.

Fortier, J.P. and Bishop, D. (2003) Setting the Agenda for Research on Cultural Competence in Health Care. Edited by C. Brach. Rockville, MD: U.S. Department of Health and Human Services Office of Minority Health and Agency for Healthcare Research and Quality.

Fox ER, Sweet BV, Jensen V, editors. Drug shortages: a complex health care crisis. Mayo Clinic Proceedings; 2014: Elsevier.

FRA - European Union Agency for Fundamental Rights (2012). The situation of Roma in 11 EU Member States: Survey results at a glance. Retrieved 23 April, 2015, Available from: Roma-at-a-glance_EN.pdf

Friedli, L. (2009). Mental Health, Resilience and Inequalities. Copenhagen: WHO Regional Office for Europe.

Gaal P, McKee M. Informal payment for health care and the theory of 'INXIT'. Int J Health Plann Manage. 2004 Apr-Jun;19(2):163-78.

Gaal P, Belli PC, McKee M, Szocska M. Informal payments for health care: definitions, distinctions, and dilemmas. J Health Polit Policy Law. 2006 Apr;31(2):251-93.

Garcia-Perez MA, Amaya C, Otero A. Physicians' migration in Europe: an overview of the current situation. BMC health services research. 2007;7:201.

Garner AA et al (2015) The head injury retrieval trial: a single-centre randomised controlled trial of physician prehospital management of severe blunt head injury compared with management by paramedics only. Emerg Med J 2015 Mar 20.

Garner AA, Mann KP, Fearnside M, Poynter E, Gebiski V. The Head Injury Retrieval Trial (HIRT): a single-centre randomised controlled trial of physician prehospital management of severe blunt head injury compared with management by paramedics only. Emergency medicine journal : EMJ. 2015 Mar 20.

Giannakopoulos GF et al (2013). Helicopter Emergency Medical Services save lives: outcome in a cohort of 1,073 polytraumatized patients. Eur J Emerg Med 2013 Apr; 20(2): 79-85

Goddard M, Smith P: Equity of access to health care services: theory and evidence from the UK. Soc Sci Med 2001, 53(9):1149-1162.

Grimshaw JM, Thomas RE, MacLennan G, et al. Effectiveness and efficiency of guideline dissemination and implementation strategies. Health Technol Assess. 2004 FEB;8(6):III-IV, 1-72.

Grimshaw J, Eccles M, Tetroe J. Implementing clinical guidelines: current evidence and future implications. J Contin Educ Health Prof.2004 Fall;24 Suppl 1:S31-7.

groups in Europe: a qualitative study of expert views in 14 countries. BMC

Gulliford M and M Morgan 2003 Access to health care, Routledge.

Haggerty JL, Reid RJ, Freeman GK, Starfield BH, Adair CE, McKendry R. Continuity of care: a multi-disciplinary review. BMJ 2003;327(7425):1219-21.

Hajioff, S., & McKee, M. (2000). The health of the Roma people: a review of the published literature. Journal of Epidemiology and Community Health, 54(11), 864-869.

Hasselberg M, Beer N, Blom L, Wallis LA, Laflamme L. Image-based medical expert teleconsultation in acute care of injuries. A systematic review of effects on information accuracy, diagnostic validity, clinical outcome, and user satisfaction. PloS one. 2014;9(6):e98539.

Healy J, McKee M. Accessing health care: responding to diversity. Oxford: Oxford University Press; 2004.

Hill A et al (2014). Minimum costs for providing Hepatitis C Direct Acting Antivirus for use in large-scale treatment access programs in developing countries. *Clinical Infectious Diseases Advance Access publication* February 13, 2014.

Hill et al 2014

HLS-EU Consortium (2012). Comparative report of health literacy in eight EU member states. The European health literacy survey HLS-EU. Accessible online publication: <http://www.health-literacy.eu>

Holcnerova, P. et al. (2012) Service provision and barriers to care for homeless people with mental health problems across 14 European capital

Honer, D. (2004). The enigma of the Gypsy patient.

Hunter DJ, McKee CM, Black NA, Sanderson CF. Health care sought and received by men with urinary symptoms, and their views on prostatectomy. *Br J Gen Pract.* 1995 Jan;45(390):27-30.

Illich I *Medical Nemesis*. London: Calder & Boyars. 1974.

IOM - Institute of Medicine (2013). *Integrating Health Literacy with Health Care Performance Measurement*.

IOM - Institute of Medicine. (2004). *Health literacy: A prescription to end confusion*. Washington DC: the National Academies.

Jarauta MJP, Arive MAG, Merino BM (2010). Spain: Health Promotion among Navarre Ethnic Minorities programme. In: *Poverty and social exclusion in the European Region: Health systems respond*. Copenhagen, WHO Regional Office for Europe.

Jarcuska, P., Bobakova, D., Uhrin, J., Bobak, L., Babinska, I., Kolarcik, P., et al. (2013). Are barriers in accessing health services in the Roma population associated with worse health status among Roma? *International Journal of Public Health*, 58(3), 427-434.

Jensen JD, King AJ, Guntzviller LM, Davis LA: Patient-provider communication and low-income adults: age, race, literacy, and optimism predict communication satisfaction. *Patient Educ Couns* 2010, 79:30-35.

Kickbusch, I., Pelikan, J.M., Apfel, F. and Tsouros, A. (Eds,) (2013). *Health Literacy: The Solid Facts*. Copenhagen: World Health Organization Regional Office for Europe.

Kühlbrandt C1, Footman K2, Rechel B2, McKee M2. *Eur J Public Health.* 2014 Oct;24(5):707-12. An examination of Roma health insurance status in Central and Eastern Europe.

Kutzin, J. (2010). Conceptual framework for analysing health financing systems and the effects of reforms, in J Kutzin et al (eds.) *Implementing health financing reform: lessons from countries in transition*. Copenhagen: WHO Regional Office for Europe (European Observatory on Health Systems and Policies).

Lamata F, Oñorbe M (2014). *Crisis (esta crisis) y Salud (nuestra salud)*. Bubok Publishing, Madrid 2014.

Legido-Quigley H, D Panteli, J Car, M McKee and R Busse, eds (2013), Clinical guidelines for chronic conditions in the European Union, Copenhagen: WHO/European Observatory on Health Systems and Policies.

Light and Warburton 2011

Light DW, Kantarjian H. Market spiral pricing of cancer drugs. *Cancer* 2013 Nov; 119 (22): 3900-3902. doi: 10.1002/cncr.28321
<http://onlinelibrary.wiley.com/doi/10.1002/cncr.28321/abstract;jsessionid=C56893E6A8DE26DC7C1A17D7CCF89000.f04t01>

Mackenbach JP, Stirbu I, Roskam A-JR, Schaap MM, Menvielle G, Leinsalu M, et al. Socioeconomic inequalities in health in 22 European countries. *New England Journal of Medicine*. 2008;358(23):2468-81.

Mailankody and Prasal 2015

Maresso A, Mladovsky P, Thomson S, Sagan A, Karanikolos M, Richardson E, Cylus J, Evetovits T, Jowett M, Figueras J and Kluge H, eds (2015). Economic crisis, health systems and health in Europe: country experience, Copenhagen: WHO/European Observatory on Health Systems and Policies.

Martinez-Gonzalez NA, Rosemann T, Tandjung R, Djalali S. The effect of physician-nurse substitution in primary care in chronic diseases: a systematic review. *Swiss medical weekly*. 2015;145:w14031.

Maxwell, R (1992). Dimensions of quality revisited: from thought to action. *Quality in Health Care*, (1):171-177

MedTech 2014

MINECO (2013). Programa Nacional de Reformas. Reino de España. 2013. Ministerio de Economía y Competitividad. Gobierno de España.

Ministry of Health of Spain 2015

Mistry H, Garnvwa H, Oppong R. Critical appraisal of published systematic reviews assessing the cost-effectiveness of telemedicine studies. *Telemedicine journal and e-health : the official journal of the American Telemedicine Association*. 2014 Jul;20(7):609-18.

Mladovsky, P. (2007). Migration and Mental Health in the EU. Research Note for the European Commission from the Health and Living Conditions Network of the European Observatory on the Social Situation and Demography. London School of Economics and Political Science, UK.

Moynihan R, Cassels A (2005) Selling sickness. How the world's biggest pharmaceutical companies are turning us all into patients. New York: Nation Books. 254 p.

Moynihan R, Henry D (2006) The Fight against Disease Mongering: Generating Knowledge for Action. *PLoS Med* 3(4): e191. doi:10.1371/journal.pmed.0030191

Murphy P. (1999) Primary Health Care for Travellers Project: Implementation Report 1996-1999. Dublin: Pavee Point.

Nolte E, McKee M. Caring For People With Chronic Conditions: A Health System Perspective: A Health System Perspective: McGraw-Hill International; 2008.

Nolte E, McKee M. Variations in amenable mortality—trends in 16 high-income nations. *Health Policy*. 2011;103(1):47-52.

Nordheim LV, Haavind MT, Iversen MM. Effect of telemedicine follow-up care of leg and foot ulcers: a systematic review. *BMC health services research*. 2014;14:565.

Nutbeam 2000

O'Malley AS, Forrest CB. The Mismatch Between Urban Women's Preferences for and Experiences with Primary Care. *Women Health Iss* 2002;12(4):191-203.

OECD 2004 Private health insurance, Paris: OECD.

OECD 2013

OECD 2013 waiting times

OECD 2014 drug patent

OECD budget survey 2014

OECD (2014). Health at a Glance: Europe 2014. OECD 3 Dec 2014

OECD health data 2015 <http://www.oecd.org/health/>

OJEU 2006 Common values

Omachi, Theodore A.; Sarkar, Urmimala; Yelin, Edward H.; et al. *JOURNAL OF GENERAL INTERNAL MEDICINE* Volume: 28 Issue: 1 Pages: 74-81 Published: JAN 2013

Open Society Institute. (2005) *Mediating Romani Health: Policy and Program Opportunities*. New York, NY: Open Society Institute Network Public Health Program.

Parker RM, Ratzan SC. Health literacy: a second decade of distinction for Americans. *J Health Commun* 2010;15:20-33

Patel V, Flisher AJ, Hetrick S, McGorry P. Mental health of young people: a global public-health challenge. *The Lancet*. 2007;369(9569):1302-13.

Peiró and Alan Maynard 2015 Variations in health care delivery within the European Union http://eurpub.oxfordjournals.org/content/25/suppl_1/1

Pickard L, Jimenez-Martin S, Vegas R, Prieto CV. The supply of informal care in Europe. Brussels: European Network of Economic Policy Research Units (ENEPRI); 2011.

PICUM – Platform for International Cooperation on Undocumented Migrants (2010). *Undocumented Migrants' Health Needs and Strategies to Access Health Care in 17 EU Countries*. Summary report in the framework of the project Healthcare in NowHereland. Brussels.

PICUM - Platform for International Cooperation on Undocumented Migrants (2014). *Access to healthcare for people facing multiple health vulnerabilities. Obstacles in access to care for children and pregnant women in Europe*.

PICUM – Platform for International Cooperation on Undocumented Migrants (2015) *Protecting undocumented children-Promising policies and practices from governments*.

Poduval S1, Howard N1, Jones L1, Murwill P1, McKee M1, Legido-Quigley H2. *Int J Health Serv.* 2015;45(2):320-33. Experiences among undocumented migrants accessing primary care in the United Kingdom: a qualitative study.

Pope CJ, Roberts JA, Black NA. Dissecting a waiting list. *Health services management research : an official journal of the Association of University Programs in Health Administration / HSMC, AUPHA.* 1991 Jul;4(2):112-9.

Priebe, S., Matanov, A., Schor, R., Strasmayr, C., Barros, H., Barry, M.M., Diaz-Olalla, J.M. et al. (2012) Good practice in mental health care for socially marginalized *Public Health*, 12: 248.

QUALICOPC 2015

Rechel, B., Mladovsky, P., Devillé, W. Rijks, B., Petrova-Benedict, R. and McKee, M. (2011) *Migration and Health in the European Union.* World Health Organization on behalf of the European Observatory on health Systems and policies. Berkshire: Open University Press.

Reeves A, Basu S, McKee M, Meissner C, Stuckler D. Does investment in the health sector promote or inhibit economic growth? *Global Health.* 2013;9:43.

Reeves A, McKee M, Stuckler D. The attack on Universal Health Coverage in Europe: recession, austerity, and unmet needs. *Eur J Publ Health.* 2015:doi: 10.1093/eurpub/ckv040.

Rudd, R.E. (2004). Adult education and public health partner to address health literacy needs. *Adult Learning*, 15(1), 7-9.

Sagan A and S Thomson 2015 *Voluntary health insurance in Europe: role, regulation and implications for policy*

Saltman R, Bankauskaite V, Vrangbaek K. *Decentralization in health care: strategies and outcomes:* McGraw-Hill International; 2006.

Siciliani L, Moran V, Borowitz M. *Measuring and comparing health care waiting times in OECD countries.* OECD Health working paper 67. Paris: OECD Publishing, 2013

Sorensen K, Van den Broucke S, Fullam J, et al. Health literacy and public health: a systematic review and integration of definitions and models. *BMC Public Health* 2012;12:80.

Sorensen, K. 2012: Health literacy and public health: A systematic review and integration of definitions and models, *BMC Public Health*, 12(80).

Sørensen, K., Broucke, S. V. D., Fullam, J., Doyle, G., Pelikan, J., Slonska, Z., & Brand, H. (2012). Health literacy and public health: a systematic review and integration of definitions and models. *BMC Public Health*, 12(80), 1-13. doi: doi: 10.1186/1471-2458-12-80.

Sorenson, C., M. Drummond and P. Kanavos (2008). *Ensuring value for money in health care. The role of health technology assessment in the European Union.* Copenhagen, World Health Organization, on behalf of the European Observatory on Health Systems and Policies.

Starkiene L, Smigelskas K, Padaiga Z, Reamy J. The future prospects of Lithuanian family physicians: a 10-year forecasting study. *BMC family practice.* 2005 Oct 4;6:41.

Stevens and Gillam 1998 <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1113121/>

Strassmayr, C.C., Matanov, A.A., Priebe, S.S., Barros, H., Canavan, R., Diaz-Olalla, J.M. et al. (2012). Mental health care for irregular migrants in Europe: Barriers and how they are overcome. *BMC Public Health*, 12: 367.

Stuckler D, Basu S (2013). *The body economic: why austerity kills*. New York, NY. Basic Books.

Sutherland A: Gypsies and health care, In *Cross-cultural Medicine [Special Issue]*. *West J Med* 1992 Sep; 157:276-280)

Swartz, K. (2010). *Cost-sharing: effects on spending and outcomes*. Princeton, Robert Wood Johnson Foundation. 2011.

Taylor CB et al. (2010) A systematic review of the costs and benefits of helicopter emergency medical services. *Injury* 2010 Jan; 41(1): 10-20

Tefferi et al 2014

Thomas et al 2000

Thompson CR, McKee M. An analysis of hospital capital planning and financing in three European countries: Using the principal-agent approach to identify the potential for economic problems. *Health Policy*. 2011 Feb;99(2):158-66.

Thomson S and E Mossialos 2009 *Private health insurance in the European Union*, Brussels: European Commission.

Thomson S, Figueras J, Evetovits T, Jowett M, Mladovsky P, Maresso A, Cylus J, Karanikolos M, Kluge H (2014). Policy Summary. Economic crisis, health Systems and health in Europe: impact and implications for policy. World Health Organization on behalf of the European Observatory on Health Systems and Policies, 2014.

Thomson S, Figueras J, Evetovits T, Jowett M, Mladovsky P, Maresso A, Cylus J, Karanikolos M and Kluge H (2015). *Economic crisis, health systems and health in Europe: impact and implications for policy*, Maidenhead: Open University Press.

Tudor Hart, J. (1971). The inverse care law. *Lancet*, 1(7696):405-412.

Undocumented Migrants in 11 European Countries. Paris: Médecins Sans Frontieres

United National Economic and Social Council (2010) Health literacy and the millennium development goals: United Nations Economic and Social Council (ECOSOC) regional meeting background paper. *Journal of Health Communication* 15, (suppl 2):211-23

Van Den Muijsenbergh M. (2007). Maternity care and undocumented
van Ryn M, Burke J: The effect of patient race and socio-economic status on physicians' perceptions of patients. *Soc Sci Med* 2000, 50(6):813-828.

Velasco Garrido, M., F. Børlum Kristensen, C. Palmhøj Nielsen and R. Busse (2008). *Health Technology Assessment and Health Policy-Making in Europe. Current status, challenges and potential*. Copenhagen, World Health Organization, on behalf of the European Observatory on Health Systems and Policies.

Velényi E and M Smitz (2014), Cyclical patterns in government health expenditures between 1995 and 2010: are countries graduating from the procyclical trap or

Verlinde et al. (2012). The social gradient in doctor-patient communication. *International Journal for Equity in Health* 2012, 11:12

Wahlbeck, K. and Huber, M. (2009) Access to health care for people with mental disorders in Europe. Policy Brief, April 2009. European Centre for Social Welfare Policy and Research. Accessible at: http://www.euro.centre.org/data/1240307367_27951.pdf

Wahlbeck, K. (2010) Moving towards integrated addiction treatment systems. *Nordic Studies on Alcohol and Drugs*, 27:699-702.

WHA (2015) World Health Assembly addresses antimicrobial resistance, immunization gaps and malnutrition. New release. 25 May 2015. <http://www.who.int/mediacentre/news/releases/2015/wha-25-may-2015/en/>

WHO (2010), World health report 2010: Health systems financing - the path to universal coverage, Geneva: World Health Organization.

WHO (2008). Emergency Medical Service Systems in the European Union. WHO Regional Office for Europe.

World Health Organization. The Tallinn Charter: Health systems for health and wealth. Tallinn: World Health Organization; 2008.

WHO How health systems can address health inequities linked to migration and ethnicity. Copenhagen, WHO Regional Office for Europe, 2010.

WHO (2012) Research and Development to Meet Health Needs in Developing Countries: Strengthening Global Financing and Coordination. Report of the Consultative Expert Working Group on Research and Development: Financing and Coordination. World Health Organization, 2012.

WHO 2012a

WHO 2012b

WHO 2013

World Health Organization (2013). Mental Health Action Plan. Geneva: World Health Organization.

World Health Organization (2014). Global health estimates 2014 summary tables: YLD by cause, age and sex by WHO region, 2000-2012. Geneva: World Health Organization.

WHO 2014 global atlas med devices

WHO 2015 new meds report

WHO health expenditure data 2015 <http://www.who.int/gho/database/en/>

WHO (2015) Access to new medicines in Europe: technical review of policy initiatives and opportunities for collaboration and research. WHO, Regional Office for Europe, March 2015. <http://www.euro.who.int/en/health-topics/Health-systems/medicines/publications2/2015/access-to-new-medicines-in-europe-technical-review-of-policy-initiatives-and-opportunities-for-collaboration-and-research>

WHO XXXX

WHO, WTO, WIPO (2013). Promoting Access to Medical Technologies and Innovations. Intersections between health, intellectual property and trade. World Health Organization, World Trade Organization, World Intellectual Property Organization.

Wilcock GK. The prevalence of osteoarthritis of the hip requiring total hip replacement in the elderly. *International journal of epidemiology*. 1979 Sep;8(3):247-50.

Willems 2005

Wismar M, McKee M, Ernst K, Srivastava D, Busse R. Health targets in Europe: learning from experience. Brussels: European Observatory on Health Systems and Policies; 2008.

Wittchen, H. U., Jacobi, F., Rehm, J., Gustavsson, A., Svensson, M., Jonsson, B., Steinhausen, H. C. (2011). The size and burden of mental disorders and other disorders of the brain in Europe 2010. *Eur Neuropsychopharmacology*, 21:665–79.

Woodward, A., Howard, N. and Wolffers, I. (2014) Access to health care for undocumented migrants living in the EU: a scoping review. *Health Policy and Planning*, 29(7): 818-830.

WTO (2001) Agreement on Trade-Related aspects of Intellectual Property rights.

Xu K, Saksena P, Jowett M, Carrin G., Kutzin J, & Evans D. (2010). Exploring the thresholds of health expenditure for protection against financial risk. *World Health Report 2010 Background Paper 19*. Geneva: World Health Organization.